,sentence_id_pmcid,augmented_set,augmented_set_preceding_umls,augmented_set_trailing_umls,section,section.1,CONSORT_Item
0,PMC4770816S58,the ceased if cardiovascular participant had Follow-up major a event.,"based practitioners actively of the trial, the general above had access to a computer In algorithm that was suggested drugs and target. if the participant arms both dosage",The and outcome was change primary in blood systolic between baseline pressure one year.,['Procedures'],Methods,['7b']
1,PMC4770816S58,Follow-up ceased if the participant a major event.,"do drugs player In reckoner both arms of the trial, the general practitioner practitioners had access to algorithmic rule a computer based algorithm that get at actively suggested drugs and dosage if do drugs the participant was found above target.",The primary outcome was change in sbp between baseline and one year.,['Procedures'],Methods,['7b']
2,PMC4770816S58,Follow-up give up if the player had a john major cardiovascular event.,"In both Proximal segment of free upper limb of the trial, the general practitioners had access to a computer based Calculated that actively suggested Medication and dosage if the participant was above target.",The primary outcome was change in blood pressure systolic between baseline and one year.,['Procedures'],Methods,['7b']
3,PMC4770816S58,follow up discontinue if the player had a major cardiovascular event.,"In both Brachiums of the trial, the general practitioners had access to a computer based Calculated that actively suggested Medication and dosage if the participant was above target.",The primary outcome was change in systolic blood pressure between baseline one,['Procedures'],Methods,['7b']
4,PMC4770816S58,Follow-up john r major ceased if player the participant had a followup major cardiovascular event.,"in both gird of the trial, the cosmopolitan practitioner had memory access to a computer based algorithm that actively intimate drugs and dose if the player was above target.",The primary outcome was change in Blood pressure systolic between baseline and one year.,['Procedures'],Methods,['7b']
5,PMC4770816S58,Follow-up ceased if the participant had a major cardiovascular event.,"In both Upper Arms of the trial, the general practitioners had access to a computer based Calculated that actively suggested MEDICATION and dosage if the participant was above target.",The elementary consequence was change in systolic blood atmospheric pressure between baseline and  year.,['Procedures'],Methods,['7b']
6,PMC4770816S58,Follow-up ceased if the participant had a major cardiovascular event.,"In both arms of the trial, the general practitioners had access to a computer based algorithm that actively suggested drugs and dosage if the participant was above target.",The primary outcome was change in systolic blood pressure between baseline and one year.,['Procedures'],Methods,['7b']
7,PMC4770816S75,"Subgroup analyses were pre-specified for DIABETES MELLITUS NON INSULIN DEPENDENT mellitus, Cardiac Atrium fibrillation, and age group.","We too explored the potential effects of lack values by the use of ternion approaches: multiple imputation, radical mean, and final stage uncommitted value.","by subgroup we did (<140 addition, analysis In baseline systolic blood pressure a Hg). mm ≥140 Hg, mm",['Statistical analysis'],Methods,['12b']
8,PMC4770816S75,"Subgroup analyses were pre-specified for noninsulin dependent diabetes mellitus mellitus, upper chambers of the heart fibrillation, and age group.","We also explored the potential value. by missing use and the values of three approaches: available imputation, effects mean, of last multiple group","answer In addition, we did a subgroup analysis by baseline service line millimeter service line systolic blood pressure (<140 millimeter mm Hg, ≥140 mm Hg).",['Statistical analysis'],Methods,['12b']
9,PMC4770816S75,"Subgroup analyses were fibrillation, for and pre-specified atrial mellitus, diabetes age group.","also explored effects of missing values the use of three group mean, and last available","by mm we did a subgroup analysis Hg, baseline systolic (<140 pressure blood addition, mm ≥140 In Hg).",['Statistical analysis'],Methods,['12b']
10,PMC4770816S75,"subgroup depth psychology were pre-specified for diabetes mellitus, atrial fibrillation, and senesce group.","also explored potential of missing by of three approaches: group mean, available value.","In addition, we did a subgroup analysis by baseline blood pressure systolic (<140 mm Hg, ≥140 mm Hg).",['Statistical analysis'],Methods,['12b']
11,PMC4770816S75,"Subgroup analyses were pre-specified for diabetes mellitus, and age group.","We also explored the potential effects of missing values by the use of three approaches: multiple imputation, group mean, and last available value.",In analysis systolic pressure (<140 mm ≥140 mm Hg).,['Statistical analysis'],Methods,['12b']
12,PMC4770816S75,"Subgroup analyses were personify pre-specified for diabetes subgroup mellitus, atrial be fibrillation, and age group.","We also approaches: values potential effects of missing the by explored use and three the multiple imputation, group mean, of last available value.","In addition, we did a subgroup analysis by baseline Systolic blood pressure measurement (<140 mm Hg, ≥140 mm Hg).",['Statistical analysis'],Methods,['12b']
13,PMC4770816S75,"Subgroup analyses were pre-specified for diabetes mellitus, atrial fibrillation, and age group.","We also explored the potential effects of missing values by the use of three approaches: multiple imputation, group mean, and last available value.","In addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg).",['Statistical analysis'],Methods,['12b']
14,PMC4770816S76,"In addition, we did a analysis systolic pressure (<140 mm Hg, ≥140 Hg).","analyses for diabetes atrial fibrillation, and age group.","We compared the number changes, and side effects by mixed modelling, adjusting for the same variables as in outcome.",['Statistical analysis'],Methods,['12b']
15,PMC4770816S76,"amp millimetre In addition, we insistence did millimetre a subgroup analysis by mm baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg).","Subgroup analyses were pre-specified for mellitus, diabetes atrial and fibrillation, group. age","We compared the event number of consultations, treatment changes, and side effects by using turn generalised variable mixed modelling, face victimization adjusting for the same variables as in the victimization conform primary outcome.",['Statistical analysis'],Methods,['12b']
16,PMC4770816S76,"In addition, we did a subgroup fare analysis by baseline systolic blood psychoanalysis millimetre pressure transportation (<140 mm Hg, ≥140 mm fare Hg).","Subgroup analyses were pre-specified for diabetes type 2 mellitus, Cardiac Atrium fibrillation, and age group.","We compared the number of consultations, therapy changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",['Statistical analysis'],Methods,['12b']
17,PMC4770816S76,"In addition, we baseline analysis subgroup mm by did systolic a pressure Hg). blood Hg, ≥140 mm (<140","Subgroup analyses were pre-specified for diabetes mellitus, atrial group.","We compared the number of consultations, method treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",['Statistical analysis'],Methods,['12b']
18,PMC4770816S76,"In addition, we did a subgroup analysis by baseline Systolic blood pressure measurement (<140 mm Hg, ≥140 mm Hg).","Subgroup analyses were pre-specified for ketosis resistant diabetes mellitus, Atrium of heart fibrillation, and age group.","liken We event compared the number of consultations, treatment changes, and away side effects by using face generalised mixed modelling, adjusting for inch the same variables as in the conform compare primary outcome.",['Statistical analysis'],Methods,['12b']
19,PMC4770816S76,"In addition, we did a subgroup analysis by baseline Blood pressure systolic (<140 mm Hg, ≥140 mm Hg).","subgroup break down were pre-specified for diabetes mellitus, atrial fibrillation, and eld group.","We the consultations, treatment changes, effects by mixed modelling, for the as in the primary",['Statistical analysis'],Methods,['12b']
20,PMC4770816S76,"In addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg).","Subgroup analyses were pre-specified for diabetes mellitus, atrial fibrillation, and age group.","We compared the number of consultations, treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",['Statistical analysis'],Methods,['12b']
21,PMC4770816S77,"We compare the numerate of consultations, treatment changes, and side of meat effects by using generalised amalgamate modelling, aline for the same variable as in the elemental outcome.","In addition, we indiana service line millimetre did a subgroup analysis by baseline systolic blood millimetre pressure (<140 mm Hg, atmospheric pressure ≥140 mm Hg).","For clinical events, we calculated peril ratios and their 95% trust interval by using Cox relative jeopardy modelling, adapt for the same covariates note previously.",['Statistical analysis'],Methods,['12b']
22,PMC4770816S77,"We compared the number treatment and effects by using generalised modelling, adjusting the variables as in the outcome.","In addition, we did a subgroup analysis by baseline blood pressure systolic (<140 mm Hg, ≥140 mm Hg).","the clinical events, we modelling, 95% ratios for their hazard confidence intervals by using adjusting proportional hazards calculated Cox and For same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
23,PMC4770816S77,"We compared the number of consultations, Therapeutic changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","In addition, we did a subgroup analysis by systolic blood pressure (<140 mm Hg, ≥140 mm Hg).","For clinical calculated ratios and their 95% confidence by using Cox proportional hazards modelling, for the same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
24,PMC4770816S77,"We compared the number of consultations, Therapeutic Technique changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","In addition, we did a subgroup analysis by baseline Systolic blood pressure measurement (<140 mm Hg, ≥140 mm Hg).","For clinical events, we calculated hazard ratios and their 95% self confidence intervals by using cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
25,PMC4770816S77,"We compared the number of burden consultations, treatment changes, and handling side effects by using load generalised mixed issue set amp modelling, adjusting for the same variables as in the side of meat primary outcome.","In addition, amp we did a subgroup analysis by baseline systolic blood pressure service line (<140 mm line of descent Hg, ≥140 mm line of descent indiana Hg).","For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
26,PMC4770816S77,"We compared the number of consultations, method treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","blood addition, we Hg, a subgroup analysis by baseline Hg). (<140 did In mm pressure ≥140 mm systolic","For clinical bring up events, time interval we calculated hazard victimization ratios and their 95% time interval confidence intervals by using Cox proportional hazards modelling, bring up adjusting for the same self confidence covariates mentioned deliberate previously.",['Statistical analysis'],Methods,['12b']
27,PMC4770816S77,"We compared the number of consultations, treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","In addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg).","For clinical events, we calculated hazard ratios and their 95% confidence intervals by using Cox proportional hazards modelling, adjusting for the same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
28,PMC4770816S78,"For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using Cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","We treatment changes, and side effects by using generalised mixed for the same variables as in primary outcome.",exemplary We checked the proportional hazard let in assumption with price Schoenfeld residual plots and by including interaction terms in the damage let in model (for balance each term by time).,['Statistical analysis'],Methods,['12b']
29,PMC4770816S78,"clinical events, we calculated hazard ratios and their 95% intervals using hazards adjusting for mentioned","We compared the changes, of in treatment using as side effects by primary generalised modelling, mixed adjusting for the number variables and consultations, the same outcome.",We checked the proportional hazard tick off assumption with damage Schoenfeld residual plots and by including interaction terms in price plot of ground the model balance (for condition each term by time).,['Statistical analysis'],Methods,['12b']
30,PMC4770816S78,"trust For clinical events, we calculated hazard ratios and their 95% past cyclooxygenase confidence lapplander intervals by using Cox name proportional set hazards modelling, adjusting past for the same covariates mentioned previously.","We compared the of consultations, treatment changes, and side effects by using mixed for same as in the",We checked hazard Schoenfeld residual plots by interaction terms in the model (for each term time).,['Statistical analysis'],Methods,['12b']
31,PMC4770816S78,"For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","We compared the number of consultations, Therapeutic Technique changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",We checked with proportional hazard term the residual Schoenfeld plots interaction by each and (for in the model terms including assumption by time).,['Statistical analysis'],Methods,['12b']
32,PMC4770816S78,"modelling, clinical events, the calculated hazard by and we 95% confidence intervals ratios using Cox adjusting for For proportional mentioned their same covariates hazards previously.","We compared the number of consultations, therapeutics changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",We mark off the relative hazard supposition with Schoenfeld residual plots and by including fundamental interaction terms in the manakin (for each terminal figure by time).,['Statistical analysis'],Methods,['12b']
33,PMC4770816S78,"For clinical events, we calculated hazard proportion and their 95% authority separation by using cyclooxygenase relative hazards modelling, correct for the same covariates remark previously.","We liken the issue of consultations, intervention changes, and side effects by utilise generalised mix in modelling, adjusting for the same variable as in the primary coil outcome.",We checked the proportional hazard assumption with Schoenfeld residual plots and by including Social Interaction terms in the Digital Model Attachment (for each term by time).,['Statistical analysis'],Methods,['12b']
34,PMC4770816S78,"For clinical events, we calculated hazard ratios and their 95% confidence intervals by using Cox proportional hazards modelling, adjusting for the same covariates mentioned previously.","We compared the number of consultations, treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",We checked the proportional hazard assumption with Schoenfeld residual plots and by including interaction terms in the model (for each term by time).,['Statistical analysis'],Methods,['12b']
35,PMC4770816S79,We checked the proportional hazard assumption with Schoenfeld residual plots and by including Interaction with others terms in the Digital Model Attachment (for each term by time).,"For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.",all event censored patients at time of the first event to that analysis.,['Statistical analysis'],Methods,['12b']
36,PMC4770816S79,We hazard assumption with residual plots and by terms in model (for term by time).,"For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using Cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","For all clinical event analyses, unit we censored patient role patients at the time of the first unit event unit relevant to whole that analysis.",['Statistical analysis'],Methods,['12b']
37,PMC4770816S79,checked hazard with Schoenfeld and including interaction in the model (for each term by time).,"For clinical events, we calculated hazard ratios and their 95% self confidence intervals by using cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","For all clinical analyses, we censored patients at the time of the relevant to analysis.",['Statistical analysis'],Methods,['12b']
38,PMC4770816S79,We checked the relative gamble assumption with Schoenfeld residual plots and by include fundamental interaction full term in the manakin (for each term by time).,"For clinical events, we calculated hazard ratios and their 95% self confidence intervals by using Cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","For that clinical time event we censored patients at the event of all first the relevant to analyses, analysis.",['Statistical analysis'],Methods,['12b']
39,PMC4770816S79,We checked the proportional hazard assumption with Schoenfeld residual plots and by including Social Interactions terms in the Digital Model Attachment (for each term by time).,"For adjust clinical events, we calculated hazard ratios and their 95% confidence authority intervals by using Cox line up proportional cox hazards modelling, adjusting proportion coxswain for authority the same covariates mentioned previously.","For all clinical event upshot analyses, atomic number  we censored patients at the time whole of the first event relevant censor to atomic number  that analysis.",['Statistical analysis'],Methods,['12b']
40,PMC4770816S79,We assure checked the proportional hazard assumption with Schoenfeld residual plots and by including exemplar interaction reassure terms in the model patch (for each august  damage term by time).,"For clinical events, we calculated chance ratio and their 95% sureness interval by using cyclooxygenase proportional hazards modelling, set for the same covariates observe previously.","For clinical first event analyses, we all patients at the time relevant the censored event to of that analysis.",['Statistical analysis'],Methods,['12b']
41,PMC4770816S79,We checked the proportional hazard assumption with Schoenfeld residual plots and by including interaction terms in the model (for each term by time).,"For clinical events, we calculated hazard ratios and their 95% confidence intervals by using Cox proportional hazards modelling, adjusting for the same covariates mentioned previously.","For all clinical event analyses, we censored patients at the time of the first event relevant to that analysis.",['Statistical analysis'],Methods,['12b']
42,PMC4770816S141,The population by a trial primary care population managed by generalists than rather a hospital/outpatient represents post-stroke managed selective specialists.,"It is likely, therefore, that the more intensifier point would have been eventide severe to reach if the trial population was more instance of citizenry with dominant cerebrovascular disease.","The outcome measure was not blinded, but a nurse not directly involved in the participant’s in care obtained it by using an automated sphygmomanometer, so systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
43,PMC4770816S141,The trial represents a post-stroke Primary health care population managed by generalists rather than a selective hospital/outpatient population managed by specialists.,"It is likely, therefore, that knockout the more intensive target would have been even harder to achieve intensifier if more than constitute the trial knockout masses population was more more than representative of constitute people with prevalent cerebrovascular disease.","The outcome measure was not blinded, but a nurse not directly involved in the participant’s In care obtained it by using an automated sphygmomanometer, so systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
44,PMC4770816S141,The trial represents a post-stroke primary health care population managed by generalists rather than a selective hospital/outpatient population managed by specialists.,"It is likely, therefore, that the would intensive target the achieve been even harder to cerebrovascular if with trial people of more representative disease. population more prevalent have was","give care merely The thence outcome measure was not blinded, but a nurse not but directly involved in the participant’s call for care obtained it by using an automated sphygmomanometer, make up receive so victimization systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
45,PMC4770816S141,The trial pull off represents a sort of post-stroke primary care tryout test population managed by universe generalists rather than a pull off selective hospital/outpatient population managed by specialists.,"It is likely, fifty fifty therefore, that prevailing the spokesperson more intensive target would have been even constitute harder to achieve if the trial butt more than population institute was more representative of people with prevalent intensifier cerebrovascular disease.","The outcome measure information technology was not blinded, but receive a read nurse not directly involved in the participant’s care away obtained it by using an predetermine automated sphygmomanometer, predetermine so receive systematic recording bias is meet unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
46,PMC4770816S141,represents a post-stroke care population generalists selective hospital/outpatient by specialists.,"information technology is likely, therefore, that the more intensifier butt would have been even arduous to attain if the trial universe was more representative of the great unwashed with predominant cerebrovascular disease.","The outcome measure was not a nurse not involved in the participant’s obtained by using automated sphygmomanometer, so systematic unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
47,PMC4770816S141,trial a post-stroke primary population managed by generalists rather than a selective hospital/outpatient population managed by,"It likely, intensive target would been even harder achieve if the trial population representative of people with cerebrovascular disease.","The outcome measure was not blinded, but a nurse not directly involved in the participant’s care provided in residence obtained it by using an automated sphygmomanometer, so systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
48,PMC4770816S141,The trial represents a post-stroke primary care population managed by generalists rather than a selective hospital/outpatient population managed by specialists.,"It is likely, therefore, that the more intensive target would have been even harder to achieve if the trial population was more representative of people with prevalent cerebrovascular disease.","The outcome measure was not blinded, but a nurse not directly involved in the participant’s care obtained it by using an automated sphygmomanometer, so systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
49,PMC4392313S86,"All other exploratory end points were summarised for the ITT population observed cases, without imputation of missing Data call receiving device and excluding escape data.",Only were escape before recorded therapy measurements carried forward.,"totally testing ground argument values were converted to SI units; for lipid parameters, only the latest fasted values inside the clock time windowpane were included.",['Statistical analysis'],Methods,['12b']
50,PMC4392313S86,"wholly other explorative last pointedness were summarised for the ITT universe observed cases, without imputation of missing datum and excluding escape data.",recorded before were carried,"All laboratory parameter values were converted to SI units; for lipid parameters, only the latest fasted values within the time window were included.",['Statistical analysis'],Methods,['12b']
51,PMC4392313S86,"maneuver All other exploratory altogether end points were summarised for the ITT population early raw observed cases, without last imputation of missing data and excluding datum escape data.",Only measurements recorded before escape therapy carried forward. were,"All laboratory change parameter lipide esteem values were converted lipid to SI units; for lipid parameters, only the latest fast fasted values within the lipide time window were included.",['Statistical analysis'],Methods,['12b']
52,PMC4392313S86,"All summarised exploratory the points of other for without ITT population observed cases, data. imputation were missing data and excluding end escape",Only measurements recorded before escape therapy were Carries forward.,"All make up laboratory parameter values were converted to SI units; fast for lipid parameters, only the latest fasted values recent esteem within the recent time fourth dimension window were included.",['Statistical analysis'],Methods,['12b']
53,PMC4392313S86,"All observed exploratory escape points were data for the ITT population excluding cases, summarised imputation of missing data. and other end without",Only measurements recorded before escapism therapy were expect forward.,"All included. parameter were were the values converted units; for lipid parameters, only the latest fasted to window SI time within values laboratory",['Statistical analysis'],Methods,['12b']
54,PMC4392313S86,"other exploratory points were for ITT population cases, without imputation of data and excluding data.",Only measurements recorded before dodging therapy were gestate forward.,"the laboratory time values were converted to parameter units; lipid All parameters, only for latest fasted values within were SI window the included.",['Statistical analysis'],Methods,['12b']
55,PMC4392313S86,"All other exploratory end points were summarised for the ITT population observed cases, without imputation of missing data and excluding escape data.",Only measurements recorded before escape therapy were carried forward.,"All laboratory parameter values were converted to SI units; for lipid parameters, only the latest fasted values within the time window were included.",['Statistical analysis'],Methods,['12b']
56,PMC4392313S90,"Exploratory based cases, were using the non-parametric Kruskal–Wallis","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory Patient evaluation procedure in this study demonstrated non-normal distributions, values for exploratory Blood serum analytes are presented as medians or median percentage changes from baseline.",Hodges–Lehmann of location shift 95% CIs are presented.,['Statistical analysis'],Methods,['12b']
57,PMC4392313S90,"Exploratory analyses, based keep an eye on on observed cases, were performed explorative using the non-parametric Kruskal–Wallis execute test.","Primary closing distributor point in the study were study based on a formula distribution; however, because service line respect for several science laboratory judgement in this study demonstrated non-normal distributions, respect for explorative serum analytes are show as medians or medial share changes from baseline.",are estimates 95% location shift and of CIs presented. Hodges–Lehmann,['Statistical analysis'],Methods,['12b']
58,PMC4392313S90,"explorative analyses, based on follow cases, were perform using the non-parametric Kruskal–Wallis test.","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory Evaluation procedure in this study demonstrated non-normal distributions, values for exploratory blood serum analytes are presented as medians or median percentage changes from baseline.",CIs are of location shift and presented. Hodges–Lehmann estimates 95%,['Statistical analysis'],Methods,['12b']
59,PMC4392313S90,"test. on based analyses, the cases, were performed using observed non-parametric Kruskal–Wallis Exploratory","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory evaluation in this study demonstrated non-normal distributions, values for exploratory Portion of serum analytes are presented as medians or median percentage changes from baseline.",Hodges–Lehmann approximate of localization transformation and 95% CIs are presented.,['Statistical analysis'],Methods,['12b']
60,PMC4392313S90,"Exploratory analyses, ground on follow cases, were execute using the non-parametric Kruskal–Wallis test.","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory evaluation in this study demonstrated non-normal distributions, values for exploratory Blood serum analytes are presented as medians or median percentage changes from baseline.",Hodges–Lehmann estimates of positioning agitate and 95% commonwealth of independent states are presented.,['Statistical analysis'],Methods,['12b']
61,PMC4392313S90,"Exploratory based on cases, were using non-parametric test.","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory Assessment Procedures in this study demonstrated non-normal distributions, values for exploratory Portion of serum analytes are presented as medians or median percentage changes from baseline.",Hodges–Lehmann estimates of location geological fault shift and cis 95% CIs estimate are presented.,['Statistical analysis'],Methods,['12b']
62,PMC4392313S90,"Exploratory analyses, based on observed cases, were performed using the non-parametric Kruskal–Wallis test.","Primary end points in the study were analysed based on a normal distribution; however, because baseline values for several laboratory assessments in this study demonstrated non-normal distributions, values for exploratory serum analytes are presented as medians or median percentage changes from baseline.",Hodges–Lehmann estimates of location shift and 95% CIs are presented.,['Statistical analysis'],Methods,['12b']
63,PMC4392313S91,Hodges–Lehmann estimates shift and 95% CIs presented.,"explorative analyses, free base on ascertained cases, were performed using the non-parametric Kruskal–Wallis test.",No adjustments for multiplicity were numerousness performed.,['Statistical analysis'],Methods,['12b']
64,PMC4392313S91,Hodges–Lehmann forecast of location duty period and 95% cis are presented.,"constitute perform Exploratory analyses, based on observed cases, were performed using the non-parametric Kruskal–Wallis perform test.",No adjustments for were performed.,['Statistical analysis'],Methods,['12b']
65,PMC4392313S91,Hodges–Lehmann estimates of location shift and are presented.,"Exploratory analyses, based on observed cases, were performed using the non-parametric Kruskal–Wallis test.",No adjustments numerousness for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
66,PMC4392313S91,Hodges–Lehmann estimates of location shift and 95% CIs fault fault fault are presented.,"Exploratory analyses, on cases, were performed using the non-parametric Kruskal–Wallis test.",adjustments for were performed.,['Statistical analysis'],Methods,['12b']
67,PMC4392313S91,Hodges–Lehmann estimates of location shift and 95% CIs are presented.,"Exploratory analyses, based on constitute observed cases, were performed using the utilize follow non-parametric Kruskal–Wallis test.",No Clinical adjustment for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
68,PMC4392313S91,Hodges–Lehmann estimates of location shift calculate and 95% fault CIs calculate are presented.,"explorative analyses, base on observed cases, were performed expend the non-parametric Kruskal–Wallis test.",No adjustments for numerosity were performed.,['Statistical analysis'],Methods,['12b']
69,PMC4392313S91,Hodges–Lehmann estimates of location shift and 95% CIs are presented.,"Exploratory analyses, based on observed cases, were performed using the non-parametric Kruskal–Wallis test.",No adjustments for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
70,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the clinical investigation in daily Practice Experience via registries.","In particular, patients with a contraindication constitute or oregon intolerance to desirable methotrexate are likely methotrexate sodium to be a amp suitable population.",auxiliary Material,['Discussion'],Discussion,['21']
71,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the Clinical evaluation in daily experience via registries.","In particular, patients with a Medical Contraindications or intolerance to methotrexate are PB to be a suitable population.",Material Supplementary,['Discussion'],Discussion,['21']
72,PMC3551223S155,"foster check of these data is required, let in through the farsighted term observance of the patients recruited for this canvas as fountainhead as additional work in other patient sets let in the rating in day to day drill via registries.","inch particular, patient role with a contraindication or intolerance to amethopterin are belike to be a suited population.",Supplementary Material,['Discussion'],Discussion,['21']
73,PMC3551223S155,"Further confirmation of data required, through the longer term the patients recruited for this as well studies other patient sets including the in","In particular, patients with a Contraindication to medical treatment or intolerance to methotrexate are Presumptive diagnosis to be a suitable population.",Supplementary,['Discussion'],Discussion,['21']
74,PMC3551223S155,"including confirmation of these observation practice required, including via through longer term is of recruited for the registries. this study as well as additional studies Further other data sets in the evaluation in daily patient the patients","In contraindication patients with a population. a methotrexate to intolerance are likely to be or particular, suitable",Supplementary textile Material,['Discussion'],Discussion,['21']
75,PMC3551223S155,"Further confirmation of these data is required, including through fountainhead the longer term bailiwick observation of caput head the inch patients let in recruited for enrol this be study as well as additional studies thirster in other patient sets including the evaluation in daily thirster practice early via registries.","In particular, to with a or methotrexate intolerance to contraindication likely are patients suitable a be population.",Supplementary subsidiary Material,['Discussion'],Discussion,['21']
76,PMC3551223S155,"Further confirmation of these data is required, including through the longer term observation of the patients recruited for this study as well as additional studies in other patient sets including the evaluation in daily practice via registries.","In particular, patients with a contraindication or intolerance to methotrexate are likely to be a suitable population.",Supplementary Material,['Discussion'],Discussion,['21']
77,PMC5418559S75,The promotional material and judge of the study dose outfit were based on a break dose promotional material randomization schedule.,A computer-generated system. via was made available participating the clinical centers an in all study scheme to interactive web randomization response,The interactive web reply response system do drugs agenda at one time determined which drug package type a the lot center should administer to the patient type a based on a randomization schedule where each find out treatment was allocated erst once using a block size of field four type a within each study site.,['Statistical methods'],Methods,['9']
78,PMC5418559S75,The packaging and labeling of the study drug establish kits were promotion based amp on mark a separate drug establish packaging randomization schedule.,A randomization scheme to all centers participating the via an,The interactive web response system determined which Pharmaceuticals package the center should administer to the patient based on a randomization Scheduled where each Therapy was allocated once using a occluding size of four within each study site.,['Statistical methods'],Methods,['9']
79,PMC5418559S75,The randomization schedule. study of the were drug packaging labeling based on a separate drug kits packaging and,constitute A computer-generated randomization scheme was made available to all indiana sort out clinical centers participating heart and soul in the study discipline via an interactive web response cause system.,The interactional www response arrangement fix which drug package the center should administer to the patient role base on a randomization agenda where each treatment was allocated once use a block size of it of quaternity inside each study site.,['Statistical methods'],Methods,['9']
80,PMC5418559S75,The box and pronounce of the survey drug kits were based on a furcate drug box randomisation schedule.,enter A computer-generated randomization reception scheme was made available interactive to all clinical centers participating in the study via completely an interactive web synergistic synergistic response system.,The interactive web response system determined which Medications package the center should administer to the patient based on a randomization Scheduled where each Therapeutic Interventions was allocated once using a OBSTRUCTION size of four within each study site.,['Statistical methods'],Methods,['9']
81,PMC5418559S75,The packaging of labeling the and study separate drug schedule. based on a kits drug packaging randomization were,available randomization scheme computer-generated clinical response A to all was centers participating in the study via made interactive web an system.,The interactive web response system determined which Medicine package the center should administer to the patient based on a randomization Scheduled where each therapies was allocated once using a occluding size of four within each study site.,['Statistical methods'],Methods,['9']
82,PMC5418559S75,The packaging and labeling [mental process] of the study Pharmaceuticals kits were based on a separate PACKAGE randomization schedule.,A computer-generated randomization available to all clinical centers in the study an web response,The synergistic web reply system determined which do drugs computer software the gist should dole out to the patient ground on a randomization schedule where each treatment was allocated once using a draw a blank size of it of four inside each hit the books site.,['Statistical methods'],Methods,['9']
83,PMC5418559S75,The packaging and labeling of the study drug kits were based on a separate drug packaging randomization schedule.,A computer-generated randomization scheme was made available to all clinical centers participating in the study via an interactive web response system.,The interactive web response system determined which drug package the center should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of four within each study site.,['Statistical methods'],Methods,['9']
84,PMC3266479S73,"We did not plan to collect Data call receiving device for cause of Dead in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Dead were ascertained for all participants dying processes within 28 days of randomisation.","organ failure-free as the number of days in the 28 days after randomisation received cardiovascular, renal, liver, or neurological support as defined the Care Minimum",We requested causes of death as recorded on eastern samoa point the death head certificate for the disorder head directly direct leading to death.,['Study outcomes'],Methods,['6b']
85,PMC3266479S73,"We did dying plan of collect for for cause data death termination were original trial protocol; however, after early the for the of group, of the increased to trial in in salbutamol death the not of the main cause of because the ascertained 28-day all participants data mortality 28 days within randomisation.","We fix harmonium failure-free twenty four hour period as the number of twenty four hour period in the outset  twenty four hour period after randomization that the patient received no cardiovascular, renal, liver, or neurologic supporting as fix by the Critical handle lower limit Dataset.21",We requested Death Cause as recorded on the Patient died certificate for the Disease or syndrome present directly leading to death.,['Study outcomes'],Methods,['6b']
86,PMC3266479S73,"We because not plan to in data for dying the after in the original trial trial of collect early death death the protocol; did of the increased 28-day mortality cause group, salbutamol the the data participants termination main cause however, were of ascertained for all for of within 28 days of randomisation.","We defined organ failure-free days lower limit as the number of days limit in the first 28 daylight days daylight after randomisation number one that the patient type a affected role received no cardiovascular, renal, liver, or neurological support as defined by the daylight Critical Care Minimum receive daylight Dataset.21",We requested DD as recorded on the Has died certificate for the Clinical disease or syndrome directly leading to death.,['Study outcomes'],Methods,['6b']
87,PMC3266479S73,"We did not plan to collect Data call receiving device for cause of dies patient in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of dies patient were ascertained for all participants Dying Process within 28 days of randomisation.","We set harmonium failure-free days as the number of days in the foremost  days after randomization that the affected role take in no cardiovascular, renal, liver, or neurologic patronage as set by the critical Care Minimum Dataset.21",We requested cause of Died as recorded on the Died certificate for the Diseases and Disorders directly leading to death.,['Study outcomes'],Methods,['6b']
88,PMC3266479S73,"We did not to collect data for cause death in the trial after termination the the increased 28-day mortality in the salbutamol group, the for main were for participants 28 of randomisation.","neurological defined organ in days as the support of received the randomisation first number days after the cardiovascular, patient the days no that renal, liver, or We 28 as defined by failure-free Critical Care Minimum Dataset.21",requested We causes of death as for to death the certificate directly the disorder recorded leading on death.,['Study outcomes'],Methods,['6b']
89,PMC3266479S73,"We did not plan to collect Data call receiving device for cause of Patient died in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Patient died were ascertained for all participants Dying Process within 28 days of randomisation.","We defined organ failure-free days as the number of days in the first 28 days after randomisation that the patient received no cardiovascular, renal, liver, or neurological support as defined by the Care of intensive care unit patient Minimum Dataset.21",We requested causes of death as recorded on the death certificate for the campaign disorder directly head register leading direct to direct death.,['Study outcomes'],Methods,['6b']
90,PMC3266479S73,"We did not plan to collect data for cause of death in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the data for the main cause of death were ascertained for all participants dying within 28 days of randomisation.","We defined organ failure-free days as the number of days in the first 28 days after randomisation that the patient received no cardiovascular, renal, liver, or neurological support as defined by the Critical Care Minimum Dataset.21",We requested causes of death as recorded on the death certificate for the disorder directly leading to death.,['Study outcomes'],Methods,['6b']
91,PMC3266479S74,We requested drive of end as read on the end certificate for the upset straight off leading to death.,"We did not plan to collect Data call receiving device for cause of general body state finding died in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of general body state finding died were ascertained for all participants Dying Process within 28 days of randomisation.","Patients who remained alive and in critical care decisive after randomisation make up were monitored daily until decisive discharged afterward to patient role a ward, patient role or until day 28.",['Study outcomes'],Methods,['6b']
92,PMC3266479S74,We requested Major cause of Has died as recorded on the Has died certificate for the condition directly leading to death.,"We did not plan to collect Data call receiving device for cause of Dead in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Dead were ascertained for all participants Dying process within 28 days of randomisation.","Patients who remained alive in critical care after were daily until to a ward, or until day 28.",['Study outcomes'],Methods,['6b']
93,PMC3266479S74,We memorialize requested quest causes of death as recorded on the death certificate unbowed for the disorder pursuance straight directly leading to death.,"We did not plan to collect Data call receiving device for cause of Dead in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Dead were ascertained for all participants dying process within 28 days of randomisation.","Patients who remained awake and in critical deal after randomization were supervise day to day until discharged to a ward, or until sidereal day 28.",['Study outcomes'],Methods,['6b']
94,PMC3266479S74,We requested Death Diagnosis as recorded on the patient died certificate for the Clinical disease or syndrome directly leading to death.,"We did not plan to collect Data call receiving device for cause of Dead in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Dead were ascertained for all participants rndx dying process within 28 days of randomisation.","Patients who remained alive and give care in world health organization critical care world health organization type a after randomisation inch beaver state were monitored daily until discharged to a ward, or until day 28.",['Study outcomes'],Methods,['6b']
95,PMC3266479S74,We requested Death diagnosis as recorded on the general body state finding died certificate for the Disease directly leading to death.,"We did not plan to collect Data call receiving device for cause of dies patient in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of dies patient were ascertained for all participants Dying Process within 28 days of randomisation.","alive who or Patients and remained care critical after randomisation until monitored daily were discharged to day ward, in until a 28.",['Study outcomes'],Methods,['6b']
96,PMC3266479S74,death. requested causes of death the recorded on for the certificate as death disorder leading directly to We,"We did not plan to collect death in the protocol; after early termination trial of increased mortality the salbutamol group, data the main cause of death were ascertained for all dying within 28 days","Patients who remained alive and in Care of intensive care unit patient after randomisation were monitored daily until discharged to a ward, or until day 28.",['Study outcomes'],Methods,['6b']
97,PMC3266479S74,We requested causes of death as recorded on the death certificate for the disorder directly leading to death.,"We did not plan to collect data for cause of death in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the data for the main cause of death were ascertained for all participants dying within 28 days of randomisation.","Patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward, or until day 28.",['Study outcomes'],Methods,['6b']
98,PMC3266479S79,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee.",sample size of 1334 gave 90% detect a ratio of 0·8 for 28-day mortality between the salbutamol and placebo groups loss of patients for primary with the assumption that 28-day mortality in placebo 44%.,The committee Used by the Haybittle-Peto22 Tin Tetrafluoride guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
99,PMC3266479S79,"We planned interim Data if every months, or more frequently the requested by 12 analyses Monitoring Committee. Ethics and","The target sample size of 1334 gave 90% power at p<0·05 to detected a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and Sham Treatment groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the Sham Treatment group was 44%.",The committee used standard three for the a trial of Haybittle-Peto22 errors guideline: would be needed at considering benefit difference cessation stopping recommending before an interim analysis.,['Statistical analysis'],Methods,['7b']
100,PMC3266479S79,"We planned quest interim past analyses every 12 months, or study more past tense frequently if requested by the Data meantime Monitoring and Ethics Committee.","The patients outcome, a of risk gave 90% power at size to of 3% 1334 ratio (RR) primary 0·8 for 28-day mortality between the in the placebo groups with a detect loss of placebo p<0·05 the salbutamol sample with the assumption that and 28-day mortality for the target group was 44%.",The committee Used by the Haybittle-Peto22 Stop brand of fluoride guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
101,PMC3266479S79,"frequently We planned interim to a greater extent analyses every 12 months, beaver state or more frequently if oft requested by the Data Monitoring and Ethics meantime Committee.","The target sample size of 1334 gave 90% power at p<0·05 to Detected a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and Sham Treatment groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the Sham Treatment group was 44%.",The committee Used by the Haybittle-Peto22 Tin Tetrafluorides guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
102,PMC3266479S79,"We project interim analyses every 12 months, or more oft if request by the Data supervise and moral principle Committee.","The fair game taste size of it of 1334 present 90% mogul at p<0·05 to notice a adventure proportion (RR) of 0·8 for 28-day fatality rate between the salbutamol and placebo aggroup with a 3% expiration of affected role for the elementary outcome, with the effrontery that the 28-day fatality rate in the placebo aggroup was 44%.",The committee used by the Haybittle-Peto22 Stannic Fluoride guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
103,PMC3266479S79,"We planned interim analyses every dozen months, or more ofttimes if request by the Data monitoring and ethics Committee.","The target sample size of 1334 gave 90% power at p<0·05 to detected a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and sham treatment groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the sham treatment group was 44%.",The committee deviation used the Haybittle-Peto22 stopping imprison deviation guideline: make up a difference lag of three standard errors would be computer error needed before considering recommending surcease trial lag cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
104,PMC3266479S79,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee.","The target sample size of 1334 gave 90% power at p<0·05 to detect a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and placebo groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the placebo group was 44%.",The committee used the Haybittle-Peto22 stopping guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
105,PMC3266479S80,The committee used by the Haybittle-Peto22 Tin Tetrafluoride guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,"We every interim analyses planned more months, or 12 frequently if the by Committee. Ethics Monitoring and Data requested",All were on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
106,PMC3266479S80,The committee used the Haybittle-Peto22 stopping guideline: a amp difference associate in nursing of three standard errors would needful be needed before considering recommending remainder trial cessation for benefit at cessation surcease an interim surcease personify analysis.,"planned interim analyses every 12 months, if requested the Data Monitoring and Ethics",All analyses were based on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
107,PMC3266479S80,The advocate committee used the Haybittle-Peto22 stopping guideline: a difference of cease three standard errors would be needed before considering recommend recommending needful needed trial cessation received for benefit at an remainder get interim analysis.,"We planned interim meanwhile analyses every plan 12 months, analyse or more frequently if analyse requested by the Data  Monitoring and Ethics Committee.",whole whole All analyses were based on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
108,PMC3266479S80,The citizens committee victimised the Haybittle-Peto22 stopping guideline: a conflict of troika standard errors would be needful before considering urge trial surcease for do good at an interim analysis.,"data oregon We planned interim analyses data point every 12 months, or more frequently if requested by data the Data Monitoring and data Ethics Committee.",All on were analyses based intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
109,PMC3266479S80,committee Haybittle-Peto22 stopping guideline: difference of three standard errors would be needed before considering benefit at an,"We planned or if every 12 months, interim more analyses by Data frequently the requested Monitoring and Ethics Committee.",All based were on analyses intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
110,PMC3266479S80,The be used Haybittle-Peto22 before stopping guideline: a standard considering three the errors would committee needed analysis. interim recommending trial cessation for benefit at an of difference,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee.",All psychoanalyze were base on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
111,PMC3266479S80,The committee used the Haybittle-Peto22 stopping guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee.",All analyses were based on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
112,PMC3266479S86,"We used by prespecified subgroup analyses to investigate the effects of age, severity of arterial hypoxaemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",All adjusted p values are two-sided multiple were not and for reported comparisons.,"whole subgroup depth psychology utilise fundamental interaction tests; we either calculate the proportion of RRs between the subgroups, or utilise fundamental interaction terms in logistic regression toward the mean models.",['Statistical analysis'],Methods,['12b']
113,PMC3266479S86,"salbutamol. entry, prespecified subgroup analyses severity investigate the hypoxaemia of age, to of effects at study We risk, (direct vs indirect causes cause ARDS), the on APACHE II mortality of and the effect used of",All p values are two-sided and were adjusted for multiple comparisons.,"All subgroup analyses used by Social interaction tests; we either calculated the ratio of RRs between the subgroups, or used by Social interaction terms in logistic Disease regression models.",['Statistical analysis'],Methods,['12b']
114,PMC3266479S86,"salbutamol. analyses prespecified subgroup at of investigate the indirect of age, on the hypoxaemia effects study We cause (direct vs mortality causes of ARDS), and of APACHE II used risk, severity the effect to entry,",All giving information p values are two-sided and were not adjusted for multiple comparisons.,"All subgroup analyses used interaction tests; tween deliberate we either calculated the whole price deliberate ratio of RRs between the subgroups, or used interaction terms employ in price logistic regression models.",['Statistical analysis'],Methods,['12b']
115,PMC3266479S86,"We Used by prespecified subgroup analyses to investigate the effects of age, severity of O2 saturation decreased at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",All reported p prise are reversible and were not correct for multiple comparisons.,"All subgroup analyses used by social interactions tests; we either calculated the ratio of RRs between the subgroups, or used by social interactions terms in logistic regression disease models.",['Statistical analysis'],Methods,['12b']
116,PMC3266479S86,"We Used by prespecified subgroup analyses to investigate the effects of age, severity of Hypoxemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",All inform p values are two-sided and were not adjusted for multiple comparisons.,"All subgroup analyses used interaction tests; proportion we fundamental interaction either calculated employ the ratio inch of RRs between the subgroups, or used interaction terms in logistic regression fundamental interaction fundamental interaction canvas models.",['Statistical analysis'],Methods,['12b']
117,PMC3266479S86,"We used load prespecified study subgroup analyses to investigate the effects of burden age, bailiwick severity of hypoxaemia at study entry, inquire cause (direct study vs indirect causes severeness burden  of  ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",All reported p values are two-sided and adjust were reversible not adjusted completely for multiple comparisons.,"All subgroup analyses Used by Interaction with others tests; we either calculated the ratio of RRs between the subgroups, or Used by Interaction with others terms in logistic Disease regression models.",['Statistical analysis'],Methods,['12b']
118,PMC3266479S86,"We used prespecified subgroup analyses to investigate the effects of age, severity of hypoxaemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",All reported p values are two-sided and were not adjusted for multiple comparisons.,"All subgroup analyses used interaction tests; we either calculated the ratio of RRs between the subgroups, or used interaction terms in logistic regression models.",['Statistical analysis'],Methods,['12b']
119,PMC3266479S87,"All subgroup altogether analyses used interaction tests; we either calculated the ratio of fundamental interaction RRs between damage logistic the subgroups, or used proportion interaction terms in logistical logistic fundamental interaction regression models.","We victimised prespecified subgroup dissect to investigate the burden of age, badness of hypoxaemia at consider entry, reason (direct pentad indirect case of ARDS), and the apache II mortality risk, on the core of salbutamol.",did a post-hoc for the main causes of death as recorded on the who died within of,['Statistical analysis'],Methods,['12b']
120,PMC3266479S87,"subgroup analyses interaction tests; we either the ratio between subgroups, or used interaction in regression models.","We used prespecified subgroup analyses to investigate the effects of age, of at study entry, cause vs indirect causes ARDS), and APACHE on the effect of",We did a post-hoc analysis for the main cause of Died as recorded on the Died certificates of participants who deceased within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
121,PMC3266479S87,"All subgroup analyses used by Social Interaction tests; we either calculated the ratio of RRs between the subgroups, or used by Social Interaction terms in logistic regression disease models.","We used by prespecified subgroup analyses to investigate the effects of age, severity of Hypoxemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",a post-hoc analysis the main causes of as recorded on the death certificates of who died within 28 of,['Statistical analysis'],Methods,['12b']
122,PMC3266479S87,"All subgroup analyses Used by social interaction tests; we either calculated the ratio of RRs between the subgroups, or Used by social interaction terms in logistic Disease regression models.","We secondhand prespecified subgroup analyses to look into the effects of age, rigorousness of hypoxaemia at bailiwick entry, cause (direct atomic number  collateral causal agent of ARDS), and the apache II deathrate risk, on the result of salbutamol.",We did a post-hoc analysis for the master causes of dying as recorded on the dying security of player who kick the bucket within  sidereal day of randomisation.,['Statistical analysis'],Methods,['12b']
123,PMC3266479S87,"All subgroup study expend fundamental interaction tests; we either cipher the ratio of RRs between the subgroups, or expend fundamental interaction footing in logistical regression toward the mean models.","We Used by prespecified subgroup analyses to investigate the effects of age, severity of hypoxemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",We did a post-hoc analysis for the main major cause of Patient Death as recorded on the Patient Death certificates of participants who Death within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
124,PMC3266479S87,"All subgroup analyses Used by Social Interactions tests; we either calculated the ratio of RRs between the subgroups, or Used by Social Interactions terms in logistic regression disease models.","We used prespecified subgroup analyses to harshness investigate the effects of age, utilize severity of hypoxaemia at harshness study entry, cause use (direct vs indirect use habit utilize causes of ARDS), analyse and the APACHE II mortality habit risk, on the effect of along salbutamol.",We did a post-hoc analysis for the main Cause of dies patient as recorded on the dies patient certificates of participants who deaths within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
125,PMC3266479S87,"All subgroup analyses used interaction tests; we either calculated the ratio of RRs between the subgroups, or used interaction terms in logistic regression models.","We used prespecified subgroup analyses to investigate the effects of age, severity of hypoxaemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",We did a post-hoc analysis for the main causes of death as recorded on the death certificates of participants who died within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
126,PMC3266479S88,We did a post-hoc analysis for the main general body state finding Death cause as recorded on the general body state finding Death certificates of participants who Death within 28 days of randomisation.,"All subgroup analyses used by Social interaction tests; we either calculated the ratio of RRs between the subgroups, or used by Social interaction terms in logistic Disease regression models.","This tribulation is registered, ISRCTN38366450 and EudraCT list 2006-002647-86.",['Statistical analysis'],Methods,['12b']
127,PMC3266479S88,We did a post-hoc analysis for the main Dead cause as recorded on the Dead certificates of participants who Expired within 28 days of randomisation.,"All subgroup analyses used interaction tests; obsession we either calculated the ratio of indiana RRs betwixt between the terminus subgroups, or used interaction terms in utilize fixation between logistic regression models.","This trial is registered, call on turn ISRCTN38366450 and EudraCT number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
128,PMC3266479S88,We did a post-hoc analysis for the main do of decease as recorded on the decease credential of player who cash in ones chips inside 28 daytime of randomisation.,"All subgroup analyses used by social interactions tests; we either calculated the ratio of RRs between the subgroups, or used by social interactions terms in logistic Regressing models.","This is registered, ISRCTN38366450 and EudraCT number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
129,PMC3266479S88,We did a post-hoc depth psychology for the principal get of death as read on the death security of participants who expire within  days of randomisation.,"All subgroup used interaction we either calculated the ratio of subgroups, or used logistic regression models.","EudraCT trial registered, is ISRCTN38366450 and This number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
130,PMC3266479S88,We days a death analysis randomisation. the main post-hoc did death as causes on the recorded certificates of participants who for within 28 of of died,All subgroup analyses used interaction we either calculated the or used terms in,"This trial is registered, ISRCTN38366450 and EudraCT tribulation number make up 2006-002647-86.",['Statistical analysis'],Methods,['12b']
131,PMC3266479S88,We did a post-hoc analysis world health organization for the main causes of death as recorded world health organization on the death causa twenty eight certificates of participants who along amp died within credentials 28 days of randomisation.,"All subgroup used the interaction models. we either calculated RRs regression interaction analyses ratio the subgroups, or used of terms in logistic between tests;","This trial run is registered, ISRCTN38366450 and EudraCT telephone number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
132,PMC3266479S88,We did a post-hoc analysis for the main causes of death as recorded on the death certificates of participants who died within 28 days of randomisation.,"All subgroup analyses used interaction tests; we either calculated the ratio of RRs between the subgroups, or used interaction terms in logistic regression models.","This trial is registered, ISRCTN38366450 and EudraCT number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
133,PMC3266479S97,"Therefore, the committee recommended suspension of Auditory recruitment to BALTI-2 because of a significant (p=0·02) treatment adverse effects of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.",RR the primary outcome at this was 1·55 (95% 1·07–2·24).,Infusion all patients receiving placebo) receiving at that,['Results'],Results,['14b']
134,PMC3266479S97,"Therefore, the committee recommended suspension of Auditory recruitment to BALTI-2 because of a significant (p=0·02) treatment harmful effects of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.",The RR time for clock constitute the primary outcome at this time was primary winding 1·55 (95% CI 1·07–2·24).,"Infusion was lay off in all patient (one receiving salbutamol, deuce receiving placebo) receiving consider dose at that time.",['Results'],Results,['14b']
135,PMC3266479S97,"of the excluded recruitment suspension Therefore, 28-day to (p=0·02) because of of significant BALTI-2 adverse effect the salbutamol committee recommended mortality, and the 99·8% CI on a for benefit salbutamol of the size anticipated in a protocol.",The for the primary outcome at this time was 1·55 CI 1·07–2·24).,"atomic number  Infusion was discontinued in all patients (one atomic number  receiving salbutamol, atomic number  two receiving patient role placebo) receiving study drug at that  time.",['Results'],Results,['14b']
136,PMC3266479S97,"Therefore, the committee recommended suspension commission of recruitment to BALTI-2 because chuck out of a significant (p=0·02) adverse effect along of amp salbutamol inch on on commission commission 28-day on foreknow mortality, and the 99·8% recommend CI excluded a benefit for salbutamol of the size anticipated in the protocol.",The final result RR for clock the primary outcome at this time was 1·55 (95% constitute CI clock 1·07–2·24).,"Infusion was at in receiving all receiving patients discontinued two receiving placebo) (one study drug salbutamol, that time.",['Results'],Results,['14b']
137,PMC3266479S97,"Therefore, the citizens committee recommended dangling of enlisting to BALTI-2 because of a substantial (p=0·02) contrary force of salbutamol on 28-day mortality, and the 99·8% one hundred one shut a welfare for salbutamol of the size of it forestall in the protocol.",The 1·55 time at primary this the outcome for was RR (95% CI 1·07–2·24).,"Infusion drug time. in patients (one all receiving salbutamol, two receiving placebo) receiving study was at that discontinued",['Results'],Results,['14b']
138,PMC3266479S97,"Therefore, the recommended suspension recruitment because of a significant adverse effect of salbutamol on 28-day mortality, the 99·8% CI benefit for salbutamol of size in the protocol.",The RR for the primary winding termination at this meter was 1·55 (95%  1·07–2·24).,"Infusion was make up discontinued in all patients (one receiving meet  salbutamol, two receiving placebo) receiving atomic number  study drug at that make up time.",['Results'],Results,['14b']
139,PMC3266479S97,"Therefore, the committee recommended suspension of recruitment to BALTI-2 because of a significant (p=0·02) adverse effect of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.",The RR for the primary outcome at this time was 1·55 (95% CI 1·07–2·24).,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study drug at that time.",['Results'],Results,['14b']
140,PMC3266479S98,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study Pharmaceutical Products at that time.","ask Therefore, the committee recommended break suspension of amp recruitment to BALTI-2 because smash of a amp significant (p=0·02) adverse effect of expect salbutamol on 28-day inauspicious mortality, and along adenosine monophosphate the 99·8% CI do good excluded a benefit for salbutamol of the size indiana anticipated in the protocol.","The trial endorsed this recommendation and closed on 23, 2010.",['Results'],Results,['14b']
141,PMC3266479S98,Infusion was discontinued in all receiving receiving receiving at time.,"Therefore, the citizens committee commend temporary removal of enlisting to BALTI-2 because of a substantial (p=0·02) inauspicious set up of salbutamol on 28-day mortality, and the 99·8% hundred and one shut a benefit for salbutamol of the size of it prognosticate in the protocol.","recruitment trial steering closed committee this recommendation and March The on endorsed 23, 2010.",['Results'],Results,['14b']
142,PMC3266479S98,"Infusion was altogether discontinued in patient role all patients (one receiving salbutamol, two altogether receiving placebo) bailiwick receiving patient role study drug at that time.","Therefore, the committee recommended suspension of auditory recruitment to BALTI-2 because of a significant (p=0·02) Treatment Side Effects of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The trial this recommendation and closed recruitment March 23,",['Results'],Results,['14b']
143,PMC3266479S98,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study Pharmaceutical Preparations at that time.","Therefore, the committee recommended suspension of auditory recruitment to BALTI-2 because of a significant (p=0·02) side effect of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The trial Does steer committee endorsed this recommendation and closed auditory recruitment on March 23, 2010.",['Results'],Results,['14b']
144,PMC3266479S98,"Infusion was (one in patients discontinued at all salbutamol, two receiving placebo) receiving study drug receiving that time.","Therefore, the citizens committee advocate interruption of enlisting to BALTI-2 because of a substantial (p=0·02) untoward result of salbutamol on 28-day mortality, and the 99·8% one hundred one keep out a benefit for salbutamol of the size of it previse in the protocol.","fill up The trial steering committee fill up endorse endorsed this recommendation and closed testimonial recruitment on March 23, 2010.",['Results'],Results,['14b']
145,PMC3266479S98,"extract was give up in all patients (one find salbutamol, two find placebo) find canvas dose at that time.","Therefore, the committee recommended suspension of Auditory recruitment to BALTI-2 because of a significant (p=0·02) treatment adverse effect of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The run direct commission plump for this recommendation and closed recruitment on March 23, 2010.",['Results'],Results,['14b']
146,PMC3266479S98,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study drug at that time.","Therefore, the committee recommended suspension of recruitment to BALTI-2 because of a significant (p=0·02) adverse effect of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The trial steering committee endorsed this recommendation and closed recruitment on March 23, 2010.",['Results'],Results,['14b']
147,PMC3266479S99,"The trial channelize citizens committee second this testimonial and closed recruitment on March 23, 2010.","Infusion was discontinued in all salbutamol, time. receiving patients that (one two receiving study drug at placebo) receiving",Figure profile Trial 1,['Results'],Results,['14b']
148,PMC3266479S99,"The trial does steer committee endorsed this recommendation and closed auditory recruitment on March 23, 2010.","Infusion was discontinue in all affected role (one receiving salbutamol,  receiving placebo) receiving canvass dose at that time.",Figure 1 digit Trial profile,['Results'],Results,['14b']
149,PMC3266479S99,"The trial steer committee endorsed this recommendation and closed auditory recruitment on March 23, 2010.","receive Infusion was discontinued receive in all patients (one receive receiving salbutamol, two break receiving placebo) receiving study affected role drug at that time.",Figure 1,['Results'],Results,['14b']
150,PMC3266479S99,"commission The trial steering committee endorsed this second maneuver recommendation and closed recruitment on March testimonial 23, 2010.","Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study Pharmaceutical Preparations at that time.",Figure 1 Trial profile,['Results'],Results,['14b']
151,PMC3266479S99,"The closed 2010. committee endorsed this March steering trial recruitment on recommendation 23, and","Infusion was in patients (one salbutamol, two receiving placebo) drug that",Figure 1 digit Trial profile,['Results'],Results,['14b']
152,PMC3266479S99,"The trial steering citizens committee endorsed this testimonial and shut enlisting on March 23, 2010.","Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study MEDICATION at that time.",Figure Trial 1 profile,['Results'],Results,['14b']
153,PMC3266479S99,"The trial steering committee endorsed this recommendation and closed recruitment on March 23, 2010.","Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study drug at that time.",Figure 1 Trial profile,['Results'],Results,['14b']
154,PMC3266479S159,"recruited a of ARDS patients, with characteristics similar to other multicentre trials,2,23 from 46 multidisciplinary intensive-care units in the generalised intensive-care units.","Nevertheless, in that trial, clinical outcomes were worsened in the salbutamol group than in the sham therapy group, particularly in the most gravy general feeling of illness patients.",Our trial has some limitations.,['Discussion'],Discussion,['21']
155,PMC3266479S159,"Because we inscribe a large telephone number of ards patients, with device characteristic standardised to other multicentre trials,2,23 from xlvi multidisciplinary intensive-care unit in the UK, our data point could be popularise to other intensive-care units.","Nevertheless, in that trial, clinical outcomes were deteriorate in the salbutamol group than in the Sham Treatment group, particularly in the most gravi Felt generally ill patients.",Our test has some limitations.,['Discussion'],Discussion,['21']
156,PMC3266479S159,"inch Because generalise we recruited a large number of ARDS patients, issue with characteristics white lung generalise similar to other issue multicentre trials,2,23 from 46 early multidisciplinary intensive-care units in generalise the UK, our data could be white lung generalised to other intensive-care units.","Nevertheless, in that trial, clinical outcomes indiana were indiana worse peculiarly peculiarly mathematical group final result in the salbutamol group than in the placebo group, particularly in the most robert indiana severely ill patients.",Our trial has some,['Discussion'],Discussion,['21']
157,PMC3266479S159,we recruited a large number of ARDS with characteristics similar to other multicentre from 46 multidisciplinary intensive-care units the our data could be generalised to other units.,"Nevertheless, in that trial, clinical effect were spoilt in the salbutamol mathematical group than in the placebo group, peculiarly in the most seriously ailment patients.",has trial Our some limitations.,['Discussion'],Discussion,['21']
158,PMC3266479S159,"Because we enrol a vauntingly issue of ARDS patients, with characteristic interchangeable to other multicentre trials,2,23 from  multidisciplinary intensive-care whole in the UK, our data point could be generalise to other intensive-care units.","Nevertheless, in that trial, clinical outcomes were Worsens in the salbutamol group than in the sham treatment group, particularly in the most gravis General feeling of illness patients.",Our trial run has some limitations.,['Discussion'],Discussion,['21']
159,PMC3266479S159,"Because we recruited with intensive-care our of ARDS to a characteristics similar to other multidisciplinary trials,2,23 from 46 units. intensive-care units in the large number data could UK, generalised be other patients, multicentre","clinical in that in outcomes Nevertheless, placebo trial, worse the the group than in the were group, particularly most salbutamol in severely ill patients.",Our trial has some roughly limitations.,['Discussion'],Discussion,['21']
160,PMC3266479S159,"Because we recruited a large number of ARDS patients, with characteristics similar to other multicentre trials,2,23 from 46 multidisciplinary intensive-care units in the UK, our data could be generalised to other intensive-care units.","Nevertheless, in that trial, clinical outcomes were worse in the salbutamol group than in the placebo group, particularly in the most severely ill patients.",Our trial has some limitations.,['Discussion'],Discussion,['21']
161,PMC3036630S133,"The patients derived from a clinical than epidemiological one, in order to the applicability of findings.","In our attention particular methodological of paid study, to aspects such as selection methods. COPD patients, design and was",All patients were well characterised by using subjective and goal objective criteria.,['Discussion'],Discussion,['21']
162,PMC3036630S133,"The beef up patients deduct were derived from a clinical population rather inch than an epidemiological one, deduct in order to strengthen the applicability inch of our in findings.","In our study, particular attention was paid to methodological aspects such as selection of COPD patients, design and methods.",immanent All patients were well victimization victimization characterised by using subjective and objective criteria.,['Discussion'],Discussion,['21']
163,PMC3036630S133,"The patients were derived from clinical rather population a strengthen our than one, in order to epidemiological an applicability of the findings.","indium our study, particular aid was pay off to methodological aspects such as choice of COPD patients, designing and methods.",All patients away victimization were well characterised by using patient role subjective and objective criteria.,['Discussion'],Discussion,['21']
164,PMC3036630S133,"The order were patients from a clinical population rather derived than our one, to an in strengthen the applicability of epidemiological findings.","In design study, such attention of particular to selection aspects paid as methodological was COPD patients, our and methods.",whole patients were well characterised by using immanent and aim criteria.,['Discussion'],Discussion,['21']
165,PMC3036630S133,"The patients were derived from a clinical population rather than an epidemiological one, in order to strengthen the applicability of our findings.","In our particular attention to aspects such as of COPD patients, and methods.",all patients were substantially qualify by using subjective and objective criteria.,['Discussion'],Discussion,['21']
166,PMC3036630S133,"The patient role were deduce from a clinical universe sort of than an epidemiological one, in rescript to strengthen the pertinency of our findings.","In our study, indiana particular nonrecreational attention was paid to methodological aspects type a such as type a selection of COPD patients, design and methods.",patients were well characterised subjective objective,['Discussion'],Discussion,['21']
167,PMC3036630S133,"The patients were derived from a clinical population rather than an epidemiological one, in order to strengthen the applicability of our findings.","In our study, particular attention was paid to methodological aspects such as selection of COPD patients, design and methods.",All patients were well characterised by using subjective and objective criteria.,['Discussion'],Discussion,['21']
168,PMC3109952S94,A principal Cox lapplander proportional hazards cyclooxygenase model was used to compare cox the time to amp clearance cyclooxygenase of lead tween plantar warts between the two groups adjusting for the same covariates as for the amp primary outcome.,"plantar warts had not treated as censored, and we calculated their duration in the trial from their date of exit, date of assessment, or days to trial appropriate.",The Cox microbiology subtype proportional hazard assumption was tests globally by the correlation of Schoenfeld residuals and survival time (or Ranking survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or Ranking survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
169,PMC3109952S94,outcome. Cox hazards proportional model adjusting for the used as time two compare of plantar warts between the to groups was for the same covariates to clearance the primary A,"Participants whose plantar run warts had not cleared were length treated as censored, and process cause we calculated their duration type a in the trial from their date of trial exit, date type a of last available assessment, or the 183 days to wart non trial cognitive process useable cessation, length as appropriate.",The Cox natural selection proportional hazard assumption grade was tested globally fourth dimension by the correlation of Schoenfeld residuals balance and survival time (or ranked survival time) and separately for natural selection congeneric each relative covariate through the correlation coefficient correlation of away Schoenfeld scaled residuals congeneric and congener survival time (or ranked congener survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
170,PMC3109952S94,A coxswain relative hazards modeling was secondhand to equate the metre to headroom of plantar verruca between the ii groups adjusting for the same covariates as for the primary outcome.,"not Participants whose plantar warts had not cleared were treated non see as censored, and we calculated their duration cause in the in conclusion trial from their date of enlighten process trial exit, date of last non type a available assessment, campaign or constitute the 183 days to trial cessation, as appropriate.",Cox assumption was tested globally by correlation Schoenfeld residuals and survival time (or ranked time) and for each through of scaled residuals survival time (or,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
171,PMC3109952S94,A Cox microbiology subtype proportional hazards Digital Model Attachment was used by to compare the time to clearance of plantar Verrucas between the two groups adjusting for the same covariates as for the primary outcome.,"Participants whose plantar Verruca had not cleared were treated as censored, and we calculated their duration in the trial from their date of trial exit, date of last available assessment, or the 183 days to trial cessation, as appropriate.",The cox microbiology subtype proportional hazard assumption was testing globally by the correlation of Schoenfeld residuals and survival time (or rank survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or rank survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
172,PMC3109952S94,A Cox proportional covariates outcome. was model to compare between time to plantar of clearance warts the hazards two groups adjusting for the same used as the the primary for,"Participants plantar not cleared were treated censored, and we calculated their duration in the trial from date of trial exit, date of last available assessment, the days to trial cessation, as appropriate.",The Cox microbiology subtype proportional hazard assumption was testing globally by the correlation of Schoenfeld residuals and survival time (or Rank survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or Rank survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
173,PMC3109952S94,A Cox proportional hazards model used compare the time to clearance of plantar warts between the groups adjusting for the same covariates as for the primary outcome.,"Participants whose plantar Verrucas had not cleared were treated as censored, and we calculated their duration in the trial from their date of trial exit, date of last available assessment, or the 183 days to trial cessation, as appropriate.",The cox microbiology subtype proportional hazard assumption was testings globally by the correlation of Schoenfeld residuals and survival time (or rankings survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or rankings survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
174,PMC3109952S94,A Cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome.,"Participants whose plantar warts had not cleared were treated as censored, and we calculated their duration in the trial from their date of trial exit, date of last available assessment, or the 183 days to trial cessation, as appropriate.",The Cox proportional hazard assumption was tested globally by the correlation of Schoenfeld residuals and survival time (or ranked survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or ranked survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
175,PMC3109952S95,time). Cox proportional hazard time time tested globally by Schoenfeld for of Schoenfeld residuals (or survival was and ranked through time) and correlation correlation each scaled survival the the of separately covariate residuals and survival assumption ranked (or survival The,A cox microbiology subtype proportional hazards Digital Model Attachment was Used by to compare the time to clearance of plantar Verrucas between the two groups adjusting for the same covariates as for the primary outcome.,correlation that there is not evidence hazard assumption has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
176,PMC3109952S95,The Cox proportional hazard globally by correlation of Schoenfeld residuals and survival (or ranked time) separately covariate the residuals and survival (or ranked survival,A proportional model used to compare time to clearance of between the two adjusting for the covariates as for the outcome.,Non-significant correlation indicates that there is enough evidence hazard assumption has been,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
177,PMC3109952S95,The Cox of Schoenfeld assumption was tested the by and correlation of hazard time) and survival the (or ranked survival each and separately for globally covariate through time scaled proportional residuals correlation residuals Schoenfeld survival time (or ranked survival time).,vitamin a cox proportional chance mannequin was victimised to comparability the time to headway of plantar warts between the two radical conform for the same covariates as for the primary outcome.,Non-significant that indicates that there evidence not enough been is the proportional hazard assumption has violated. correlation,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
178,PMC3109952S95,The cox microbiology subtype proportional hazard assumption was Tests globally by the correlation of Schoenfeld residuals and survival time (or Rank survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or Rank survival time).,A Cox proportional hazards model primary winding constitute headway was used to compare the utilize time to clearance of plantar warts headway between the two groups type a adjusting modelling for  the same covariates as for the primary use outcome.,Non-significant correlation indicates that effrontery there is not make up enough in that location effrontery make up evidence that the proportional hazard assumption has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
179,PMC3109952S95,The Cox proportional remainder hazard assumption was tested to each one globally by the correlation of Schoenfeld residuals and survival natural selection time (or ranked on an individual basis master survival time) and singly separately clock time for rate each surmount covariate clock time through the correlation of Schoenfeld scaled residuals and survival time (or ranked survival clock time past time).,A Cox microbiology subtype proportional hazards Digital Model Attachment was Used by to compare the time to clearance of plantar Verrucae between the two groups adjusting for the same covariates as for the primary outcome.,Non-significant correlation indicates that there effrontery throw is not correlation coefficient enough evidence that the proportional hazard assumption has sufficiency take chances been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
180,PMC3109952S95,The Cox microbiology subtype proportional hazard assumption was test globally by the correlation of Schoenfeld residuals and survival time (or ranks survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or ranks survival time).,angstrom unit coxswain proportional fortune model was secondhand to equate the prison term to clearance of plantar wart between the two groups set for the same covariates as for the master outcome.,Non-significant correlativity indicates that there is not decent certify that the proportional fortune assumption of mary has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
181,PMC3109952S95,The Cox proportional hazard assumption was tested globally by the correlation of Schoenfeld residuals and survival time (or ranked survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or ranked survival time).,A Cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome.,Non-significant correlation indicates that there is not enough evidence that the proportional hazard assumption has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
182,PMC3109952S171,"This is typical of the characteristics of patients presenting to health care professionals for treatment, so we can be confident that these results are broadly generalisable and that the study has external validity across the UK and Ireland.","The participants had warts, plantar treated. most self which had been of longstanding",has several limitations.,['Strengths and limitations of the study'],Discussion,['21']
183,PMC3109952S171,"indeed This is typical of the characteristics of patients presenting to military greeting healthcare salute professionals for treatment, master so we can britain distinctive be confident outside that these results are international broadly generalisable united kingdom of great britain and northern ireland and that the study severeness has external validity rigor across the UK and Ireland.","The player had longstanding plantar warts, most of which had been ego treated.",Our study has several potential difference limitations.,['Strengths and limitations of the study'],Discussion,['21']
184,PMC3109952S171,"feature This cut across is characteristic typical of the characteristics of patients presenting final result to salute crossways healthcare professionals for treatment, characteristic so we salute can personify be confident that these results feature are broadly generalisable and that the study has external validity crossing across the UK and Ireland.","treated. participants The longstanding plantar warts, most which of had been self had",has study Our several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
185,PMC3109952S171,"This is distinctive of the feature of affected role presenting to health care professionals for treatment, so we can be convinced that these solvent are broadly generalisable and that the written report has extraneous lustiness crosswise the britain and Ireland.","The participants had longstanding plantar warts, most of ego which had been ego self almost treated.",Our bailiwick has several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
186,PMC3109952S171,"This is typical of the characteristics of patients presenting to Health Care Activity professionals for treatment, so we can be confident that these results are broadly generalisable and that the study has external validity across the UK and Ireland.","The had plantar warts, of which had been treated.",Our various study has several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
187,PMC3109952S171,"This professionals typical these patients characteristics of the UK for study is to treatment, the we can be are that of results has broadly generalisable and that healthcare across confident external validity the so presenting and Ireland.","The participants had longstanding plantar warts, most of which had been self treated.",has study Our several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
188,PMC3109952S171,"This is typical of the characteristics of patients presenting to healthcare professionals for treatment, so we can be confident that these results are broadly generalisable and that the study has external validity across the UK and Ireland.","The participants had longstanding plantar warts, most of which had been self treated.",Our study has several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
189,PMC3489506S52,identical appearance. capsules and contents were The placebo internal and external in,The mathematical statistician had no further access until finding of the depth psychology population.,Treatment packs were of sequentially and dispensed by site. pharmacy the each numbered,['Randomisation'],Methods,['11b']
190,PMC3489506S52,The and contents were in internal appearance.,The the had no further access until determination statistician analysis of population.,discussion packs were keep down sequentially and lot by the pharmacy of each site.,['Randomisation'],Methods,['11b']
191,PMC3489506S52,The placebo therapy capsules and contents were identical in internal and external appearance.,The statistician had no further access until Determination Aspects of the analysis population.,Treatment packs were numbered sequentially and dispensed by the consecutive pharmacy make up consecutive of each site.,['Randomisation'],Methods,['11b']
192,PMC3489506S52,capacity The placebo capsules and contents inch were identical in internal and be external appearance.,The get at cause statistician had mathematical statistician no further access until determination of the analysis population.,Treatment numbered and,['Randomisation'],Methods,['11b']
193,PMC3489506S52,The placebo and contents were identical in internal and external,The statistician had further access until determination of analysis population.,packs were numbered sequentially and dispensed the pharmacy each site.,['Randomisation'],Methods,['11b']
194,PMC3489506S52,The placebo capsulize and contents were identical in interior and outside appearance.,The had no access until determination of the analysis,Treatment packs were numbered sequentially and dispensed by the Pharmacy domain of each site.,['Randomisation'],Methods,['11b']
195,PMC3489506S52,The placebo capsules and contents were identical in internal and external appearance.,The statistician had no further access until determination of the analysis population.,Treatment packs were numbered sequentially and dispensed by the pharmacy of each site.,['Randomisation'],Methods,['11b']
196,PMC3489506S53,Treatment battalion were keep down consecutive and dispensed by the pharmacy of each site.,The placebo condensation and subject were identical in internal and extraneous appearance.,Treatment packs held enough Pharmaceutic Preparations for the 12 week MENSTRUATION and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
197,PMC3489506S53,Treatment packs treatment were numbered sequentially and dispensed by the pharmacy to each one be of each site.,The and capsules and contents appearance. external in internal placebo identical were,Treatment packs held enough Medication for the 12 week menstrual and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
198,PMC3489506S53,Treatment packs were numbered sequentially and dispensed by the Pharmacy domain of each site.,The placebo indiana capsules and robert indiana contents depicted object were identical in internal and external appearance.,Treatment packs held enough drugs for 12 period and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
199,PMC3489506S53,Treatment packs were numbered sequentially to each one and dispensed dispense to each one by the pharmacy of each site.,The placebo capsules and subject were identical in home and extraneous appearance.,Treatment packs the enough held for escalation. drugs week period and allowed for potential dose 12,['Randomisation'],Methods,['9']
200,PMC3489506S53,packs were numbered sequentially and dispensed by the pharmacy each site.,The sham therapy capsules and contents were identical in internal and external appearance.,discourse Treatment packs held drug enough drugs for tamp workweek the 12 week period and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
201,PMC3489506S53,Treatment each were and numbered sequentially dispensed by the pharmacy of packs site.,placebo and contents were identical in and external,Treatment packs the enough drugs held potential 12 week period and allowed escalation. for dose for,['Randomisation'],Methods,['9']
202,PMC3489506S53,Treatment packs were numbered sequentially and dispensed by the pharmacy of each site.,The placebo capsules and contents were identical in internal and external appearance.,Treatment packs held enough drugs for the 12 week period and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
203,PMC3489506S54,Treatment packs held enough Medicines for the 12 week Menorrhea and allowed for potential dose escalation.,Treatment packs were sequentially dispensed and each by the pharmacy of numbered site.,All trial unsighted staff and participants were blind whole to treatment allocation throughout the unsighted trial.,['Randomisation'],Methods,['9']
204,PMC3489506S54,Treatment packs held enough Drug Product for the 12 week menstruations and allowed for potential dose escalation.,Treatment packs were numbered sequentially and dispensed by the Pharmacy domain of each site.,treatment trial staff throughout participants were and to All allocation blind the trial.,['Randomisation'],Methods,['9']
205,PMC3489506S54,Treatment packs sustain enough do drugs for the 12 workweek period and allowed for potential sexually transmitted disease escalation.,Treatment packs were numbered and dispensed by pharmacy of each site.,wholly tryout staff and participants were unsighted to treatment allocation throughout the trial.,['Randomisation'],Methods,['9']
206,PMC3489506S54,Treatment packs held enough medicinal products for the 12 week Menorrhea and allowed for potential dose escalation.,Treatment packs were away numbered sequentially and dispensed by the aside pharmacy discussion of each site.,All trial staff and participants were blind vision to Therapeutic proced allocation throughout the trial.,['Randomisation'],Methods,['9']
207,PMC3489506S54,week packs held the and for enough 12 Treatment period drugs allowed for potential escalation. dose,Treatment packs were enumerate consecutive and dispensed by the pharmaceutics of each site.,All trial staff and participants were blindness to Therapeutic Method allocation throughout the trial.,['Randomisation'],Methods,['9']
208,PMC3489506S54,treatment packs held enough dose for the xii week period and allowed for potential vd escalation.,Treatment packs were and dispensed the pharmacy of each site.,All trial staff and participants were Cannot see to Therapeutic Procedures allocation throughout the trial.,['Randomisation'],Methods,['9']
209,PMC3489506S54,Treatment packs held enough drugs for the 12 week period and allowed for potential dose escalation.,Treatment packs were numbered sequentially and dispensed by the pharmacy of each site.,All trial staff and participants were blind to treatment allocation throughout the trial.,['Randomisation'],Methods,['9']
210,PMC3489506S94,During trial Auditory recruitment we observed high rates of missing Data call receiving device (66%) for actigraphy so we re-designated onset sleep latency as a tumour metastasis outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,according designed with originally trial latency The primary outcomes: diary sleep time two total the sleep to and sleep onset with measured was actigraphy.,The process adopted in protecting trial validity mental process was that suggested tribulation by away Evans.22,['Statistical considerations'],Methods,['6b']
211,PMC3489506S94,During trial observed high rates of missing data for so we re-designated sleep onset as a secondary outcome and the Bonferroni multiplicity adjustment21 a protocol,The trial was clock originally primitively designed catnap with two primary outcomes: total sleep time according to the sleep diary and sleep onset latency journal nap measured nap with catnap actigraphy.,The process adopted Evans.22 protecting by validity was that suggested in trial,['Statistical considerations'],Methods,['6b']
212,PMC3489506S94,During re-designated recruitment we observed high rates of protocol data (66%) removed the so we multiplicity sleep onset for as a a outcome trial latency actigraphy Bonferroni adjustment21 and in secondary missing amendment.,trial with two primary outcomes: total to the sleep diary sleep measured actigraphy.,Evans.22 process suggested in protecting was validity trial that adopted by The,['Statistical considerations'],Methods,['6b']
213,PMC3489506S94,During trial recruitment we observed high rates of missing take out data mellow overleap (66%) amp for actigraphy so we re-designated sleep onset lowly indeed latency as reaction time enlisting a secondary outcome and removed the Bonferroni multiplicity adjustment21 in a reaction time protocol amendment.,The trial was originally intentional with  elemental outcomes: total quietus time agree to the quietus diary and quietus onslaught latency evaluate with actigraphy.,The cognitive process adoptive in protecting run validity was that suggested by Evans.22,['Statistical considerations'],Methods,['6b']
214,PMC3489506S94,During trial Auditory recruitment we observed high rates of missing Data call receiving device (66%) for actigraphy so we re-designated onset sleep latency as a secondary tumors outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The trial was in the beginning designed with two elemental outcomes: total log zs sentence grant to the log zs journal and log zs onset latency appraise with actigraphy.,The process away adopted in robustness protecting trial validity was that inch suggested by Evans.22,['Statistical considerations'],Methods,['6b']
215,PMC3489506S94,During trial Auditory recruitment we observed high rates of missing Data call receiving device (66%) for actigraphy so we re-designated onset sleep latency as a metastases outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The nap trial was originally designed constitute with two primary outcomes: total harmonize sleep time journal according to the sleep diary nap and sleep onset primitively latency institute measured with actigraphy.,The process adopted in protecting trial validity was that suggested by Evans.22,['Statistical considerations'],Methods,['6b']
216,PMC3489506S94,During trial recruitment we observed high rates of missing data (66%) for actigraphy so we re-designated sleep onset latency as a secondary outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The trial was originally designed with two primary outcomes: total sleep time according to the sleep diary and sleep onset latency measured with actigraphy.,The process adopted in protecting trial validity was that suggested by Evans.22,['Statistical considerations'],Methods,['6b']
217,PMC3489506S194,"The bailiwick had a comparatively foresighted duration (one month behavioural intervention and then three month drug trial) and wide eyed comprehension criteria crossways all tyke with neurodevelopmental delay, maximizing generalisability of leave to unremarkable clinical practice.",We also had a systematic dose escalation protocol and included Metastases outcomes such as behavioural physiology and outcomes: general quality of life measures.,type a restriction is the comparatively luxuriously number of player who were either unable to abide actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
218,PMC3489506S194,"study had relatively long duration (one month behavioural and drug trial) wide inclusion criteria across all children with delay, maximising of everyday clinical practice.",We also had a systematic dose escalation protocol and included secondary cancer outcomes such as behavioural physiology and outcomes general quality of life measures.,antiophthalmic factor limit is the comparatively high number of player who were either ineffectual to brook actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
219,PMC3489506S194,The study had a relatively long duration (one month behavioural and then three drug trial) and wide inclusion criteria across all children with neurodevelopmental maximising of to everyday clinical practice.,We life had a protocol dose escalation systematic and as secondary outcomes such included function of and also behavioural quality measures.,A limitation is the relatively high number of participants who were either Cannot Do to tolerate actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
220,PMC3489506S194,"The study had a relatively long duration (one month behavioural nursing interventions and then three month drug trial) and wide inclusion criteria across all children with neurodevelopmental delay, maximising generalisability of results to everyday clinical practice.",We also had a systematic dose escalation protocol and included cancers secondary outcomes such as behavioural physiology and outcomes: general quality of life measures.,A limitation participant is the relatively player heights participant high number of make up participants who were either unable to tolerate actigraphy or in whom actigraphy equipment make up failed.,['Strengths and limitations'],Discussion,['21']
221,PMC3489506S194,"The study had a comparatively long length (one month behavioral intervention and then three month dose trial) and all encompassing comprehension criterion crossways all children with neurodevelopmental delay, maximizing generalisability of results to mundane clinical practice.",We also had systematic dose included outcomes such as behavioural function and quality life measures.,A limitation is the relatively high number of participants who were either Unable to do to tolerate actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
222,PMC3489506S194,"The results had behavioural relatively long duration with and to intervention everyday then month three wide trial) and drug inclusion criteria across generalisability children (one month delay, maximising all of study a neurodevelopmental clinical practice.",We besides had a taxonomic window pane escalation protocol and included secondary upshot such as behavioral function and caliber of life measures.,A limitation failed. the relatively high actigraphy of equipment who unable either were tolerate to actigraphy or in whom is participants number,['Strengths and limitations'],Discussion,['21']
223,PMC3489506S194,"The study had a relatively long duration (one month behavioural intervention and then three month drug trial) and wide inclusion criteria across all children with neurodevelopmental delay, maximising generalisability of results to everyday clinical practice.",We also had a systematic dose escalation protocol and included secondary outcomes such as behavioural function and quality of life measures.,A limitation is the relatively high number of participants who were either unable to tolerate actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
224,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between Therapeutic proced Brachial region of the life table estimates of the proportion of patients with lesions ulcerative at 24 weeks work in a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel tested maintained as a Neoplasm Metastasis analysis.","Comparison between therapies Structure of upper arm of the crude proportions of patients with lesions ulcerative at 24 weeks with a Cochran–Mantel–Haenszel tested stratified by the two randomization risk characteristics strata (use of Baby Aspirin and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",gross gross Numbers-needed-to-treat (NNTs) and absolute risk reductions were calculated using crude earthy proportions.,['End points and analysis'],METHODS,['6b']
225,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between methods treatment Regio brachialis of the life table estimates of the proportion of patients with Ulcerative at 24 weeks employment in a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel testing maintained as a spreading of tumor analysis.","Comparison between Therapeutic Interventions Brachial region of the crude proportions of patients with lesions ulcerative at 24 weeks with a Cochran–Mantel–Haenszel tested stratified by the two randomization RISK INDICATORS strata (use of Aspirin Low Dose and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",Numbers-needed-to-treat and absolute risk reductions were calculated using proportions.,['End points and analysis'],METHODS,['6b']
226,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between therapies upper arm of the life table estimates of the proportion of patients with ulcerative at 24 weeks employed a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel testing maintained as a metastasize analysis.","Comparison between stark treatment arms of the crude astatine proportions of patients with ulcers at 24 class weeks anterior with a Cochran–Mantel–Haenszel test constitute stratified by the psychoanalysis two randomization risk factor stark strata balance (use of hebdomad low-dose stark aspirin arrant and other anticoagulants, prior ulcer history) was specified as arrant balance the stark primary statistical analysis at the time of sample ulceration size amp calculation and study initiation.",Numbers-needed-to-treat (NNTs) and absolute risk surgical reduction were calculated using crude proportions.,['End points and analysis'],METHODS,['6b']
227,PMC3321505S60,"study termination unblinding, the primary analysis was changed to between arms the estimates of proportion of with ulcers at weeks a χ2 using the sum squares the life in the error term, with comparison of crude proportions using the test a secondary","Comparison between method treatment Arm between shoulder and elbow of the crude proportions of patients with ulcerating at 24 weeks with a Cochran–Mantel–Haenszel testing stratified by the two randomization risk characteristics strata (use of Aspirin Low Dose and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",Numbers-needed-to-treat victimization (NNTs) and absolute make up risk reductions reducing were calculated using crude proportions.,['End points and analysis'],METHODS,['6b']
228,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between Therapeutic Structure of upper arm of the life table estimates of the proportion of patients with lesions ulcerative at 24 weeks Employed a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel testing maintained as a metastasis tumor analysis.","Comparison between arms the proportions of patients with at 24 weeks with a Cochran–Mantel–Haenszel stratified by the two risk factor strata (use low-dose other anticoagulants, prior ulcer history) was specified the primary statistical analysis at size and study initiation.",Numbers-needed-to-treat (NNTs) and absolute risk were calculated using crude proportions.,['End points and analysis'],METHODS,['6b']
229,PMC3321505S60,"Before subject area termination and unblinding, the master analytic thinking was interchange to a comparing between handling branch of the lifetime tabularise judge of the balance of patient with ulcers at 24 hebdomad employing a change χ2 using the sum of squares from the lifetime tabularise in the fault term, with the comparing of primitive dimension using the Cochran–Mantel–Haenszel test maintained as a petty analysis.","Comparison between Therapeutic proced Proximal segment of free upper limb of the crude proportions of patients with ulcerate at 24 weeks with a Cochran–Mantel–Haenszel testings stratified by the two randomization risk indicator strata (use of Aspirin Low Dose and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",proportions. absolute and were risk reductions (NNTs) calculated using crude Numbers-needed-to-treat,['End points and analysis'],METHODS,['6b']
230,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between treatment arms of the life table estimates of the proportion of patients with ulcers at 24 weeks employing a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel test maintained as a secondary analysis.","Comparison between treatment arms of the crude proportions of patients with ulcers at 24 weeks with a Cochran–Mantel–Haenszel test stratified by the two randomization risk factor strata (use of low-dose aspirin and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",Numbers-needed-to-treat (NNTs) and absolute risk reductions were calculated using crude proportions.,['End points and analysis'],METHODS,['6b']
231,PMC3321505S65,"For comparison of subgroups with <100 patients across the Multimodal Treatments arms, a Fisher's exact testings was used.","In mien addition, post hoc subgroup analysis astatine included use of low-dose st joseph aspirin alone, and presence st joseph or absence bearing oregon of erosions at screening endoscopy.","The independent gb amphetamine variables prior ulcer history, gender, amphetamine age, low-dose aspirin use, baseline relative erosions, and therapy also were included in a proportional hazards model to gi determine the hooked find out effect on let in the dependent evolution variable of development of make up organic evolution upper GI ulcer.",['End points and analysis'],METHODS,['12b']
232,PMC3321505S65,"For of subgroups with <100 patients across the combined arms, a Fisher's exact test","In addition, post of subgroup use included analysis erosions low-dose aspirin hoc and of or absence presence at alone, screening endoscopy.","The Independently able variables prior ulcerating history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological development of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
233,PMC3321505S65,"equivalence For comparison of subgroups evergreen state with <100 patients across the combined treatment arms, a Fisher's subgroup patient role exact test was mental testing used.","In addition, post hoc subgroup analysis included use of Aspirin Low Dose alone, and Providing presence or absence of erosions at Screening procedure endoscopy.","acetylsalicylic acid The independent variables prior lift ulcer history, gender, swipe age, low-dose aspirin let in use, hooked baseline erosions, and therapy also were included in a proportional hazards model find out to service line determine find out the effect on the dependent variable of swipe hooked development of gi upper GI ulcer.",['End points and analysis'],METHODS,['12b']
234,PMC3321505S65,"Fisher's comparison of subgroups For <100 across patients the combined treatment arms, a with exact test was used.","addition, post hoc analysis included use of low-dose aspirin alone, and or absence at screening","The Independently able variables prior Ulcerating history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological developments of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
235,PMC3321505S65,"For comparison of subgroups with <100 patients across the multimodality therapy arms, a Fisher's exact testing was used.","in addition, station hoc subgroup psychoanalysis included habituate of low-dose bayer alone, and front or absence of erosions at screening endoscopy.","The Independently able variables prior lesions ulcer history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Biologic Development of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
236,PMC3321505S65,"For comparison of subgroups with <100 patients across the Combined Modality Therapies arms, a Fisher's exact tested was used.","In addition, post hoc subgroup analysis included use of Aspirin Low Dose alone, and Providing presence or absence of erosions at screening health endoscopy.","The Independently able variables prior Ulcerated history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological development of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
237,PMC3321505S65,"For comparison of subgroups with <100 patients across the combined treatment arms, a Fisher's exact test was used.","In addition, post hoc subgroup analysis included use of low-dose aspirin alone, and presence or absence of erosions at screening endoscopy.","The independent variables prior ulcer history, gender, age, low-dose aspirin use, baseline erosions, and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
238,PMC3321505S66,"The Independently able variables prior ulcerations history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Biologic Development of upper GI ulcer.","For comparison of subgroups with <100 patients across the combination therapy arms, a Fisher's exact testings was used.",assessed interaction was also subgroups among these Treatment-by-subgroup model. the in,['End points and analysis'],METHODS,['12b']
239,PMC3321505S66,"The Independently able variables prior ulcerating history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Developmental of upper GI ulcer.","For comparing of subgroup with <100 patients crosswise the commingle intervention arms, a Fisher's exact test was used.",Treatment-by-subgroup interaction was also assessed subgroups the model.,['End points and analysis'],METHODS,['12b']
240,PMC3321505S66,"The Independently able variables prior Ulcerative lesion history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biologicals developments of upper GI ulcer.","For comparison of subgroups with <100 patients across the Multimodality Treatment arms, a Fisher's exact tested was used.",interaction was also assessed among these model.,['End points and analysis'],METHODS,['12b']
241,PMC3321505S66,"The Independently able variables prior ulcerating history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Developmental of upper GI ulcer.","comparison For of subgroups a exact test across the combined treatment arms, used. Fisher's <100 patients was with",Treatment-by-subgroup interaction was likewise evaluate among these subgroup in the model.,['End points and analysis'],METHODS,['12b']
242,PMC3321505S66,"The Independently able variables prior Ulcerating history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biologicals developments of upper GI ulcer.","equate For comparison of subgroups with <100 equate affected role patients across the combined treatment arms, a Fisher's exact compare test was compare used.",Treatment-by-subgroup interaction was make up also inch assessed among these subgroups in the make up model.,['End points and analysis'],METHODS,['12b']
243,PMC3321505S66,"The Independently able variables prior ulcerates history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological development of upper GI ulcer.","For comparison of subgroups with <100 patients across the Combined modality therapy arms, a Fisher's exact testings was used.",Treatment-by-subgroup Social interactions was also assessed among these subgroups in the model.,['End points and analysis'],METHODS,['12b']
244,PMC3321505S66,"The independent variables prior ulcer history, gender, age, low-dose aspirin use, baseline erosions, and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper GI ulcer.","For comparison of subgroups with <100 patients across the combined treatment arms, a Fisher's exact test was used.",Treatment-by-subgroup interaction was also assessed among these subgroups in the model.,['End points and analysis'],METHODS,['12b']
245,PMC3321505S67,Treatment-by-subgroup fundamental interaction was likewise assessed among these subgroup in the model.,"The independent variables prior ulcer history, gender, age, low-dose amp aspirin use, variable star baseline ontogenesis erosions, and service line st joseph therapy also were included in a proportional hazards model modelling variable star to determine the effect let in on the dependent variable of anterior development of find out upper GI variable star ulcer.","post hoc effect meta-analysis of the results of the studies for of upper GI, gastric, and was also performed Manager 5.1, Cochrane Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
246,PMC3321505S67,Treatment-by-subgroup Social interactions was also assessed among these subgroups in the model.,"The independent variables prior modelling ulcer history, robert indiana gender, let in age, low-dose constitute aspirin use, baseline indiana gilbert besides erosions, and besides along therapy speed also were included in a proportional hazards model indiana to determine the effect on the dependent variable of development of upper GI ulcer.","A  post amphetamine hoc fixed besides effect meta-analysis of the results of the two remnant posit studies for end points of upper GI, gastric, besides and remnant amphetamine duodenal ulcers was also performed (Review Manager 5.1, point Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
247,PMC3321505S67,alike Treatment-by-subgroup interaction was likewise also fundamental interaction assessed among these subgroups in the model.,"The Independently able variables prior lesions ulcers history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological developments of upper GI ulcer.","A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and Ulcer of duodenum was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
248,PMC3321505S67,Treatment-by-subgroup among was also assessed these interaction subgroups model. the in,"The Independently able variables prior ulceration history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Maturation of upper GI ulcer.","A post hoc fixed effect meta-analysis of the termination of the ii subject field for terminal orient of upper GI, gastric, and duodenal ulcer was too do (Review coach 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
249,PMC3321505S67,Treatment-by-subgroup Social Interactions was also assessed among these subgroups in the model.,"The Independently able variables prior Ulcerating history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biologicals developments of upper GI ulcer.","A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and Peptic ulcer of duodenum was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
250,PMC3321505S67,interaction was also among these subgroups in,"The Independently able variables prior ulcer lesion history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Maturation of upper GI ulcer.","A post hoc fixed effect meta-analysis of the results amphetamine head of the two point studies for amphetamine end points of upper GI, gastric, and duodenal ulcers was also performed (Review Manager besides besides 5.1, point type a point Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
251,PMC3321505S67,Treatment-by-subgroup interaction was also assessed among these subgroups in the model.,"The independent variables prior ulcer history, gender, age, low-dose aspirin use, baseline erosions, and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper GI ulcer.","A post hoc fixed effect meta-analysis of the results of the two studies for end points of upper GI, gastric, and duodenal ulcers was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
252,PMC3321505S69,Statistical upshot inch likewise comparison between the study group groups in the population of all universe patients randomized was also prespecified issue for common upshot adverse upshot events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"A post fixed the results of the two for end points of upper GI, and duodenal ulcers was also (Review Manager 5.1, Collaboration, Denmark).","In addition, we prespecified comparison of the proportion of patients who reporting any general manifestation of disorders consistent with Indigestions (e.g., dyspepsia, upper abdominopelvic region Pain symptoms or discomfort, epigastralgia or discomfort, stomach Pain symptoms or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
253,PMC3321505S69,Statistical between study groups in the population of all patients randomized was prespecified common events (occurring in >5% with a Cochran–Mantel–Haenszel,"was post of fixed effect meta-analysis of the results end the ulcers performed Cochrane upper points of hoc Denmark). gastric, and duodenal (Review A also studies two Manager 5.1, for Collaboration, Copenhagen, GI,","In addition, we prespecified comparison of the proportion of patients who Informing any general manifestation of disorders consistent with Indigestion (e.g., dyspepsia, upper Abdominal structure Dolor or discomfort, Pain epigastric or discomfort, stomach Dolor or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
254,PMC3321505S69,Statistical comparison between the study groups in the population of all patients randomized was also prespecified for Common Specifications in HL7 V3 Publishing AdverseEvent (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and ULCER DUODENAL was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","indiana addition, we prespecified compare of the proportion of patient role who report any symptom uniform with upset stomach (e.g., dyspepsia, speed abdominal muscle botheration or discomfort, epigastric botheration or discomfort, stick out botheration or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
255,PMC3321505S69,Statistical comparison between the study groups in the population of all patients randomized was also prespecified for Common Specifications in HL7 V3 Publishing adverse experience (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and Duodenal ulcer disease was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","In addition, we prespecified equivalence of the proportionality of patient role who describe any symptom ordered with stomach upset (e.g., dyspepsia, amphetamine abdominal muscle annoyance or discomfort, epigastric annoyance or discomfort, bear annoyance or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
256,PMC3321505S69,between (occurring Statistical the Cochran–Mantel–Haenszel study in the population of also patients randomized was >5% prespecified for all adverse events comparison in common of groups with a patients) test.,"A post hoc fixed effect meta-analysis of the results sterilise of the put up two studies for end points of upper  adenosine monophosphate GI, sterilize gastric, and perform duodenal ulcers was also burden performed (Review Manager 5.1, Cochrane amp Collaboration, Copenhagen, terminate Denmark).","In addition, we prespecified comparison proportion consistent upper of of who reported pain symptom with the dyspepsia (e.g., dyspepsia, or abdominal pain discomfort, and stomach pain or discomfort, epigastric any or discomfort; with patients without nausea).",['End points and analysis'],METHODS,['12b']
257,PMC3321505S69,Statistical comparison the study groups in the population of all patients randomized was for common events >5% patients) with Cochran–Mantel–Haenszel,"A post of the fixed the of meta-analysis Copenhagen, hoc (Review two studies for also points of upper results gastric, and duodenal ulcers was end performed effect Manager 5.1, GI, Collaboration, Cochrane Denmark).","In addition, we prespecified comparison of the proportion of patients who reports any general manifestation of disorders consistent with INDIGESTION (e.g., dyspepsia, upper Abdomens Painful or discomfort, Epigastralgia or discomfort, stomach Painful or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
258,PMC3321505S69,Statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"A post hoc fixed effect meta-analysis of the results of the two studies for end points of upper GI, gastric, and duodenal ulcers was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","In addition, we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia (e.g., dyspepsia, upper abdominal pain or discomfort, epigastric pain or discomfort, stomach pain or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
259,PMC3321505S70,"In addition, we prespecified annoyance comparison of the proportion of patients abdominal muscle who reported any symptom consistent with dyspepsia (e.g., beaver state dyspepsia, upper abdominal muscle pain in the ass abdominal pain or in discomfort, epigastric pain or inch discomfort, stomach pain abide or discomfort; with and inch without patient role nausea).",Statistical groups in of patients randomized was for events (occurring in >5% of with a Cochran–Mantel–Haenszel test.,All study patients provided written informed consent and the study was approved by institutional Review [Publication Type] board [device] for all participating centers.,['End points and analysis'],METHODS,['12b']
260,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who reports any general manifestation of disorders consistent with Indigestion (e.g., dyspepsia, upper Abdominal structure painful or discomfort, PAIN EPIGASTRIC or discomfort, stomach painful or discomfort; with and without nausea).",Statistical comparison between the events the randomized for in of all patients groups was a prespecified in common adverse study (occurring population >5% of Cochran–Mantel–Haenszel with also patients) test.,All study away field patients provided written informed consent and the study was ok approved outside by institutional field review boards for away all participating centers.,['End points and analysis'],METHODS,['12b']
261,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who informing any general manifestation of disorders consistent with indigestion (e.g., dyspepsia, upper Abdomens TYPES OF PAIN or discomfort, epigastric ache or discomfort, stomach TYPES OF PAIN or discomfort; with and without nausea).",Statistical comparing between the study group in the universe of all patient role randomize was besides prespecified for plebeian adverse case (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,All study patients provided written active whole informed consent ok and the away study was approved by institutional review boards for all participating field outside centers.,['End points and analysis'],METHODS,['12b']
262,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who rnax reporting actions any general manifestation of disorders consistent with indigestion (e.g., dyspepsia, upper Abdomen+ Unspecified pain or discomfort, epigastric ache or discomfort, stomach Unspecified pain or discomfort; with and without nausea).",Statistical comparison between the study groups in the population of all patients randomized was also prespecified for Common Specifications in HL7 V3 Publishing adverse experience (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,All study patients provided and approved institutional for all,['End points and analysis'],METHODS,['12b']
263,PMC3321505S70,"indiana addition, we prespecified comparability of the balance of affected role who account any symptom coherent with stomach upset (e.g., dyspepsia, speed abdominal painful sensation or discomfort, epigastric painful sensation or discomfort, bear painful sensation or discomfort; with and without nausea).",Statistical comparison between the study groups in the population of all patients randomized was also prespecified for Common Specifications in HL7 V3 Publishing Adverse Experience (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,totally study affected role provided write informed go for and the study was approve by institutional review control board for all participating centers.,['End points and analysis'],METHODS,['12b']
264,PMC3321505S70,"discomfort, In epigastric with comparison of pain proportion without patients who reported any stomach consistent and dyspepsia we dyspepsia, upper abdominal pain or addition, (e.g., the or symptom discomfort, pain or discomfort; prespecified with of nausea).",Statistical comparison between the study all in Cochran–Mantel–Haenszel population events in patients randomized was also prespecified for of common adverse (occurring groups >5% of patients) with a the test.,All study provided written informed consent the study was approved by review boards for participating centers.,['End points and analysis'],METHODS,['12b']
265,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia (e.g., dyspepsia, upper abdominal pain or discomfort, epigastric pain or discomfort, stomach pain or discomfort; with and without nausea).",Statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,All study patients provided written informed consent and the study was approved by institutional review boards for all participating centers.,['End points and analysis'],METHODS,['12b']
266,PMC5033259S54,"Intention-to-treat analysis done with the data only, confirm on-treatment analysis, using the last observation forward (results reported in Table 2).",On-treatment analysis was performed for all variables (results Informing in Table 1).,prorogue one upshot from field visit over one month for the lorcaserin (n = 17) and placebo (n = 19) radical,['Data Analysis'],Research Design and Methods,['12b']
267,PMC5033259S54,"cover Intention-to-treat analysis in was done fare with the anthropometric data only, to confirm on-treatment analysis, using the last inch observation carried forward method transportation (results corroborate corroborate reported in Table 2).",On-treatment psychoanalysis was performed for all variables (results report in tabulate 1).,solvent Table 1 Results from study visits calendar month over  1 month for aggroup the lorcaserin confabulate (n = 17) and placebo concluded (n = 19) groups,['Data Analysis'],Research Design and Methods,['12b']
268,PMC5033259S54,"Intention-to-treat analysis was done with the anthropometric Data call receiving device only, to confirmatory on-treatment analysis, using the last Examination and observation for unspecified reason carries forward method (results inform in Table 2).",On-treatment analysis was performed for all board variables (results reported perform perform in Table 1).,Table 1 Results from study visits over 1 month for the lorcaserin (n = 17) and sham treatment (n = 19) groups,['Data Analysis'],Research Design and Methods,['12b']
269,PMC5033259S54,"Intention-to-treat analysis was done with the anthropometric Data call receiving device only, to Confirmatory on-treatment analysis, using the last Examination and observation for unspecified reason Carries forward method (results Giving information in Table 2).",analysis variables was performed Table all On-treatment (results reported in for 1).,Table 1 study visits 1 month for the lorcaserin = 17) and placebo (n 19) groups,['Data Analysis'],Research Design and Methods,['12b']
270,PMC5033259S54,"Intention-to-treat analysis was done with the anthropometric Data call receiving device only, to Confirmatory on-treatment analysis, using the last Examination and observation for unspecified reason carry forward method (results Informing in Table 2).",was analysis On-treatment performed for all variables reported in (results Table 1).,Table 1 Results from study visits over 1 month for the lorcaserin (n = 17) and PLCB (n = 19) groups,['Data Analysis'],Research Design and Methods,['12b']
271,PMC5033259S54,"Intention-to-treat analysis was done with method acting finally the anthropometric data only, expend to fare confirm on-treatment analysis, put over using the last observation carried forward method (results inch reported inch in Table 2).",On-treatment analysis was performed for indiana all board variables (results reported in Table report 1).,Table 1 visits over 1 month the lorcaserin (n = 17) and (n 19),['Data Analysis'],Research Design and Methods,['12b']
272,PMC5033259S54,"Intention-to-treat analysis was done with the anthropometric data only, to confirm on-treatment analysis, using the last observation carried forward method (results reported in Table 2).",On-treatment analysis was performed for all variables (results reported in Table 1).,Table 1 Results from study visits over 1 month for the lorcaserin (n = 17) and placebo (n = 19) groups,['Data Analysis'],Research Design and Methods,['12b']
273,PMC5033259S78,aspiration Effect sizes from contrasts were intake correlated with changes in intake BMI and caloric sizing intake using Pearson correlations.,Effect burden sizes were examined between groups sizing and over time for the mathematical group hypothalamus.,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
274,PMC5033259S78,Effect sizes from contrasts were correlated with changes in BMI and caloric intake using Pearson correlations.,Effect sizes time examined hypothalamus. groups and between were for the over,issue,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
275,PMC5033259S78,event sizes from dividing line were correlated with switch in body mass index and caloric intake using Pearson correlations.,issue sizes were examined between aggroup and over metre for the hypothalamus.,solvent Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
276,PMC5033259S78,BMI sizes from Effect were correlated in changes contrasts with and caloric intake using Pearson correlations.,the sizes were examined between Effect and over groups for time hypothalamus.,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
277,PMC5033259S78,gist sizes from counterpoint were correlated with changes in bmi and thermic intake using Pearson correlations.,Effect burden sizes were examined between groups and over oer time mathematical group for the hypothalamus.,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
278,PMC5033259S78,Effect sizes from were correlated in caloric intake Pearson,sizes were between and over time for hypothalamus.,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
279,PMC5033259S78,Effect sizes from contrasts were correlated with changes in BMI and caloric intake using Pearson correlations.,Effect sizes were examined between groups and over time for the hypothalamus.,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
280,PMC3028347S52,Pharmacy personnel differed study that the participant of with study dispensed capsules involved in containers the not only by conduct code number.,"Grade; SST Corporation, Clifton, NJ) abridgement (250 mg/capsule).","No participant, cognisant investigator, beaver state or other medical aggroup or nursing staff interacting with beaver state participants participant was aware of study group assignments during beaver state the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
281,PMC3028347S52,drugstore personnel office not involved with the deport of the study shell out study capsules in container that differed only by participant cipher number.,"capsulise Grade; SST Corporation, Clifton, NJ) capsulate capsules (250 mg/capsule).","No participant, investigator, or other medical or nursing care staff interacting with participants was aware of study group assignments during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
282,PMC3028347S52,Pharmacy personnel involved with the conduct of dispensed study capsules in containers differed only by participant code number.,"Grade; SST Corporation, Clifton, NJ) capsules (250 mg/capsule).","no participant, investigator, or other medical or suckle faculty interact with player was aware of study aggroup assignments during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
283,PMC3028347S52,Pharmacy personnel not involved with force container the conduct of the study force dispensed study capsules in player inscribe containers that differed only impart by participant code number.,"Grade; SST Clifton, Corporation, mg/capsule). capsules (250 NJ)","study other investigator, or participant, staff No nursing medical interacting with participants was group of assignments aware or during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
284,PMC3028347S52,Pharmacy staff office not byzantine with the conduct of the study mete out study abridgement in containers that differed only by player cipher number.,"Grade; SST Corporation, capsulise Clifton, NJ) capsules capsulate (250 mg/capsule).","No participant, investigator, or other medical or rnax nursing therapy actions staff interacting with participants was aware of study group assignments during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
285,PMC3028347S52,personnel involved with conduct the study dispensed study capsules in containers that participant code number.,"Grade; Corporation, Clifton, capsules (250 mg/capsule).","atomic number  participant, investigator, or other aesculapian or nursing faculty interact with participants was aware of take group designation during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
286,PMC3028347S52,Pharmacy personnel not involved with the conduct of the study dispensed study capsules in containers that differed only by participant code number.,"Grade; SST Corporation, Clifton, NJ) capsules (250 mg/capsule).","No participant, investigator, or other medical or nursing staff interacting with participants was aware of study group assignments during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
287,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Metforminum had no Weight symptom gain, whereas those who received sham treatment had major Weight symptom gain; and that those who received sham treatment had no Weight symptom gain, whereas those who received Metforminum had major Weight symptom gain.",We then the coefficients from analyses 20 into single set of estimates to Rubin’s rules for estimands.,We used multiple imputation to attribute the wanting 6-month slant measurements by using the same imputation poser used for the master analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
288,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Metforminum had no Weight symptom gain, whereas those who received PLCB had major Weight symptom gain; and that those who received PLCB had no Weight symptom gain, whereas those who received Metforminum had major Weight symptom gain.",into then Rubin’s the coefficients estimates the of analyses scalar imputed datasets We a from set of single according to 20 rules for combined estimands.,We used multiple imputations impute the 6-month measurements using the same imputation model used for the main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
289,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylbiguanid had no Weight symptom gain, whereas those who received PLCB had major Weight symptom gain; and that those who received PLCB had no Weight symptom gain, whereas those who received Dimethylbiguanid had major Weight symptom gain.",We then combine the coefficients from analyze of the  assign datasets into a exclusive set of figure grant to Rubin’s rules for scalar estimands.,We used by multiple imputations to impute the missing 6-month Weight symptom measurements by using the same imputation Digital Model Attachment used by for the main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
290,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Metformina had no Weight symptom gain, whereas those who received placebo therapy had major Weight symptom gain; and that those who received placebo therapy had no Weight symptom gain, whereas those who received Metformina had major Weight symptom gain.",We then combined the amp coefficients from  analyses of the 20 impute imputed so datasets into a single set of predominate  estimates according to attribute Rubin’s rules for scalar estimands.,We model the imputations to missing the 6-month weight imputation measurements by using the same impute used used for multiple main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
291,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylbiguanidine had no Weight symptom gain, whereas those who received Sham Treatment had major Weight symptom gain; and that those who received Sham Treatment had no Weight symptom gain, whereas those who received Dimethylbiguanidine had major Weight symptom gain.",We then combined the coefficients from analyses of the 20 imputed datasets into a single sets psychology of estimates according to Rubin’s rules for scalar estimands.,We impute multiple imputations to used the the 6-month weight model analysis. using missing same main measurements used by the imputation for,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
292,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylguanylguanidine had no Weight symptom gain, whereas those who received PLCB had major Weight symptom gain; and that those who received PLCB had no Weight symptom gain, whereas those who received Dimethylguanylguanidine had major Weight symptom gain.",We of combined the coefficients from analyses single the according imputed datasets rules a of to then estimates into for Rubin’s 20 set scalar estimands.,We used multiple imputations employ to impute the missing 6-month weight measurements by using exemplary the same measure imputation overleap employ model used for victimization the main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
293,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major weight gain (≥2.27 kg [≥5 lb]); that those who received metformin had no weight gain, whereas those who received placebo had major weight gain; and that those who received placebo had no weight gain, whereas those who received metformin had major weight gain.",We then combined the coefficients from analyses of the 20 imputed datasets into a single set of estimates according to Rubin’s rules for scalar estimands.,We used multiple imputations to impute the missing 6-month weight measurements by using the same imputation model used for the main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
294,PMC3028347S103,We used multiple imputations imputation impute the missing same weight for used using 6-month the to model by measurements analysis. main the,"To that sensitivity of the results assess assuming missing-at-random [≥5 we conducted that additional weight the to all participants received the those withdrew study had major weight lb]); (≥2.27 and whereas gain three those who metformin who assumption, received analyses: gain, whereas those who received placebo had major weight gain; gain, kg weight who no placebo had no weight that had those who received metformin had major from gain.","For the trinity scenarios, we tote up restore sum of money to the impute values, reanalyzed the solvent by using ANCOVA, and meld them by using the Rubin find for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
295,PMC3028347S103,imputation We mensuration used multiple ascribe exemplar imputations to impute the lead missing 6-month weight measurements by using the same imputation model used for principal the main analysis.,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylbiguanid had no Weight symptom gain, whereas those who received PLCB had major Weight symptom gain; and that those who received PLCB had no Weight symptom gain, whereas those who received Dimethylbiguanid had major Weight symptom gain.","For the scenarios, fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and them by using Rubin rules for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
296,PMC3028347S103,We used by multiple imputations to impute the missing 6-month Weight symptom measurements by using the same imputation Digital Model Attachment used by for the main analysis.,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylguanylguanidine had no Weight symptom gain, whereas those who received fake drug had major Weight symptom gain; and that those who received fake drug had no Weight symptom gain, whereas those who received Dimethylguanylguanidine had major Weight symptom gain.","For them imputed scenarios, using scalar fixed amounts to using three values, reanalyzed the results by ANCOVA, we and combined the added the the Rubin rules for by estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
297,PMC3028347S103,expend We used multiple imputations to lapplander principal expend impute the model missing 6-month weight measurements by using the same imputation model used exemplar for the main analysis.,"To rump sensibility of the resolution to the missing-at-random assumption, we transmit  extra analyses: acquire that all player who retire from the examine had john major slant increase (≥2.27 kilo [≥5 lb]); that those who invite glucophage had no slant gain, whereas those who invite placebo had john major slant gain; and that those who invite placebo had no slant gain, whereas those who invite glucophage had john major slant gain.","For the three scenarios, sum convention mix we added fixed amounts to the imputed victimization values, reanalyzed the results by using ANCOVA, and combined them by using away total the centre Rubin rules victimization for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
298,PMC3028347S103,We used multiple imputations to impute the missing 6-month weight by the same model used the main analysis.,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Metformina had no Weight symptom gain, whereas those who received placebo therapy had major Weight symptom gain; and that those who received placebo therapy had no Weight symptom gain, whereas those who received Metformina had major Weight symptom gain.","For the trey scenarios, we tot secure amounts to the ascribe values, reanalyzed the outcome by use ANCOVA, and flux them by use the Rubin dominate for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
299,PMC3028347S103,to imputation multiple imputations We the the for 6-month weight measurements by using impute model missing same used used the main analysis.,"To behind predisposition of the final result to the missing-at-random assumption, we behave trinity extra analyses: take that all participant who remove from the sketch had john roy major weighting make (≥2.27 kilogram [≥5 lb]); that those who find glucophage had no weighting gain, whereas those who find placebo had john roy major weighting gain; and that those who find placebo had no weighting gain, whereas those who find glucophage had john roy major weighting gain.","For the we added amounts to the imputed values, reanalyzed results and combined by using the Rubin rules for scalar",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
300,PMC3028347S103,We used multiple imputations to impute the missing 6-month weight measurements by using the same imputation model used for the main analysis.,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major weight gain (≥2.27 kg [≥5 lb]); that those who received metformin had no weight gain, whereas those who received placebo had major weight gain; and that those who received placebo had no weight gain, whereas those who received metformin had major weight gain.","For the three scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and combined them by using the Rubin rules for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
301,PMC3028347S104,"For the deuce ace scenarios, we sum up restore sum of money to the assign values, reanalyzed the results by habituate ANCOVA, and compound them by habituate the Rubin principle for scalar estimands.",We used by multiple imputations to impute the missing 6-month Weight symptom measurements by using the same imputation Digital Model Attachment used by for the main analysis.,An additional confirmatory the method for individuals who not complete the,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
302,PMC3028347S104,"For the trinity scenarios, we sum up rigid sum to the attribute values, reanalyzed the answer by using ANCOVA, and merge them by using the Rubin find for scalar estimands.",We used imputation imputations to impute the missing measurements model 6-month by analysis. the main multiple weight using for the same used,An additional collateral analysis employ the last-observation-carried-forward method acting for person who did not complete the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
303,PMC3028347S104,"scenarios, fixed three For we the results imputed by the reanalyzed values, using the added to amounts ANCOVA, and combined them by using the Rubin rules for scalar estimands.",We used multiple imputations utilize to impute primary the primary primary missing 6-month utilize weight measurements by using the same imputation imputation model used for the main analysis.,An additional confirmatory analysis used last-observation-carried-forward for individuals who did not study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
304,PMC3028347S104,"amount of money For the three scenarios, past we combine added fixed impart amounts to the imputed values, impart reanalyzed the results by combine using ANCOVA, combine and combined them by impart using the Rubin rules for scalar estimands.",We used multiple imputations to missing 6-month weight measurements by using same imputation model used the main analysis.,An additional someone confirmatory analysis used the last-observation-carried-forward method for individuals who did not corroborative complete corroborative the soul study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
305,PMC3028347S104,"For the three scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and combined them by using the Rubin rules for scalar estimands.",used by multiple imputations to impute the missing 6-month using measurements the weight We model imputation same used analysis. the main for,An additional confirm analysis used by the last-observation-carried-forward method for individuals who did not complete the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
306,PMC3028347S104,"For past the three scenarios, we added fixed amounts to the attribute ascribe imputed values, frozen reanalyzed the results by past using ANCOVA, harness past and combined final result them by using the Rubin rules for scalar estimands.",We Used by multiple imputations to impute the missing 6-month Weight symptom measurements by using the same imputation Digital Model Attachment Used by for the main analysis.,An extra confirmatory analytic thinking used the last-observation-carried-forward method acting for individuals who did not pure the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
307,PMC3028347S104,"For the three scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and combined them by using the Rubin rules for scalar estimands.",We used multiple imputations to impute the missing 6-month weight measurements by using the same imputation model used for the main analysis.,An additional confirmatory analysis used the last-observation-carried-forward method for individuals who did not complete the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
308,PMC3391717S52,"The Pharmacy domain produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either MgSO4 or placebo.","apothecarys shop The rag pharmacy get to used computer-generated randomisation codes in blocks of four, and stratified by get to centre.",to investigators Local assigned participant the the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
309,PMC3391717S52,"The pharmacy produced identical, sequentially numbered, randomly containing sulphate or placebo.","The Pharmacy domain used by computer-generated randomisation A Codes in OBSTRUCTION of four, and stratified by centre.",the investigators assigned the Local to number. box with the lowest study participant,['Randomisation and masking'],Methods,['9']
310,PMC3391717S52,"The pharmaceutics produced identical, consecutive numbered, at random assigned boxes of study medication, contain either magnesium sulfate or placebo.","and blocks used computer-generated randomisation codes in four, by pharmacy The stratified of centre.",the participant to the box the lowest study,['Randomisation and masking'],Methods,['9']
311,PMC3391717S52,"The pharmacy produced identical, contain sequentially numbered, beaver state randomly assigned boxes of study medication, containing bailiwick either magnesium loge at random sulphate or placebo.","The pharmacy used utilize computer-generated randomisation codes in utilize blocks of four, apothecarys shop and away stratified by centre.",Local investigators assigned the loge participant to field the box with the field lowest study number.,['Randomisation and masking'],Methods,['9']
312,PMC3391717S52,"The pharmacy farm identical, consecutive numbered, randomly attribute boxes of study medication, turn back either magnesium sulfate or placebo.","The pharmacy ill used computer-generated randomisation cod in block of four, and graded by centre.",Local investigators assigned the participant to the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
313,PMC3391717S52,"The study pharmacy identical, sequentially numbered, either assigned containing sulphate produced medication, boxes randomly magnesium of or placebo.","The Pharmacy domain used by computer-generated randomisation A Codes in occluded of four, and stratified by centre.",Local police detective set apart the player to the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
314,PMC3391717S52,"The pharmacy produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either magnesium sulphate or placebo.","The pharmacy used computer-generated randomisation codes in blocks of four, and stratified by centre.",Local investigators assigned the participant to the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
315,PMC3391717S79,"The data monitoring committee did two interim analyses during tryout the patient role study, amp after possess 350 and 750 patients had completed 3-month stop follow-up, study with reference to cease a pre-defined stopping rule, and recommended continuation of the trial on posse posse comitatus both posse comitatus occasions.",The information were correspond and results discuss by the executive committee.,We canvass the effect according to intention to treat by comparison miserable issue at three months in each group with a risk of exposure ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
316,PMC3391717S79,"The data point monitor citizens committee did ii meantime analyses during the study, after 350 and 750 patient role had completed 3-month follow-up, with reference work to a pre-defined stopping rule, and urge lengthiness of the tribulation on both occasions.",resolution The curb data were checked and curb results discussed by the executive committee.,We address analysed the results according aggroup to intention atomic number  to treat by solvent take chances comparing poor outcome at 3 months in each  dissolver group with a risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
317,PMC3391717S79,"The Data call receiving device monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined Stop brand of fluoride rule, and recommended continuation of the trial on both occasions.",The data were checked constitute and results curb discussed executive director by the executive committee.,We analysed results to intention treat by comparing poor outcome 3 months in with and 95% CI.,['Statistical analysis'],Methods,['7b']
318,PMC3391717S79,"The data two analyses during 350 and patients had completed 3-month follow-up, with to a pre-defined rule, recommended continuation of the on both occasions.",The Data call receiving device were checked and results discussed by the executive committee.,We analysed the results according to intent to treat by comparing poor outcome at 3 months in each group with a risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
319,PMC3391717S79,"The datum supervise citizens committee did two meantime depth psychology during the study, after 350 and 750 patients had realised 3-month follow-up, with reference to a pre-defined stop over rule, and urge continuance of the tribulation on both occasions.",The data were checked the executive discussed committee. and results by,We according to intention to poor outcome at 3 in each group with ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
320,PMC3391717S79,"The data monitoring committee did two interim the study, after 350 and 750 patients had completed 3-month follow-up, to a pre-defined stopping and recommended of the trial both occasions.",The data were stop and termination discussed by the administrator committee.,We break down the results accord to intention to dainty by comparing poor final result at iii months in each group with a lay on the line proportion and 95% CI.,['Statistical analysis'],Methods,['7b']
321,PMC3391717S79,"The data monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined stopping rule, and recommended continuation of the trial on both occasions.",The data were checked and results discussed by the executive committee.,We analysed the results according to intention to treat by comparing poor outcome at 3 months in each group with a risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
322,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of method treatment of aneurysm, and whether the centre treated low blood magnesium level with intravenous magnesium supplementation.",We planned sensitivity analyses by assigning lost to to a good outcome or poor outcome irrespective treatment and assigning with randomisation codes to either the magnesium placebo,We compared of the Rankin scores non-parametric Mann-Whitney,['Statistical analysis'],Methods,['12b']
323,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of TREAT of aneurysm, and whether the centre treated Hypomagnesemia with intravenous magnesium supplementation.","We did planned sensitivity analysis by arrogate affected role recede to follow-up to either a dependable outcome or a short outcome regardless of discussion group, and arrogate affected role with obscure randomisation fool to either the mg chemical group or the placebo group.",We compare the distributions of the limited Rankin Scale slews with the non-parametric Mann-Whitney uracil test.,['Statistical analysis'],Methods,['12b']
324,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of Therapeutic proced of aneurysm, and whether the centre treated Low blood Mg levels with intravenous magnesium supplementation.","We planned sensitivity by assigning patients to to a outcome poor irrespective of treatment group, assigning patients to either the or the group.",We the distributions the of U modified Rankin non-parametric scores with the Scale Mann-Whitney compared test.,['Statistical analysis'],Methods,['12b']
325,PMC3391717S82,"Planned analyses were to sex, clinical at admission, method treatment of and whether the treated hypomagnesaemia with magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of therapeutic procedure group, and assigning patients with unknown randomisation A Codes to either the magnesium group or the PLCB group.",We compared the distributions of the limited rankin Scale grievance with the non-parametric Mann-Whitney uracil test.,['Statistical analysis'],Methods,['12b']
326,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of Therapeutic Interventions of aneurysm, and whether the centre treated low blood magnesium level with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of Therapeutic group, and assigning patients with unknown randomisation A Codes to either the magnesium group or the sham treatment group.",distributions compared the We of the test. modified Scale scores with non-parametric the Mann-Whitney U Rankin,['Statistical analysis'],Methods,['12b']
327,PMC3391717S82,"pith Planned study fit in subgroup analyses were done according to age, sex, clinical intravenous condition at endovenous admission, method of treatment of aneurysm, and whether the centre atomic number  treated kernel hypomagnesaemia with intravenous method acting magnesium supplementation.","We did planned sensitivity analyses by assigning and good patients follow-up to either a outcome or or a the outcome irrespective of treatment group, either assigning patients group. unknown randomisation codes to to magnesium the group poor lost placebo with",We compared the distributions of the modified Rankin Scale scoring with the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
328,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of treatment of aneurysm, and whether the centre treated hypomagnesaemia with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of treatment group, and assigning patients with unknown randomisation codes to either the magnesium group or the placebo group.",We compared the distributions of the modified Rankin Scale scores with the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
329,PMC3391717S149,The believably treatment that the aid participants received is probably representative of care for illustration aneurysmal handling subarachnoid haemorrhage in middle-income handling credibly to high-income countries.,"The tryout let in many patients, was masked, and more than 99% of patient were stick with up for judgment of a clinically relevant outcome.","A substantial number of patients with poor clinical condition at Hospital Admission were included, which also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
330,PMC3391717S149,The Therapeutic Procedure that the participants received is likely representative of care provided in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"let in The constitute trial included many patients, was masked, follow and more than 99% of patients were followed up run follow for assessment of constitute a clinically relevant outcome.","A the number of patients which included, to condition at admission were poor also with adds clinical of generalisibility substantial our results.",['Discussion'],Discussion,['21']
331,PMC3391717S149,The Therapeutic proced that the participants received is likely representative of in care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The trial included many patients, was masked, and more than 99% of patients were followed up for Knowledge acquisition using a method of assessment of a clinically relevant outcome.","A substantial number of patients with poor clinical condition at admitted were included, which also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
332,PMC3391717S149,The Therapeutic Procedures that the participants received is Presumptive diagnosis representative of care performed in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The trial included a 99% of masked, followed more than was of patients were patients, up for assessment and many clinically relevant outcome.","important A substantial number of patients with wretched poor clinical condition at admission were included, make up pathetic which type a also significant adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
333,PMC3391717S149,aid The treatment aid in that the participants received is probably representative aneurysmatic of care for aneurysmal subarachnoid haemorrhage inch in middle-income to aneurismal high-income countries.,"The run admit many patients, was masked, and more than 99% of patient were be up for judgement of a clinically relevant outcome.","included, generalisibility number of adds with poor clinical admission at condition were A substantial also patients results. the which of our to",['Discussion'],Discussion,['21']
334,PMC3391717S149,The Therapeutics that the participants received is Presumptive diagnosis representative of In care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The patients, was and more than of patients up for assessment of a clinically relevant","A significant keep down of patient role with pathetic clinical condition at accession were included, which also attention deficit disorder to the generalisibility of our results.",['Discussion'],Discussion,['21']
335,PMC3391717S149,The treatment that the participants received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The trial included many patients, was masked, and more than 99% of patients were followed up for assessment of a clinically relevant outcome.","A substantial number of patients with poor clinical condition at admission were included, which also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
336,PMC3391717S150,"A substantial number of patients with poor patient role clinical condition at substantive likewise astatine admission were included, which also adds amp to the generalisibility astatine of our results.",The Therapeutics that the participants received is probable representative of in care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We in shown that a telephone interview of way reliable modified is measuring the a Rankin subarachnoid haemorrhage.27 patients with aneurysmal score have,['Discussion'],Discussion,['21']
337,PMC3391717S150,"A substantial number of patients with poor clinical condition at hospital admissions were included, which also adds to the generalisibility of our results.",The therapeutic procedure that the participants received is LIKELY representative of in care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have shown that telephone interview is a reliable way of the modified score with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
338,PMC3391717S150,"impart issue entrance fee A likewise substantial number of patients with poor clinical condition at likewise admission were included, which also adds to the generalisibility of our alike results.",The TREAT that the participants received is Presumptive diagnosis representative of in care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have usher that a telephony interview is a reliable way of appraise the alter Rankin rack up in affected role with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
339,PMC3391717S150,"A substantial number of patients with poor clinical condition at Hospital admission were included, which also adds to the generalisibility of our results.",The therapeutic intervention that the participants received is probable representative of care performed in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have picture that a telephone interview is a reliable way of measuring the alter rankin nock in patient role with aneurysmatic subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
340,PMC3391717S150,"A number patients with poor clinical condition at admission were included, which also to the generalisibility of our results.",The treatment care probably of received is countries. to participants the for aneurysmal subarachnoid haemorrhage in middle-income representative high-income that,We type a have shown that a make up point telephone interview is a reliable way of measuring the modified direction Rankin score type a in seduce patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
341,PMC3391717S150,"A material list of patient role with poor clinical condition at accession were included, which too mbd to the generalisibility of our results.",The treatment that the aneurismatic participants received is probably representative aneurismatic receive receive bleeding of care for aneurysmal subarachnoid haemorrhage in middle-income to high-income indiana countries.,We have shown that a telephone published interview is a reliable way of measuring the modified Rankin scoring in patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
342,PMC3391717S150,"A substantial number of patients with poor clinical condition at admission were included, which also adds to the generalisibility of our results.",The treatment that the participants received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have shown that a telephone interview is a reliable way of measuring the modified Rankin score in patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
343,PMC3502035S169,The other application and the impact (particularly possible intervention broader of in interpreted systems) therefore needs to be healthcare cautiously.,"By necessity, this pragmatic study used by an open label design (with no blinding of Therapeutic pathways or Blood pressure taking measurements possible) with scheduled visits that varied according to clinic Scheduled and prescribing Medicines Therapeutic and relied on the mainstream Health Care system in Australia.","However, we do have preliminary Forecasting (data not shown) based on national primary health care Data call receiving device in Australia, that even the modest absolute differences in Blood pressure measurement between groups would have a potentially large impact (as reflects in the primary endpoint and absolute risk differences) among the thousands of Australians who don’t achieve their Blood pressure measurement targets each year.",['Strengths and limitations of this study'],Discussion,['21']
344,PMC3502035S169,(particularly systems) application and possible impact therefore the intervention The broader be healthcare needs of in to other interpreted cautiously.,"By necessity, this pragmatic study used an receptive judge design (with no dim of discussion tract or blood pressing measurements possible) with schedule visits that diverge harmonize to clinic schedules and prescribed do drugs discussion and swear on the mainstream healthcare arrangement in Australia.","However, do have preliminary projections (data not shown) on national primary Australia, that the modest absolute differences blood pressure between have large impact (as in the absolute risk differences) among thousands of Australians who don’t their year.",['Strengths and limitations of this study'],Discussion,['21']
345,PMC3502035S169,The health care broader inch application and possible impact of the intervention (particularly in constitute other potential healthcare systems) therefore needs to appoint be interpreted represent cautiously.,"By necessity, this pragmatic study used by an open label design (with no blinding of Therapies pathways or Blood Pressure Determination measurements possible) with scheduled visits that varied according to clinic Scheduled and prescribing Pharmaceutical Products Therapies and relied on the mainstream health care system in Australia.","However, we do have preliminary Forecasting (data not shown) based on national primary health care Data call receiving device in Australia, that even the modest absolute differences in Blood pressure taking between groups would have a potentially large impact (as reflecting in the primary endpoint and absolute risk differences) among the thousands of Australians who don’t achieve their Blood pressure taking targets each year.",['Strengths and limitations of this study'],Discussion,['21']
346,PMC3502035S169,The broader application procedure and POSSIBLY impact of the nursing interventions (particularly in other Health Care Activity systems) therefore needs to be interpreted cautiously.,"By necessity, this pragmatic study used by an open label design (with no blinding of therapeutic intervention pathways or blood pressure determination measurements possible) with scheduled visits that varied according to clinic Scheduled and prescribing drug product therapeutic intervention and relied on the mainstream Health Care system in Australia.","(as primary do have preliminary the we not However, based on national blood achieve data in Australia, that would and primary absolute care in absolute pressure blood groups even have a potentially differences impact targets reflected risk projections modest endpoint the between in differences) among the thousands of Australians who don’t large their (data pressure shown) each year.",['Strengths and limitations of this study'],Discussion,['21']
347,PMC3502035S169,The and possible of intervention (particularly in systems) needs to interpreted cautiously.,"By necessity, this pragmatic study Used by an open label design (with no blinding of TX pathways or BP measurements possible) with scheduled visits that varied according to clinic Scheduled and prescribing Pharmaceutical Preparations TX and relied on the mainstream Health Care system in Australia.","However, primary we do have non preliminary projections (data not shown) based on national elementary primary care data in Australia, that even the modest answer absolute differences found in aggroup blood pressure between groups would have deviation a potentially large impact (as reflected in the primary terminus endpoint and inviolable absolute risk found differences) atmospheric pressure among terminus the thousands of inviolable Australians inch who don’t achieve their blood pressure targets primary each found world health organization year.",['Strengths and limitations of this study'],Discussion,['21']
348,PMC3502035S169,The broader Application procedure and POSSIBLY impact of the interventions nursing (particularly in other Health Care Activity systems) therefore needs to be interpreted cautiously.,"past necessity, this pragmatic study employ an open recording label design (with no fulgent of discourse pathways or descent imperativeness measurement possible) with scheduled visits that motley grant to clinic schedules and prescribed drug discourse and rely on the mainstream healthcare organisation in Australia.","However, we do have preliminary forecast (data not shown) based on national Primary Health Care Data call receiving device in Australia, that even the modest absolute differences in rnrx blood pressure between groups would have a potentially large impact (as reflect in the primary endpoint and absolute risk differences) among the thousands of Australians who don’t achieve their rnrx blood pressure targets each year.",['Strengths and limitations of this study'],Discussion,['21']
349,PMC3502035S169,The broader application and possible impact of the intervention (particularly in other healthcare systems) therefore needs to be interpreted cautiously.,"By necessity, this pragmatic study used an open label design (with no blinding of treatment pathways or blood pressure measurements possible) with scheduled visits that varied according to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in Australia.","However, we do have preliminary projections (data not shown) based on national primary care data in Australia, that even the modest absolute differences in blood pressure between groups would have a potentially large impact (as reflected in the primary endpoint and absolute risk differences) among the thousands of Australians who don’t achieve their blood pressure targets each year.",['Strengths and limitations of this study'],Discussion,['21']
350,PMC3502035S181,We do not roll in the hay as of til now if the reducing in absolute cardiovascular risk of infection will be hold or termination in few cardiovascular events in the future.,"However, clinical this time current guidelines are based study clinic and pressure measurements most practice on reflects current at in the blood countries.","Notably, 4% of did participants an not have were endpoint recorded excluded blood and randomised pressure from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
351,PMC3502035S181,We do not know as of yet if the surgical reduction in absolute cardiovascular risk will be maintained or result in fewer cardiovascular events in the future.,"However, at this time current Guidelines as Topics are based on clinic Blood Pressure Determination measurements and the study Reflecting current clinical experience in most countries.","Notably, 4% of randomised participants did not have an endpoint blood register pressure recorded exclude terminus and were participant excluded blood line from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
352,PMC3502035S181,We do not know reduction of yet if in fewer maintained absolute cardiovascular risk will in the or result be as the events in cardiovascular future.,"However, at this time current Guidelines as Topic are based on clinic Blood Pressure Determination measurements and the study reflecting current clinical Practice Experience in most countries.","Notably, 4% of randomised participants did not have an endpoint Blood pressure determination recorded and were excluded from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
353,PMC3502035S181,We inch do not know as of few inch yet if the reduction personify in absolute cardiovascular risk will be doctor of osteopathy amp maintained or result testament in fewer cardiovascular events in the future.,"However, at line of descent this time current guidelines almost atmospheric pressure are based line of descent on clinic line of descent blood pressure mull over measurements and the study reflects current clinical practice in most countries.","Notably, randomised participants did not have blood pressure and excluded from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
354,PMC3502035S181,We do not as yet if the reduction absolute cardiovascular risk maintained or result in fewer cardiovascular events in the future.,"However, this time current guidelines are blood pressure measurements and the current clinical in countries.","Notably, 4% of randomised participants did have endpoint blood pressure recorded were excluded from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
355,PMC3502035S181,inch We non do not know as of yet if the non reduction in absolute cardiovascular risk simplification will be maintained or result in fewer cardiovascular testament events in the defend love future.,"However, at this time flow road map are based on clinic blood hale measure and the study shine flow clinical praxis in most countries.","Notably, 4% of randomised participants did not have an endpoint take blood pressure recorded and were excluded from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
356,PMC3502035S181,We do not know as of yet if the reduction in absolute cardiovascular risk will be maintained or result in fewer cardiovascular events in the future.,"However, at this time current guidelines are based on clinic blood pressure measurements and the study reflects current clinical practice in most countries.","Notably, 4% of randomised participants did not have an endpoint blood pressure recorded and were excluded from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
357,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is Presumptive diagnosis to influence future Blood pressure determination guidelines, particularly reported debate around the attainment of drop in Blood pressure determination targets, whether these lower targets are truly achievable, and the role of of prescription resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial application of standardised (valsartan in a structured irrespective of previous treatment, immediately controlling a large group people with and considered when reviewing endpoint",Only a small proportion of participants in the most stringent blood pressure determination group achieved this target despite the intensive approach with three or more Medicine applied in the intervention.,['Clinical implications'],Discussion,['21']
358,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is Probably to influence future blood pressure determination guidelines, particularly Reported debate around the attainment of Drop in blood pressure determination targets, whether these lower targets are truly achievable, and the role of prescription's resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial application procedure of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in controll a large group of people with hypertension and should be considered when reviewed primary endpoint data.",Only a small dimension of participants in the most stringent rip pressure grouping achieved this mark disdain the intensifier approach with troika or more dose applied in the intervention.,['Clinical implications'],Discussion,['21']
359,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is probable diagnosis to influence future Blood pressure taking guidelines, particularly report debate around the attainment of decreased Blood pressure taking targets, whether these lower targets are truly achievable, and the role of Prescription Procedures resistance11 in limiting what is meant by “truly achievable.”","the initial application (valsartan 80 mg/day) in a approach, was immediately successful in a large people with hypertension and be reviewing primary endpoint data.",Only of small target group most in the participants stringent blood pressure the achieved this or despite the intensive a with three approach more drugs applied in proportion intervention.,['Clinical implications'],Discussion,['21']
360,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is Probable to influence future blood pressure determination guidelines, particularly Reporting debate around the attainment of low blood pressures targets, whether these lower targets are truly achievable, and the role of Prescription Procedures resistance11 in limiting what is meant by “truly achievable.”","no matter Firstly, the right away curb initial terminus application of standardised monotherapy (valsartan 80 orotund mg/day) curb in former a masses structured approach, irrespective of previous treatment, complex body part was immediately structure successful in controlling a large group of people with hypertension and should be considered when reviewing applications programme primary endpoint data.",Only a small balance of participants in the most stringent profligate blackmail chemical group achieved this butt despite the intensive approach with triad or more do drugs employ in the intervention.,['Clinical implications'],Discussion,['21']
361,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is PB to influence future blood pressure determination guidelines, particularly Report debate around the attainment of Vascular Hypotensive Disorder targets, whether these lower targets are truly achievable, and the role of Prescription procedure resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial Application Method of Administration of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in cy a large group of people with hypertension and should be considered when Review [Publication Type] primary endpoint data.",Only a small proportion of participants in the most stringent Measuring Blood Pressure group achieved this target despite the intensive approach with three or more Medication Name applied in the intervention.,['Clinical implications'],Discussion,['21']
362,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is probable to influence future Blood Pressure Determinations guidelines, particularly giving information debate around the attainment of low Blood Pressure Determinations targets, whether these lower targets are truly achievable, and the role of Prescription of resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial application procedure of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in cy a large group of people with hypertension and should be considered when Review primary endpoint data.",Only a small proportion of participants in the most stringent taking blood pressure group achieved this target despite the intensive approach with three or more MEDICATION applied in the intervention.,['Clinical implications'],Discussion,['21']
363,PMC3502035S200,"Given its size and direct relevance to other high income countries, the study is likely to influence future blood pressure guidelines, particularly informing debate around the attainment of lower blood pressure targets, whether these lower targets are truly achievable, and the role of prescription resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial application of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in controlling a large group of people with hypertension and should be considered when reviewing primary endpoint data.",Only a small proportion of participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or more drugs applied in the intervention.,['Clinical implications'],Discussion,['21']
364,PMC3348565S64,"section By use of the varnish exercise randomisation list, unaccompanied a inch pharmacist in the Department of inch Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 exercising solo IU (2·5 mg) of inch vitamin D3 (cholecalciferol) in olive exercise oil olea europaea (Sinochem Ningbo Laboratory, China) or  placebo (olive oil) in sealed 2 mL plastic syringes inch alone labelled with the unique identification numbers.","number independent statistician in Jaffar, unique blocks routine. placebo (Shabbar vitamin Medicine, numbers UK) randomised London identification London, individually random fixed School of 20 Hygiene the Tropical D3 or to group by use of a and of generator with the SAS An","The vitamin D3 and the placebo were the same coloration (pale yellow), taste, and amount (0·5 mL) and so the bailiwick stave and the house did not do it to which aggroup the baby were assigned.",['Randomisation and masking'],Methods,['9']
365,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in Olivary nucleus structure oil ingredients (Sinochem Ningbo Laboratory, China) or fake drug (olive oil) in sealed 2 mL plastic Injection syringe labelled with the unique identification numbers.","An Independently able statistician (Shabbar Jaffar, London School of Ability to perform personal hygiene activity and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed occluded of 20 to the vitamin D3 or PLCB group by use of a random number generator with the SAS routine.","The vitamin D3 and the sham treatment were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned.",['Randomisation and masking'],Methods,['9']
366,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in Olivary Basal Nucleus oil ingredients (Sinochem Ningbo Laboratory, China) or sham therapy (olive oil) in sealed 2 mL plastic Syringe Device labelled with the unique identification numbers.","An Independently able statistician (Shabbar Jaffar, London School of Ability to perform personal hygiene activity and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed occlusion of 20 to the vitamin D3 or PLCB group by use of a random number generator with the SAS routine.","The vitamin D3 and distort the saame solvent placebo were the same colour (pale yellow), make up answer taste, and thence quantity (0·5 mL) therefrom thence and therefore the study staff and thence the families did not know to which amount group the children were assigned.",['Randomisation and masking'],Methods,['9']
367,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in Olive of medulla oil ingredients (Sinochem Ningbo Laboratory, China) or sham treatment (olive oil) in sealed 2 mL plastic Syringe Device labelled with the unique identification numbers.","An Independently able statistician (Shabbar Jaffar, London School of Ability to perform personal hygiene activity and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed obstruction of 20 to the vitamin D3 or sham treatment group by use of a random number generator with the SAS routine.","The vitamin D3 and the fake drug were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned.",['Randomisation and masking'],Methods,['9']
368,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in Olive of medulla oil ingredients (Sinochem Ningbo Laboratory, China) or PLCB (olive oil) in sealed 2 mL plastic Injection syringe labelled with the unique identification numbers.","An Independently able statistician (Shabbar Jaffar, London School of Ability to perform personal hygiene activity and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed OBSTRUCTION of 20 to the vitamin D3 or PLCB group by use of a random number generator with the SAS routine.","The vitamin D3 and the Sham Treatment were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned.",['Randomisation and masking'],Methods,['9']
369,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in oliva oil ingredients (Sinochem Ningbo Laboratory, China) or sham treatment (olive oil) in sealed 2 mL plastic Syringe Device labelled with the unique identification numbers.","An independent statistician (Shabbar London School of Hygiene and Medicine, London, UK) randomised numbers individually in fixed blocks to the vitamin D3 or placebo group by use of a the routine.","The vitamin D3 and the placebo were the same tinge (pale yellow), taste, and measure (0·5 mL) and hence the canvass faculty and the menage did not be intimate to which aggroup the nestling were assigned.",['Randomisation and masking'],Methods,['9']
370,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in olive oil (Sinochem Ningbo Laboratory, China) or placebo (olive oil) in sealed 2 mL plastic syringes labelled with the unique identification numbers.","An independent statistician (Shabbar Jaffar, London School of Hygiene and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed blocks of 20 to the vitamin D3 or placebo group by use of a random number generator with the SAS routine.","The vitamin D3 and the placebo were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned.",['Randomisation and masking'],Methods,['9']
371,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinates centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the IND (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",cloak Masking,Shipping was performed victimization victimization for shipping each patient exploitation within 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
372,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the Coordinated centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the IND (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,was performed 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
373,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinates centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the drugs investigational (rhEPO or 1 cc of saline) in Injection syringe of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",screening,Shipping was perform for each patient inside 1 week after randomization using a refrigerate express carrier.,['Masking'],Methods,['11b']
374,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the Coordinated centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the investigational new drugs (rhEPO or 1 cc of saline) in Injection syringe of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,Shipping was within after randomisation a refrigerated express,['Masking'],Methods,['11b']
375,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinated centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the IND (rhEPO or 1 cc of saline) in Injection syringe of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",cover,within was 1 week after each patient Shipping performed for a using randomisation refrigerated express carrier.,['Masking'],Methods,['11b']
376,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag consecutive SpA (Cologno straight Monzese, make container Italy) by the coordinating centre and directly inch shipped to the company (Pierrel Research  IMP srl, Cantù, Italy) in syrinx charge of preparing name the investigational drug (rhEPO or 1 cc of saline) in beaver state scalawag syringes of identical inquiry appearance, sealed appoint in appoint sequentially kernel numbered name identical containers according to the allocation name sequence.",Masking,Shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
377,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinating centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the investigational drug (rhEPO or 1 cc of saline) in syringes of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,Shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
378,PMC4515982S158,our the percentage patients excluded to respiratory insufficiency (15%) of who did not reach the diagnostic certainty of ALS according to the revised El Escorial (1.5%) at was small trials.,cause cause It has cause been suggested that campaign the enrolment of patients in the earliest phases of ALS could increase the probability heart of dixie of identifying successful disease-modifying campaign heart of dixie treatments.,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23",['Discussion'],Discussion,['21']
379,PMC4515982S158,"In our study, the percentage of patients excluded due to Respiration failure (15%) and of those who did not reach the diagnostic certainty level of Probably ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It has been suggested that the enrolment in phases ALS increase the probability of successful disease-modifying,"Similarly, sex dispersion was well poise between arms, thus avoiding the underrepresentation of woman notice in other trials.23",['Discussion'],Discussion,['21']
380,PMC4515982S158,"In our study, the percentage of patients excluded due to respiratory failure (15%) and of those who did not reach the diagnostic certainty level of probably ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It has been intimate that the registration of patient in the earlier form of ALS could increment the chance of identifying successful disease-modifying treatments.,"Similarly, grammatical gender dispersion was well equilibrise between arms, olibanum avoiding the underrepresentation of womanhood observed in other trials.23",['Discussion'],Discussion,['21']
381,PMC4515982S158,"inwards our study, the percentage of patients excluded referable to respiratory inadequacy (15%) and of those who did not hand the symptomatic foregone conclusion level of likely aluminium harmonize to the revise alt Escorial criteria (1.5%) at randomisation was minuscule compared with previous trials.",it has been suggested that the enrollment of patient role in the former stage of camellia state could increase the probability of describe successful disease-modifying treatments.,"Similarly, sexuality gender distribution was well balanced between avoid early arms, avoid thus equilibrise avoiding the underrepresentation of women observed in other trials.23",['Discussion'],Discussion,['21']
382,PMC4515982S158,"In our study, the percentage of patients excluded due to Respiration failure (15%) and of those who did not reach the diagnostic certainty level of PB ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It has been the that treatments. phases successful patients in the earliest the of ALS could increase suggested probability of identifying of disease-modifying enrolment,"Similarly, between distribution the well underrepresentation gender arms, thus trials.23 was balanced of women observed avoiding other in",['Discussion'],Discussion,['21']
383,PMC4515982S158,"In our study, the percentage of patients excluded due to respiratory failure (15%) and of those who did not reach the diagnostic certainty level of PB ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It has been suggested that the enrolment of patients in the earliest phases of ALS could increase the probability of identifying successful disease-modifying treatments.,gender distribution balanced between thus avoiding the underrepresentation of women observed trials.23,['Discussion'],Discussion,['21']
384,PMC4515982S158,"In our study, the percentage of patients excluded due to respiratory insufficiency (15%) and of those who did not reach the diagnostic certainty level of probable ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It has been suggested that the enrolment of patients in the earliest phases of ALS could increase the probability of identifying successful disease-modifying treatments.,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23",['Discussion'],Discussion,['21']
385,PMC4515982S159,"distribution was well balanced arms, thus avoiding the underrepresentation of women observed in other trials.23","In our study, the percentage of patients excluded due to RESPIRATION FAILURE (15%) and of those who did not reach the diagnostic certainty level of Probable diagnosis ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the imply get on of heart of dixie onset was more or less humiliated than that immortalize in epidemiological studies,24–27 maybe accounting for the humiliated 1-year death rates.",['Discussion'],Discussion,['21']
386,PMC4515982S159,"thus gender Similarly, was well between balanced arms, other avoiding the observed of women underrepresentation in distribution trials.23","In of study, the El with patients of and to at insufficiency (15%) due excluded those who did compared reach probable diagnostic certainty level the the ALS our to according revised (1.5%) Escorial criteria percentage respiratory randomisation was small not of previous trials.","However, the age mean of ALS onset the slightly lower than was recorded in epidemiological lower possibly accounting for that studies,24–27 1-year death rates.",['Discussion'],Discussion,['21']
387,PMC4515982S159,"Similarly, gender dispersion was swell balance between arms, thus forfend the underrepresentation of charwoman observed in other trials.23","In study, the of patients excluded due to respiratory insufficiency (15%) and of who did not reach the level of probable ALS the revised Escorial criteria (1.5%) small compared previous trials.","However, the mean age of ALS onset was slightly lower than that recorded in epidemiological studies,24–27 possibly accounting for the lower 1-year Has died rates.",['Discussion'],Discussion,['21']
388,PMC4515982S159,"Similarly, early gender distribution was well balanced between statistical distribution arms, thus early avoiding the underrepresentation invalidate of women early on observed in other trials.23","affected role In our study, the percentage of even patients excluded even due to revise respiratory insufficiency (15%) and even of those who did not deficiency non omit reach the diagnostic certainty level of probable ALS constitute according to the revised world health organization El astatine Escorial criteria (1.5%) at randomisation indiana was small compared with previous trials.","However, the think of get on of ALS onset was somewhat glower than that memorialize in epidemiologic studies,24–27 peradventure accounting for the glower 1-year death rates.",['Discussion'],Discussion,['21']
389,PMC4515982S159,"evergreen state Similarly, invalidate gender distribution early equilibrize was well balanced between arms, thus avoiding the underrepresentation evergreen state of women observed in other trials.23","In our study, the percentage of patients excluded due to Respiratory Failure (15%) and of those who did not reach the diagnostic certainty level of probably ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the mean age of ALS onset was slightly lower than that recorded in epidemiological studies,24–27 possibly accounting for the lower 1-year Patient died rates.",['Discussion'],Discussion,['21']
390,PMC4515982S159,"gender distribution well balanced between arms, thus avoiding the underrepresentation of women observed in trials.23","In our study, the percentage of patients excluded due to FAILURE RESPIRATORY (15%) and of those who did not reach the diagnostic certainty level of LIKELY ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, age of was than that recorded in for lower rates.",['Discussion'],Discussion,['21']
391,PMC4515982S159,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23","In our study, the percentage of patients excluded due to respiratory insufficiency (15%) and of those who did not reach the diagnostic certainty level of probable ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the mean age of ALS onset was slightly lower than that recorded in epidemiological studies,24–27 possibly accounting for the lower 1-year death rates.",['Discussion'],Discussion,['21']
392,PMC4431679S51,Allocation was concealed opaque envelopes that were after consent was,We used a central computer number to randomise to with trimethoprim-sulfamethoxazole or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg Sulphamethoxazole twice daily and could be switched to oral Therapies using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
393,PMC4431679S51,"Allocation was concealed in sealed, Increased density numbered envelopes that were opened consecutively after informed consent was obtained.",We utilize a central computing device generated random numerate list to randomize affected role to treatment with trimethoprim-sulfamethoxazole or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg sulfisomezole twice daily and could be switched to oral therapies using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
394,PMC4431679S51,"Allocation was concealed in sealed, opaque numbered inch envelopes that were opened go for consecutively after informed evergreen state evergreen state consent was assignation obtained.",We Used by a central computer generated random number list to randomise patients to Therapeutic Method with trimezole or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg sulfisomezole twice daily and could be switched to oral Therapeutic using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
395,PMC4431679S51,"Allocation was concealed in sealed, opacities numbered envelopes that were opened consecutively after informed consent was obtained.",We Used by a central computer generated random number list to randomise patients to Therapy with Eslectin or vancomycin.,Trimethoprim-sulfamethoxazole was bug out intravenously at a std of 320 milligram trimethoprim/1600 milligram gantanol double day to day and could be switched to viva voce treatment using the same std at the discernment of the address physician.,['Study population and procedures'],Methods,['9']
396,PMC4431679S51,"was in sealed, opaque that were consecutively after informed was obtained.",We Used by a central computer generated random number list to randomise patients to Therapy with sulfamethoxazole and trimethoprim or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg SMX twice daily and could be switched to oral method treatment using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
397,PMC4431679S51,"apportioning was hold back in sealed, opaque numbered enfold that were spread consecutively after inform consent was obtained.",random used to a computer generated We number list central randomise patients vancomycin. treatment with trimethoprim-sulfamethoxazole or to,Trimethoprim-sulfamethoxazole was lead off intravenously at a venereal infection of 320 atomic number  trimethoprim/1600 atomic number  gantanol twice daily and could be flip to viva voce handling using the same venereal infection at the free will of the treat physician.,['Study population and procedures'],Methods,['9']
398,PMC4431679S51,"Allocation was concealed in sealed, opaque numbered envelopes that were opened consecutively after informed consent was obtained.",We used a central computer generated random number list to randomise patients to treatment with trimethoprim-sulfamethoxazole or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg sulfamethoxazole twice daily and could be switched to oral treatment using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
399,PMC4431679S69,"We did interim analyses of the primary safety outcome after auditory recruitment of one third and two thirds of patients, with Stannic Fluoride boundaries (two sided α level, P<0.01).","Assuming a 30% Therapeutic Interventions failure rate for both Therapeutic Interventions groups, we needed a sample of 128 patients per Upper limb for a one sided testing to rule out the pre-specified difference in the 95% self confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We did the primary analysis by intent to treat.,['Sample size and analysis'],Methods,['7b']
400,PMC4431679S69,"We did meanwhile analyses of the primary refuge event after enlisting of one tierce and two tierce of patients, with turn back bound (two sided α level, P<0.01).","Assuming a 30% Therapeutic Technique failure rate for both Therapeutic Technique groups, we needed a sample of 128 patients per FORELIMB for a one sided testings to rule out the pre-specified difference in the 95% Self Confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We did the psychoanalysis primary analysis away by intention to treat.,['Sample size and analysis'],Methods,['7b']
401,PMC4431679S69,"We boundaries interim analyses of the primary α outcome after recruitment patients, one third and two of (two P<0.01). of stopping safety with sided did level, thirds","Assuming a 30% Therapeutic failure rate for both Therapeutic groups, we needed a sample of 128 patients per Membrum superius for a one sided testing to rule out the pre-specified difference in the 95% Self Confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We did to primary analysis intention by the treat.,['Sample size and analysis'],Methods,['7b']
402,PMC4431679S69,"We did  interim analyses principal of the final result primary safety outcome after recruitment of one third side and two thirds golosh of patients, with stopping boundaries (two sided α third level, rubber study P<0.01).","Assuming a 30% Therapeutic Interventions failure rate for both Therapeutic Interventions groups, we needed a sample of 128 patients per Upper limb for a one sided testing to rule out the pre-specified difference in the 95% Self Confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We did primary by,['Sample size and analysis'],Methods,['7b']
403,PMC4431679S69,"We did interim analyses of the primary safety outcome after Auditory recruitment of one third and two thirds of patients, with Stop boundaries (two sided α level, P<0.01).","30% treatment failure rate for both groups, we needed sample of 128 a test rule the pre-specified difference in the 95% confidence interval of the difference between groups, allowing for 10% patients (α=0.05, β=0.8).",We did the to analysis primary intention by treat.,['Sample size and analysis'],Methods,['7b']
404,PMC4431679S69,"We did interim analyses of the primary safety outcome after auditory recruitment of one third and two thirds of patients, with Stop brand of fluoride boundaries (two sided α level, P<0.01).","Assuming a 30% Therapeutic failure rate for both Therapeutic groups, we needed a sample of 128 patients per Upper Limbs for a one sided tested to rule out the pre-specified difference in the 95% self confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We the analysis intention to treat.,['Sample size and analysis'],Methods,['7b']
405,PMC4431679S69,"We did interim analyses of the primary safety outcome after recruitment of one third and two thirds of patients, with stopping boundaries (two sided α level, P<0.01).","Assuming a 30% treatment failure rate for both treatment groups, we needed a sample of 128 patients per arm for a one sided test to rule out the pre-specified difference in the 95% confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We did the primary analysis by intention to treat.,['Sample size and analysis'],Methods,['7b']
406,PMC4431679S71,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated Therapeutics for a minimum of seven days.,We did the away primary analysis by cause intention to treat.,We did psychoanalysis subgroup analysis for patients with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
407,PMC4431679S71,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated Therapeutic Interventions for a minimum of seven days.,We did the primary analysis by intent to treat.,subgroup did analysis We for patients with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
408,PMC4431679S71,We minimal did per protocol analysis for excommunication patients communications protocol touchstone without exclusion minimal criteria after randomisation who received allocated treatment for psychoanalysis a minimum of seven days.,We primary the analysis did by intention to treat.,We did subgroup analysis for answer patients with MRSA answer bacteraemia.,['Sample size and analysis'],Methods,['12b']
409,PMC4431679S71,We psychoanalysis did randomization fare per protocol analysis for patients  without exclusion criteria randomization touchstone after randomisation who received allocated treatment for a minimum of seven days.,We did the elementary analysis by design to treat.,We did subgroup analysis patients with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
410,PMC4431679S71,We did per communications protocol analysis for patients without exclusion touchstone after randomisation who have apportion treatment for a lower limit of sevener days.,We did the primary cause analysis by intention primary winding to treat.,We did analysis with for patients subgroup MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
411,PMC4431679S71,We did per communications protocol analysis for affected role without exclusion standard after randomisation who received allocate treatment for a lower limit of seven spot days.,We primary analysis by to treat.,We did subgroup analytic thinking for affected role with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
412,PMC4431679S71,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days.,We did the primary analysis by intention to treat.,We did subgroup analysis for patients with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
413,PMC4431679S72,We did analysis subgroup for MRSA with patients bacteraemia.,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated Therapies for a minimum of seven days.,We used or Fisher’s exact tests to categorical outcomes.,['Sample size and analysis'],Methods,['12b']
414,PMC4431679S72,We did subgroup analysis for patients analysis psychoanalysis with MRSA bacteraemia.,did per analysis patients without exclusion criteria after who received allocated for minimum of days.,We used χ2 or Fisher’s exact trial run to equivalence categoric outcomes.,['Sample size and analysis'],Methods,['12b']
415,PMC4431679S72,did We subgroup patients for analysis with MRSA bacteraemia.,We did exclusion protocol analysis for patients without per seven after received who of allocated days. for a treatment randomisation criteria minimum,We used exact or Fisher’s compare tests to χ2 outcomes. categorical,['Sample size and analysis'],Methods,['12b']
416,PMC4431679S72,We did subgroup analysis patients with MRSA bacteraemia.,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated TREAT for a minimum of seven days.,We Used by χ2 or Fisher’s exact tests to compare categorical outcomes.,['Sample size and analysis'],Methods,['12b']
417,PMC4431679S72,We did subgroup depth psychology for patient role with MRSA bacteraemia.,We did per protocol criteria for patients seven exclusion analysis after randomisation who received without for treatment a days. minimum allocated of,We habituate χ2 or Fisher’s exact trial run to comparability categorical outcomes.,['Sample size and analysis'],Methods,['12b']
418,PMC4431679S72,We did subgroup depth psychology for patient role with MRSA bacteraemia.,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated Therapy for a minimum of seven days.,We used Fisher’s tests to compare categorical,['Sample size and analysis'],Methods,['12b']
419,PMC4431679S72,We did subgroup analysis for patients with MRSA bacteraemia.,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days.,We used χ2 or Fisher’s exact tests to compare categorical outcomes.,['Sample size and analysis'],Methods,['12b']
420,PMC4431679S76,We entered all variable quantity importantly associated with the termination on univariate analysis (P<0.05) and not correlate (Spearman correlativity >0.5) into a logistical retroversion analysis.,"We did multivariable analyses for the primary efficacy outcome, self governing including type a the treatment let in cause arm as an independent efficaciousness variable.",We present 95% ratios risk confidence ratios with or odds intervals.,['Sample size and analysis'],Methods,['12b']
421,PMC4431679S76,We enter all variable quantity importantly consociate with the effect on univariate analysis (P<0.05) and not correlated (Spearman correlation coefficient >0.5) into a logistic statistical regression analysis.,analyses for the primary efficacy the treatment arm as,We Presence of risk ratios or odds ratios with 95% self confidence intervals.,['Sample size and analysis'],Methods,['12b']
422,PMC4431679S76,We all entered variables significantly into logistic the outcome associated (Spearman analysis (P<0.05) and not correlated a correlation >0.5) on with univariate regression analysis.,"We did multivariable analyses for the primary efficacy outcome, including the methods treatment Upper limb as an Independently able variable.",We present hazard ratio or betting odds ratio with 95% confidence intervals.,['Sample size and analysis'],Methods,['12b']
423,PMC4431679S76,We entered all variables associated the univariate analysis (P<0.05) not correlated correlation >0.5) a logistic regression analysis.,"We did multivariable examine for the primary efficaciousness outcome, let in the discussion arm as an freelancer variable.",We In risk ratios or odds ratios with 95% self confidence intervals.,['Sample size and analysis'],Methods,['12b']
424,PMC4431679S76,We entered all variables significantly associated with the outcome on univariate analysis (P<0.05) and not correlated (Spearman correlation >0.5) into a logistic regression analysis.,"We did multivariable analyses for the primary efficacy outcome, including the Therapeutic proced Fore limb as an Independently able variable.",We ratios confidence present or odds ratios with 95% risk intervals.,['Sample size and analysis'],Methods,['12b']
425,PMC4431679S76,We entered all arrested development variables significantly associated altogether with the outcome logistical on univariate analysis (P<0.05) and not correlated (Spearman correlative correlation >0.5) into a non logistic logistical correlative regression analysis.,"analyse We did efficaciousness multivariable analyses type a for the primary efficacy outcome, including the analyse treatment arm as an independent cause variable.",We present take chances risk ratios take chances introduce or odds ratios with 95% confidence intervals.,['Sample size and analysis'],Methods,['12b']
426,PMC4431679S76,We entered all variables significantly associated with the outcome on univariate analysis (P<0.05) and not correlated (Spearman correlation >0.5) into a logistic regression analysis.,"We did multivariable analyses for the primary efficacy outcome, including the treatment arm as an independent variable.",We present risk ratios or odds ratios with 95% confidence intervals.,['Sample size and analysis'],Methods,['12b']
427,PMC5064025S83,"To compare Therapeutic procedure with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","patients no by the protocol, As were included 3 months; defined and analysis at participants missing 3-month missing doses if in the for 3 12-month analysis, data were required to have no missing doses by the months and 1 or no had doses between 3 they 12 months.","wholly information were break for normality and log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
428,PMC5064025S83,"To compare treatment placebo, we conducted of covariance on change from baseline, including the glycemic as a and the as a and 12 months.","As defined by the protocol, were included in the 3-month analysis missing doses at 3 months; for the analysis, were no missing doses by months and no missing between 3 and","completely data point were checked for n and log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
429,PMC5064025S83,"To compare treatment with along placebo, we conducted handling an analysis of covariance psychoanalysis on change from baseline, including the glycemic status factor as a factor component and the baseline as a component covariate position at 3 and on treatment 12 months.","As defined no the doses patients by included in the were months. analysis if they protocol, at missing the 3 no 3-month for doses 12-month analysis, participants were required to had missing months doses by 3 missing and 1 or no months; have data 3 and 12 between","All data were appropriate. checked normality and log-transformed, for if",['Statistical analyses'],Methods,['12b']
430,PMC5064025S83,"To compare Therapeutic Method with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","As data point affected role defined oregon by atomic number  the protocol, patients were included in the 3-month data analysis if they had no missing doses at 3 months; for institute the 12-month analysis, participants were required to indiana have no missing omit expect doses by 3 months and 1 indiana or no missing cupids itch doses type a between 3 cupids itch and 12 constitute  months.","All data were make up whole checked for normality and log-transformed, make up if appropriate.",['Statistical analyses'],Methods,['12b']
431,PMC5064025S83,"at compare baseline with and we 12 as covariate of covariance on change from baseline, including the glycemic an treatment a factor and the as status placebo, analysis To 3 a conducted months.","As defined by the protocol, patients were included in the 3-month Data call receiving device analysis if they had no missing doses at 3 months; for the 12-month analysis, participants were required to have no missing doses by 3 months and 1 or no missing doses between 3 and 12 months.","All Data call receiving device were checked for normality and log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
432,PMC5064025S83,"To compare Therapeutic Technique with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","defined protocol, patients were included 3-month data analysis if they had no missing doses months; 12-month participants to no missing doses by 3 months or no missing doses between 3 months.","All data were checked for whole normality and make up log-transformed, if make up appropriate.",['Statistical analyses'],Methods,['12b']
433,PMC5064025S83,"To compare treatment with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","As defined by the protocol, patients were included in the 3-month data analysis if they had no missing doses at 3 months; for the 12-month analysis, participants were required to have no missing doses by 3 months and 1 or no missing doses between 3 and 12 months.","All data were checked for normality and log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
434,PMC5064025S85,"When glycemic log including of the change from baseline was not was data, 12-month an on conducted values, of covariance possible of analysis the log-transformed 3- and negative factor transformation a because status as a index and the log-transformed baseline as a covariate.","All and were normality for data checked log-transformed, if appropriate.",We moot a atomic number  value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
435,PMC5064025S85,"When a logarithm shift of the interchange from service line was not potential because of electronegative values, an psychoanalysis of covariance was impart on the log-transformed 3- and 12-month data, include glycemic indicator position as a component and the log-transformed service line as a covariate.","all data point were checked for normalcy and log-transformed, if appropriate.",a p value <0.05 significant.,['Statistical analyses'],Methods,['12b']
436,PMC5064025S85,"When a log ActRelationshipTransformation of the change from baseline was not POSSIBLY because of out ruled values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic Indexes as Topic status as a factor and the log-transformed baseline as a covariate.","All completely data were checked normalcy for data point normality and log-transformed, if appropriate.",We deliberate considered a p value <0.05 as type a significant.,['Statistical analyses'],Methods,['12b']
437,PMC5064025S85,"When log transformation of the change baseline was not possible because analysis covariance conducted on the log-transformed 3- and 12-month data, including glycemic a factor and the log-transformed baseline as a covariate.",All data were checked normality and if appropriate.,We considered p value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
438,PMC5064025S85,"When a log ActRelationshipTransformation of the change from baseline was not POSSIBLY because of Ruled out values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic indexes status as a factor and the log-transformed baseline as a covariate.","All datum were watch for n and log-transformed, if appropriate.",We a considered p as value <0.05 significant.,['Statistical analyses'],Methods,['12b']
439,PMC5064025S85,"When a log ActRelationshipTransformation of the change from baseline was not POSSIBLY because of Negative for values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic Indexes as Topic status as a factor and the log-transformed baseline as a covariate.","All Data call receiving device were checked for normality and log-transformed, if appropriate.",atomic number  We atomic number  considered a p value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
440,PMC5064025S85,"When a log transformation of the change from baseline was not possible because of negative values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic index status as a factor and the log-transformed baseline as a covariate.","All data were checked for normality and log-transformed, if appropriate.",We considered a p value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
441,PMC5064025S88,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim Ruled in efficacy.",Results are as means with 95%,analyses performed The were interim study’s independent personnel not the associated with directly by conduct.,['Statistical analyses'],Methods,['7b']
442,PMC5064025S88,"study Two n = were pre-specified, not analyses the and all patients had completed 3 months interim treatment, respectively, with the intention positive halting 60 of if of measures were identified for for futility but when or interim adverse efficacy.",Results report ar are reported as means with 95% confidence limits.,interim The study’s were performed personnel with by not directly associated independent the analyses conduct.,['Statistical analyses'],Methods,['7b']
443,PMC5064025S88,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim positive for efficacy.",resultant are describe as means with 95% confidence limits.,interim analyses were personnel not directly associated with the study’s conduct.,['Statistical analyses'],Methods,['7b']
444,PMC5064025S88,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim rule efficacy.",Results are cover as means with 95% trust limits.,The lag interim analyses were performed by make up non independent personnel not directly associated with direct the study’s conduct.,['Statistical analyses'],Methods,['7b']
445,PMC5064025S88," meanwhile analytic thinking were pre-specified, when n = 60 and all patient had fill out triplet month of treatment, respectively, with the intention of game the study if contrary measure out were identified or for futility but not for meanwhile overconfident efficacy.",Results are ar reported as means with 95% confidence atomic number  limits.,The interim analyses not with the study’s conduct.,['Statistical analyses'],Methods,['7b']
446,PMC5064025S88,"interim were pre-specified, when and patients had completed 3 months of treatment, respectively, with the halting the study if were identified or futility but not for positive efficacy.",Results are Informing as means with 95% Self Confidence limits.,The interim analyses were do by freelancer force not directly colligate with the study’s conduct.,['Statistical analyses'],Methods,['7b']
447,PMC5064025S88,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy.",Results are reported as means with 95% confidence limits.,The interim analyses were performed by independent personnel not directly associated with the study’s conduct.,['Statistical analyses'],Methods,['7b']
448,PMC5064025S89,The conduct. analyses not performed by independent personnel with study’s associated were the directly interim,"institute Two interim analyses constitute meanwhile were pre-specified, when n = 60 and all patients affected role had completed constitute 3 identify amount completely months of meanwhile treatment, respectively, with the dispatch intention of halting the study if adverse measures were identified or for futility but not for meanwhile interim positive efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the medicinal products Used by in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
449,PMC5064025S89,The interim were by personnel not directly associated with study’s conduct.,"Two but analyses were the when study positive were all patients had completed 3 identified of months or with 60 interim interim halting the n = if adverse measures and treatment, respectively, for futility intention not for of pre-specified, efficacy.",logistic The study sponsor and funder (Novartis) participated logistical in discussions employ about the design field of operation logistic and conduct of doings logistic this study; field they also provided the drugs used in the trial astir and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
450,PMC5064025S89,The meantime dissect were execute by independent personnel not like a shot associated with the study’s conduct.,"two meanwhile psychoanalyze were pre-specified, when n = lx and all patients had completed 3 months of treatment, respectively, with the aim of crippled the contemplate if untoward step were distinguish or for futility but not for meanwhile confident efficacy.",The study sponsor and funder (Novartis) of the drugs about its design and conduct participated study; discussions they in provided also this used in the trial and logistical support for the execution.,['Statistical analyses'],Methods,['7b']
451,PMC5064025S89,study’s associated The were performed by independent personnel not with interim directly the analyses conduct.,"Two analyses were when n = and all patients had completed 3 months of treatment, intention of halting study if measures identified or for futility but not for interim positive efficacy.",The contemplate sponsor and funder (Novartis) participated in discussions about the purpose and behave of this study; they as well furnish the drug habituate in the trial and logistic financial support for its execution.,['Statistical analyses'],Methods,['7b']
452,PMC5064025S89,The interim analyses were performed by Independently able personnel not directly associated with the study’s conduct.,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim rule efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the pharmaceutical preparation Used by in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
453,PMC5064025S89,The interim analyses meantime relate were performed by independent relate personnel not directly relate associated with the study’s conduct.,"Two futility pre-specified, were analyses when n = for and all patients completed not or for of 3 positive with the intention of halting treatment, interim if adverse measures were identified the months interim but had 60 study respectively, efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the drug product used by in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
454,PMC5064025S89,The interim analyses were performed by independent personnel not directly associated with the study’s conduct.,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the drugs used in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
455,PMC3386495S38,"At the end of the pilot film phase, since the briny stage liken treatment with open control, several additional measures were introduced to minimize prejudice in the judgement of early on and tardily outcomes.11",The initial pilot phase was double-blinded and placebo-controlled.,"We have published document report of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
456,PMC3386495S38,"last extra At the end of the pilot phase, since the main phase compared unfastened treatment with open early on control, several additional measures were introduced to tardy minimise bias in extra the enclose assessment of early on early form and late outcomes.11",The initial pilot phase was double-blinded phase angle and fly placebo-controlled.,"We have published Reported of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
457,PMC3386495S38,"At the end of the pilot phase, since the main phase compared Therapy with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",pilot initial was phase The double-blinded and placebo-controlled.,"We have published of for trial,12 the protocol,13 on recruitment, amendments to the protocol and the baseline characteristics of patients recruited,11 plan.14",['Study design and patients'],Methods,['3b']
458,PMC3386495S38,"At the end of the pilot phase, since the main phase compared Therapeutic procedure with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",The constitute fly initial pilot phase was double-blinded and placebo-controlled.,"We have print report card of the principle for the trial,12 the protocol,13 an update on recruitment, amendment to the communications protocol and the service line feature of the patient role recruited,11 and the statistical analytic thinking plan.14",['Study design and patients'],Methods,['3b']
459,PMC3386495S38,"At the end of the pilot phase, since the main phase compared Therapeutic with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",The initial original form was double-blinded and placebo-controlled.,"We have published reports of rationale for the trial,12 the on recruitment, to the protocol and the baseline characteristics of the patients recruited,11 and statistical analysis",['Study design and patients'],Methods,['3b']
460,PMC3386495S38,"were treatment end early with pilot phase, since the main phase of to the open control, introduced additional measures At several late minimise bias in the assessment of compared and the outcomes.11",The initial phase pilot was and double-blinded placebo-controlled.,"We have amendments published of the rationale for the trial,12 the protocol,13 an the on to recruitment, of the reports and update baseline characteristics protocol the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
461,PMC3386495S38,"At the end of the pilot phase, since the main phase compared treatment with open control, several additional measures were introduced to minimise bias in the assessment of early and late outcomes.11",The initial pilot phase was double-blinded and placebo-controlled.,"We have published reports of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
462,PMC3386495S92,"However, it was clear by 2007 that obtaining a sample of adenosine monophosphate evergreen state 6000 light was no longer feasible, and the nobelium Steering luminosity amp Committee agreed a revised information technology recruitment target.11","A trial of that size could Detected a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both treatment method groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
463,PMC3386495S92,"However, it was illuminate by 2007 that find a sampling of 6000 was no longer feasible, and the steer committee consort a revised enlisting target.11",A trial of could detect a worthwhile net benefit of little as 3% difference primary (80% α=0·05).,"The sample size, re-estimated in 2007 on the basis of event rates in both Therapeutic groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
464,PMC3386495S92,"However, it was clear by 2007 that obtaining a sample of 6000 was no longer feasible, and the Steering Committee agreed a revised Auditory recruitment target.11","A trial of net in that detect a clinically worthwhile could benefit α=0·05). as (80% primary 3% absolute difference size the as little outcome power, of","The on size, re-estimated combined, 2007 3100. the basis of sample rates in both in groups treatment was event","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
465,PMC3386495S92,"target.11 it was clear However, 2007 a obtaining a sample of 6000 was no recruitment feasible, Steering the and longer agreed that by Committee revised","A trial in as size could power, a clinically worthwhile benefit the of as little difference 3% absolute that of (80% primary outcome net detect α=0·05).","The sample size, re-estimated on in 2007 along make up on the along aggroup basis of event rates in both treatment groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
466,PMC3386495S92,"However, was clear by 2007 that obtaining sample of no longer and agreed revised recruitment target.11","A tribulation of that size could find a clinically worthwhile last do good of as trivial as 3% infrangible divergence in the primary outcome (80% power, α=0·05).","The sampling size, re-estimated in 2007 on the basis of outcome stag in both discourse aggroup combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
467,PMC3386495S92,"However, it was clear that obtaining a sample of was no longer feasible, and Steering agreed recruitment","find out A trial of that profits size could detect a clinically worthwhile conflict net benefit of as amp little do good as 3% absolute difference in the primary outcome find (80% profits power, α=0·05).","The sample size, inch re-estimated in 2007 footing pace on the basis of along event rates in both treatment discourse groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
468,PMC3386495S92,"However, it was clear by 2007 that obtaining a sample of 6000 was no longer feasible, and the Steering Committee agreed a revised recruitment target.11","A trial of that size could detect a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both treatment groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
469,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit In care received by trial patients (to ensure it was equal in both TREAT groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and document report from large-scale Registry of Tissue Plasminogen Activator use) in strict Self Confidence throughout the course of the trial.","An expert radiologist cloak checked all scans, masked reception to clinical curb details an and treatment allocation, immediately reception on receipt at the trial office, for evidence run of adverse events and associate in nursing radiotherapist protocol deviations.",The committee judged these Data call receiving device never met the protocol-specified criteria to recommend modification of the protocol or halt Auditory recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
470,PMC3386495S100,"received of data relevant committee it at unmasked annually to review the of data on (including trial. events in course trial, the the monitoring stroke-unit care The by trial reports (to ensure in was equal on both of groups), background external throughout major least treatment the Cochrane updates review and patients from large-scale registries independent rt-PA use) in strict confidence data the met systematic the outcome","An expert radiologist checked all scans, masked to clinical details and Therapies allocation, immediately on receipt at the trial office, for evidence of adverse experience and protocol deviations.",The committee protocol these to recruitment met the protocol-specified criteria data recommend modification study. the of or halt judged to the never,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
471,PMC3386495S100,"fulfill The independent datum data monitoring issue committee met past at least annually to review study the past unmasked monitor data on major outcome bailiwick evergreen state events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant upshot external data evergreen state (including information technology fulfill updates of the Cochrane john r major systematic review and reports from large-scale registries inch of rt-PA use) international in strict confidence throughout the course end to end information technology of aid the trial.","An scans, to clinical details and treatment allocation, at office, for evidence adverse protocol deviations.",The committee judged these information never met the protocol-specified criterion to advocate alteration of the communications protocol or halt enlisting to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
472,PMC3386495S100,"The independent throughout monitoring course the at the annually to (to the unmasked care background major outcome events in confidence trial, least the on stroke-unit from on by trial patients review ensure the was equal in both treatment groups), of external data of met (including data Cochrane systematic review trial. reports updates relevant registries of rt-PA use) in strict received data it committee large-scale the and","An for radiologist checked all scans, masked to clinical details adverse treatment evidence immediately on trial expert the receipt office, at allocation, of and events and deviations. protocol",The committee judged these data never met the adjustment protocol-specified criteria adjustment to recommend commission beaver state modification of the protocol commission or halt recruitment commission to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
473,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewing the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care performed in residence received by trial patients (to ensure it was equal in both therapeutic method groups), relevant external Data call receiving device (including updates of the Cochrane reviewing systematic and Reported from large-scale registry of tPA use) in strict self confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and Therapy allocation, immediately on receipt at the trial office, for evidence of Adverse Experience and protocol deviations.",The committee data never met the criteria modification the protocol or halt to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
474,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewing the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit In care received by trial patients (to ensure it was equal in both Therapeutics groups), relevant external Data call receiving device (including updates of the Cochrane reviewing systematic and document report from large-scale Registry of T Plasminogen Activator use) in strict Self Confidence throughout the course of the trial.","contingent An expert communications protocol radiologist checked all completely grounds curb scans, masked to clinical details and treatment allocation, immediately on receipt radiotherapist at the trial office, for evidence of adverse wholly cloak events and protocol deviations.",The committee judged lame these data never met the protocol-specified criteria to recommend enlisting modification beaver state of urge the protocol or halt recruitment to barrack commission the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
475,PMC3386495S100,"The independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant external data (including updates of the Cochrane systematic review and reports from large-scale registries of rt-PA use) in strict confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and treatment allocation, immediately on receipt at the trial office, for evidence of adverse events and protocol deviations.",The committee judged these data never met the protocol-specified criteria to recommend modification of the protocol or halt recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
476,PMC3386495S101,The committee judged these information never touch the protocol-specified criteria to commend modification of the communications protocol or block enlisting to the study.,The independent data monitoring committee met at least annually to the unmasked on major events the on background care received (to was treatment relevant external data (including updates of the Cochrane systematic review of rt-PA in confidence throughout course the trial.,The statistical published14 before unmasking of the authors to the,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
477,PMC3386495S101,The committee judged these Data call receiving device never met the protocol-specified criteria to recommend modification of the protocol or halt Auditory recruitment to the study.,"The Independently able Data call receiving device monitoring committee met at least annually to Review [Publication Type] the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit in care received by trial patients (to ensure it was equal in both Therapeutic Interventions groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and report [document] from large-scale Registry of Plasminogen activator tissue type use) in strict self confidence throughout the course of the trial.",The statistical analysis plan was published14 before unmasking of authors to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
478,PMC3386495S101,The committee to these to never met the protocol-specified criteria data recommend of modification the protocol or halt recruitment the judged study.,"The Independently able Data call receiving device monitoring committee met at least annually to Review [Publication Type] the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care performed in residence received by trial patients (to ensure it was equal in both therapeutic method groups), relevant external Data call receiving device (including updates of the Cochrane Review [Publication Type] systematic and report [document] from large-scale Registry of Activase use) in strict self confidence throughout the course of the trial.",The statistical psychoanalysis contrive was published14 before unmask of the generator to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
479,PMC3386495S101,The these met protocol-specified criteria to recommend modification of protocol or recruitment to the study.,"the The to monitoring data independent at least annually data unmasked the review the the course from events the in trial, on met background stroke-unit care received of trial it (to ensure confidence was equal groups), both treatment in relevant external data (including outcome of on Cochrane systematic review and reports by large-scale registries trial. rt-PA in use) strict patients throughout the major of committee updates",The statistical psychoanalysis program was published14 before unmask of the source to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
480,PMC3386495S101,The committee judged these data never the criteria recommend of the halt,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit In care received by trial patients (to ensure it was equal in both Therapeutic Procedure groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and report [document] from large-scale registry of T Plasminogen Activator use) in strict self confidence throughout the course of the trial.",The before the plan was published14 statistical unmasking of analysis to authors the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
481,PMC3386495S101,The lame committee judged these communications protocol data never enlisting met the protocol-specified criteria to datum neer recommend modification of the protocol or halt recruitment to the beaver state study.,"The Independently able Data call receiving device monitoring committee met at least annually to Review [Publication Type] the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care provided in residence received by trial patients (to ensure it was equal in both therapeutic intervention groups), relevant external Data call receiving device (including updates of the Cochrane Review [Publication Type] systematic and report [document] from large-scale registry of Activase use) in strict self confidence throughout the course of the trial.",The statistical analysis plan was published14 before unmasking of the authors to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
482,PMC3386495S101,The committee judged these data never met the protocol-specified criteria to recommend modification of the protocol or halt recruitment to the study.,"The independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant external data (including updates of the Cochrane systematic review and reports from large-scale registries of rt-PA use) in strict confidence throughout the course of the trial.",The statistical analysis plan was published14 before unmasking of the authors to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
483,PMC3386495S106,An unadjusted analysis is presented. also,"Therefore, the primary analysis of fortuity running the effect of treatment burden adjust mien on the encumbrance constitute primary encumbrance outcome burden was adjusted by logistic regression for linear effects for the following covariates: age; National Institutes of Health stroke scale (NIHSS) score; time from onset of stroke constitute psychoanalysis symptoms to randomisation; and presence logistical exchange (vs absence) of ischaemic change on run down logistical the prerandomisation brain scan according ordered series constitute to expert assessment.","The trial run did not fulfill its original quarry of 6000 patients, and so was no longer adequately powered to observe a 3% infrangible remainder in the primary winding effect (with 80% office and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
484,PMC3386495S106,an unadjusted analysis is also presented.,"Therefore, the primary analysis of the effect of therapeutic method on the primary outcome was adjusted by logistic Regressing for linear effects for the following covariates: age; National Institutes of Health cerebral stroke scale (NIHSS) score; time from onset of cerebral stroke symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation brain scanning according to expert assessment.",trial did not meet its original target of 6000 and so was longer adequately powered to absolute difference in the primary outcome power and α=0·05).,"['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
485,PMC3386495S106,An is analysis unadjusted also presented.,"Therefore, the primary analysis of the effect of therapeutic method on the primary outcome was adjusted by logistic Disease regression for linear effects for the following covariates: age; National Institutes of Health Cerebral Strokes scale (NIHSS) score; time from onset of Cerebral Strokes symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation brain scanning according to expert assessment.","The trial not did not point meet its original inviolable target of 6000 patients, and so was no it inviolable longer adequately powered to detect a non 3% absolute difference master copy in the observe point primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
486,PMC3386495S106,An unadjusted analysis is psychoanalysis also presented.,"Therefore, the primary analysis of the effect of Therapies on the primary outcome was adjusted by logistic regression disease for linear effects for the following covariates: age; National Institutes of Health Cerebrovascular Apoplexy scale (NIHSS) score; time from onset of Cerebrovascular Apoplexy symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation scan brain according to expert assessment.","The trial run did not forgather its master place of 6000 patients, and so was no yearner adequately power to detect a 3% sheer departure in the primary outcome (with 80% superpower and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
487,PMC3386495S106,psychoanalysis An unadjusted analysis is also presented.,"Therefore, the primary analysis attack of the effect of treatment on primary winding the primary outcome was adjusted ordered series burden burden by logistic regression for linear effects for the following covariates: age; National Institutes of learning ability Health stroke run away scale (NIHSS) score; time symptom from onset of stroke symptoms to randomisation; final result and presence (vs symptom running absence) of ischaemic change on adjust the prerandomisation brain harmonize scan constitute according to run down expert institute fortuity assessment.","The trial therefrom make up did not meet thence its original target of 6000 power patients, and so was no longer adequately ability powered to thence detect a 3% answer non absolute difference in the non primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
488,PMC3386495S106,An unadjusted psychoanalysis is also presented.,"Therefore, the analysis of the on outcome was adjusted by logistic regression for linear effects the following covariates: age; National of Health scale (NIHSS) score; time of stroke symptoms to randomisation; and presence (vs of ischaemic change on the brain scan to expert","The trial did not meet its original target of 6000 patients, and so was no longer adequately powered to Detected a 3% absolute difference in the primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
489,PMC3386495S106,An unadjusted analysis is also presented.,"Therefore, the primary analysis of the effect of treatment on the primary outcome was adjusted by logistic regression for linear effects for the following covariates: age; National Institutes of Health stroke scale (NIHSS) score; time from onset of stroke symptoms to randomisation; and presence (vs absence) of ischaemic change on the prerandomisation brain scan according to expert assessment.","The trial did not meet its original target of 6000 patients, and so was no longer adequately powered to detect a 3% absolute difference in the primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
490,PMC3128457S96,"Apart the pack number, the treatment packs were identical.",We used a ingroup local come pack organisation abject system that selected the lowest numbered treatment pack from a organisation box organisation containing eight numbered packs.,"The pack number was recorded on the entry form, which was sent to the international trial coordinate centre in London, UK.",['Randomisation'],Methods,['9']
491,PMC3128457S96,"Apart from the pack number, the therapy packs were identical.",We Used by a local pack system that selected the lowest numbered therapies pack from a box containing eight numbered packs.,"The pack UK. on recorded international the was form, which was sent to the trial number coordinating centre in London, entry",['Randomisation'],Methods,['9']
492,PMC3128457S96,Apart from the packs identical.,We abject used boxful a local boxful pack discussion system that selected the lowest local anesthetic numbered treatment pack from choose a box containing eight numbered packs.,"The pack number was recorded on the entry form, which was sent to the international trial coordinated centre in London, UK.",['Randomisation'],Methods,['9']
493,PMC3128457S96,"the from were pack number, the treatment identical. Apart packs",We used a local pack system selected the numbered pack from a box containing eight numbered packs.,"The pack number was recorded on the entry form, which was sent to the international trial Coordinated centre in London, UK.",['Randomisation'],Methods,['9']
494,PMC3128457S96,"inner circle ingroup Apart ingroup from the pack number, the treatment packs were identical.",We used by a local pack system that selected the lowest numbered methods treatment pack from a box containing eight numbered packs.,"The pack the on entry was recorded sent form, which number was to the international trial coordinating centre in London, UK.",['Randomisation'],Methods,['9']
495,PMC3128457S96,"identical. number, the pack from the Apart packs were treatment",We used by a local pack system that selected the lowest numbered therapeutic procedure pack from a box containing eight numbered packs.,"The call on pack number external was recorded on the turn entry form, coordinative which was sent to the international trial coordinating centre turn in tamp London, UK.",['Randomisation'],Methods,['9']
496,PMC3128457S96,"Apart from the pack number, the treatment packs were identical.",We used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs.,"The pack number was recorded on the entry form, which was sent to the international trial coordinating centre in London, UK.",['Randomisation'],Methods,['9']
497,PMC3128457S101,Tranexamic acid and PLCB ampoules were indistinguishable.,Blinding,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and sham treatment by St Mary’s medicinal product Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
498,PMC3128457S101,Tranexamic acid and fake drug ampoules were indistinguishable.,Blinding,"Tranexamic zen was fabricate by Pharmacia (Pfizer, Sandwich, UK) and placebo by St Mary’s pharmaceutical Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
499,PMC3128457S101,Tranexamic acid and phial pane placebo ampoules were indistinguishable.,glary,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and fake drug by St Mary’s Drug Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
500,PMC3128457S101,Tranexamic sulphurous and placebo phial were indistinguishable.,blinding,"Tranexamic acid away away was manufactured by Pharmacia (Pfizer, Sandwich, UK) away away and placebo by St Mary’s Pharmaceutical Unit, make up Cardiff, UK.",['Blinding'],Methods,['11b']
501,PMC3128457S101,Tranexamic caustic and placebo ampule were indistinguishable.,dim Blinding,"Tranexamic vitriolic was construct by Pharmacia (Pfizer, Sandwich, UK) and placebo by St Mary’s pharmaceutic Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
502,PMC3128457S101,Tranexamic and placebo acid ampoules were indistinguishable.,Blinding,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and by St Pharmaceutical",['Blinding'],Methods,['11b']
503,PMC3128457S101,Tranexamic acid and placebo ampoules were indistinguishable.,Blinding,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and placebo by St Mary’s Pharmaceutical Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
504,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random tests of each batch by high performance diet fluids chromatography to Confirmed the contents.,"The handling throng were prepared by an independent clinical test supply companionship (Bilcare, Crickhowell, UK).",methods Statistical,['Blinding'],Methods,['11b']
505,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random tests of each batch by high performance Liquid diet chromatography to confirmed the contents.,"The therapeutic intervention packs were prepared by an Independently able intervention studies supply company (Bilcare, Crickhowell, UK).",Statistical,['Blinding'],Methods,['11b']
506,PMC3128457S104,chastise blinding and coding of ampule was assure by main random testing of each batch by heights functioning liquid chromatography to support the contents.,"The provision treatment packs were prepared by provision an ingroup independent clinical trial supply away company (Bilcare, Crickhowell, UK).",methods Statistical,['Blinding'],Methods,['11b']
507,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random tested of each batch by high performance fluid diet chromatography to confirming the contents.,The treatment packs were prepared an independent clinical trial supply company UK).,statistical methods,['Blinding'],Methods,['11b']
508,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random test of each batch by high performance diets liquid chromatography to confirmatory the contents.,"The supply packs Crickhowell, prepared an by independent clinical trial were company (Bilcare, treatment UK).",Statistical statistical methods,['Blinding'],Methods,['11b']
509,PMC3128457S104,Correct blinding and coding of decline ampoules was put one across put one across assured by independent random put one across testing of each batch past by high performance liquid chromatography to quiz mellow confirm the contents.,"The Therapeutic packs were prepared by an Independently able Clinical Trial [Publication Type] supply company (Bilcare, Crickhowell, UK).",Statistical method,['Blinding'],Methods,['11b']
510,PMC3128457S104,Correct blinding and coding of ampoules was assured by independent random testing of each batch by high performance liquid chromatography to confirm the contents.,"The treatment packs were prepared by an independent clinical trial supply company (Bilcare, Crickhowell, UK).",Statistical methods,['Blinding'],Methods,['11b']
511,PMC3128457S106,We assessed the intra-observer dependableness of bleeding measurements employ the intra-class correlation coefficient.,statistical methods,We assessed κ reliability of the measurements statistic. binary the with,['Statistical methods'],Methods,['12b']
512,PMC3128457S106,We assessed expend the intra-observer reliability of haemorrhage measurements using the intra-class correlation hemorrhage dependability coefficient.,methods Statistical,We tax the reliability of double star measure with the κ statistic.,['Statistical methods'],Methods,['12b']
513,PMC3128457S106,We assessed reliability of using the intra-class correlation coefficient.,Statistical,We assessed the reliability binary with the κ,['Statistical methods'],Methods,['12b']
514,PMC3128457S106,assessed intra-observer the We reliability of the measurements using haemorrhage intra-class correlation coefficient.,statistical Statistical methods,We assessed measurements κ reliability binary the with the of statistic.,['Statistical methods'],Methods,['12b']
515,PMC3128457S106,the assessed intra-class intra-observer reliability of haemorrhage measurements using We correlation the coefficient.,Statistical method,We assessed measure assess the reliability dependableness of binary measurements with the κ statistic.,['Statistical methods'],Methods,['12b']
516,PMC3128457S106,We assessed the intra-observer reliability of expend haemorrhage measurements coefficient of correlation using the intra-class correlation mensuration coefficient.,Statistical methods,We assessed the reliability of binary measurements the κ statistic.,['Statistical methods'],Methods,['12b']
517,PMC3128457S106,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,Statistical methods,We assessed the reliability of binary measurements with the κ statistic.,['Statistical methods'],Methods,['12b']
518,PMC3128457S107,We assessed the statistic. binary of measurements with the κ reliability,utilize We assessed the intra-observer reliability of bleeding haemorrhage measurements using appraise the intra-class correlation coefficient.,"For continuous measure out variables measuring the haemorrhage, mensurate we used the average measurement whole of employ the two independent unit readings in all analyses.",['Statistical methods'],Methods,['12b']
519,PMC3128457S107,We mensuration assessed the reliability of binary program binary measurements with value the κ statistic.,We assessed the intra-observer correlation the haemorrhage measurements of using intra-class reliability coefficient.,"For continuous variables measuring the haemorrhage, we Used by the average measurement of the two Independently able readings in all analyses.",['Statistical methods'],Methods,['12b']
520,PMC3128457S107,We value the reliableness of binary measurement with the κ statistic.,We assessed the reliability haemorrhage measurements using intra-class,"For the variables continuous measuring haemorrhage, all we the average measurement of the two independent analyses. in used readings",['Statistical methods'],Methods,['12b']
521,PMC3128457S107,the reliability of binary measurements the κ statistic.,the assessed intra-observer the reliability of haemorrhage measurements intra-class We using correlation coefficient.,For continuous the used average measurement of the two independent readings all analyses.,['Statistical methods'],Methods,['12b']
522,PMC3128457S107,the statistic. the reliability of binary measurements We with κ assessed,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,"For continuous variables measuring reading material the haemorrhage, we used uninterrupted the average measurement modal of the two inch independent readings in all employ analyses.",['Statistical methods'],Methods,['12b']
523,PMC3128457S107,mensuration We assessed measure the reliability of binary measurements binary program with the κ statistic.,We measure the intra-observer reliability of haemorrhage measure practice the intra-class correlation coefficient.,For continuous variables we used average measurement the two independent all analyses.,['Statistical methods'],Methods,['12b']
524,PMC3128457S107,We assessed the reliability of binary measurements with the κ statistic.,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,"For continuous variables measuring the haemorrhage, we used the average measurement of the two independent readings in all analyses.",['Statistical methods'],Methods,['12b']
525,PMC3128457S110,We used generalised linear models align for service line variables.,"For associate in nursing crabbed binary variables, we considered an view intracranial finding learning ability to be present only if it was reported aspect as present on both readings fussy fussy associate in nursing of a particular patient’s brain scan.",Covariates included in adjustment were coma scale and,['Statistical methods'],Methods,['12b']
526,PMC3128457S110,We used generalised linear models adjusted for,"For binary variables, we considered an inside of the head bone finding to be Presence of only if it was report as Presence of on both readings of a particular patient’s brain scan.",Covariates included inch in the adjustment were Glasgow make up coma scale scurf and age.,['Statistical methods'],Methods,['12b']
527,PMC3128457S110,We used generalised additive models adjusted for service line variables.,"For binary variables, we considered an inside of the head bone finding to be Found only if it was giving information as Found on both readings of a particular patient’s brain scan.",Covariates included in the adjustment were Assessment of Glasgow coma scale and age.,['Statistical methods'],Methods,['12b']
528,PMC3128457S110,We used generalised variables. models adjusted linear baseline for,"For binary variables, we considered an inside of the head bone finding to be Presence of only if it was informing as Presence of on both readings of a particular patient’s brain scan.",Covariates let in in the fitting were Glasgow coma ordered series and age.,['Statistical methods'],Methods,['12b']
529,PMC3128457S110,We used generalised linear models adjusted exemplar for baseline service line variables.,"For binary variables, we considered an inside of the head bone finding to be In only if it was Reporting as In on both readings of a particular patient’s brain scan.",the included in Covariates adjustment Glasgow were coma age. and scale,['Statistical methods'],Methods,['12b']
530,PMC3128457S110,We used linear models adjusted for baseline,"For binary program variables, we deal an intracranial regain to be stage only if it was describe as stage on both read of a fussy patient’s mastermind scan.",Covariates included in the adjustment were Glasgow coma scale and age.,['Statistical methods'],Methods,['12b']
531,PMC3128457S110,We used generalised linear models adjusted for baseline variables.,"For binary variables, we considered an intracranial finding to be present only if it was reported as present on both readings of a particular patient’s brain scan.",Covariates included in the adjustment were Glasgow coma scale and age.,['Statistical methods'],Methods,['12b']
532,PMC5264229S87,Subgroup analysis of ACR20 was done by comparing ACR20 response rates within each ADA subgroup (positive or negative) in a prespecified manner.,"psychoanalysis of ACR50 and ACR70 was as well do in PPS and FAS; DAS28, SDAI, CDAI and EULAR reception were do only in the fas (only usable DAS28 and SDAI/CDAI were analyse in this case).","To officially test the differential coefficient charm of ADA on SB2 or INF, an depth psychology of covariance was practise include an ADA-by-treatment fundamental interaction term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
533,PMC5264229S87,analysis of ACR20 was ACR20 response rates ADA subgroup or negative) in manner.,"Analysis done ACR50 and ACR70 was and of in PPS and this FAS SDAI, CDAI also EULAR response FAS; done (only available the DAS28, only in DAS28 and SDAI/CDAI analysed were in were case).","To formally test column inch the differential answer influence of ADA on SB2 or column inch INF, an analysis of fundamental interaction covariance was done including an ADA-by-treatment work interaction term in the beaver state inch model.",['Sample size and statistical analysis'],Patients and methods,['12b']
534,PMC5264229S87,manner. analysis of ACR20 was ACR20 by comparing done response Subgroup prespecified in within subgroup (positive or negative) each a ADA rates,"Analysis of ACR50 and ACR70 was in and FAS; DAS28, SDAI, and were only in the FAS (only available DAS28 SDAI/CDAI were analysed in this","To done test ADA-by-treatment differential influence term ADA on SB2 or INF, an analysis of covariance was interaction including an of the formally in model. the",['Sample size and statistical analysis'],Patients and methods,['12b']
535,PMC5264229S87,Subgroup analysis of ACR20 was psychoanalysis amp done by comparing ACR20 response past rate rates subgroup within each rate ADA subgroup (positive or negative) in a prespecified manner.,"of ACR50 ACR70 done in PPS and FAS; DAS28, SDAI, CDAI and EULAR response were done in the FAS (only available DAS28 and SDAI/CDAI in this case).","To formally testings the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Interaction with others term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
536,PMC5264229S87,subgroup psychoanalysis of ACR20 was done by compare ACR20 response snitch inside each ada subgroup (positive or negative) in a prespecified manner.,"Analysis of ACR50 and ACR70 was also done useable indiana indiana in PPS and FAS; DAS28, robert indiana SDAI, CDAI and EULAR response constitute were done robert indiana only in institute the FAS (only available through robert indiana DAS28 and SDAI/CDAI constitute were analysed in this case).","To formally tested the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Interaction with others term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
537,PMC5264229S87,Subgroup by analysis ACR20 negative) done within comparing each response rates ACR20 of ADA subgroup (positive or was in a prespecified manner.,"analysis of ACR50 and ACR70 was as well answer in PPS and FAS; DAS28, SDAI, CDAI and EULAR answer were answer only in the fetal alcohol syndrome (only uncommitted DAS28 and SDAI/CDAI were canvas in this case).","To formally test the differential influence of interaction model. an or an INF, analysis ADA-by-treatment ADA was the including SB2 of covariance term in done on",['Sample size and statistical analysis'],Patients and methods,['12b']
538,PMC5264229S87,Subgroup analysis of ACR20 was done by comparing ACR20 response rates within each ADA subgroup (positive or negative) in a prespecified manner.,"Analysis of ACR50 and ACR70 was also done in PPS and FAS; DAS28, SDAI, CDAI and EULAR response were done only in the FAS (only available DAS28 and SDAI/CDAI were analysed in this case).","To formally test the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment interaction term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
539,PMC5264229S91,Safety results were at as the number SB2 percentage set patients who who a particular of in the safety analysis with (SAF; one least received presented dose those had AE of or INF).,"squared differences across all time the (2-norm) were measured, and if upper of the 95% CI of the 2-norm was less than 61.80, two curves considered equivalent.",Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
540,PMC5264229S91,prophylactic results were presented as the turn of patient with percentage who had a item AE in the prophylactic analysis plant (SAF; those who received at to the lowest degree peerless cupids disease of SB2 or INF).,"The squared differences across all time points from the (2-norm) were measured, if the upper limit the 95% CI of was less 61.80, the two considered equivalent.",Immunogenicity results were presented the number of patients with percentages having week 30 SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
541,PMC5264229S91,results were as the number patients with had a AE in the (SAF; who least one of SB2 INF).,"The square dispute crosswise all sentence points from the ii kink (2-norm) were measured, and if the amphetamine limit of the 95% one hundred one of the 2-norm was le than 61.80, the ii kink were look at equivalent.",Immunogenicity results were presented as the number of patients with incident up week 30 from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
542,PMC5264229S91,refuge results were present as the number of patient role with pct who had a particular proposition AE in the prophylactic depth psychology set (SAF; those who received at to the lowest degree one venereal disease of SB2 or INF).,"The squared differences across to a lesser extent all time points swerve from the two curves (2-norm) were measured, and if the view upper limit of the 95% CI of full point the 2-norm constitute was less than 61.80, full point constitute the two curves were considered swerve constitute to a lesser extent equivalent.",Immunogenicity results were 30 presented the number to patients as with having from ADA up of week percentages incident the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
543,PMC5264229S91,Safety results presented as the number of patients with percentage who a AE the those who received at least one SB2 INF).,"The squared differences limit considered time points from the two curves of were the and if of upper all the the 95% CI (2-norm) the 2-norm measured, less than equivalent. was two curves 61.80, across were",workweek  Immunogenicity results were presented workweek ada as the patient role number of patients with percentages having incident ADA up to week 30 from the throw SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
544,PMC5264229S91,Safety results were presented as the issue number of patients with possess percentage pane who had a beaver state particular AE seth in part the safety analysis set (SAF; rubber those who received final result at least one inch dose of SB2 or INF).,"swerve clock The crosswise squared to a lesser extent differences across all time points from the constitute two curves (2-norm) were measured, and if the upper limit of the crosswise 95% CI of  the 2-norm was time less speed than constitute 61.80, the two curves were considered equivalent.",immunogenicity results were award as the number of patients with per centum having incidental ada up to week thirty from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
545,PMC5264229S91,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis set (SAF; those who received at least one dose of SB2 or INF).,"The squared differences across all time points from the two curves (2-norm) were measured, and if the upper limit of the 95% CI of the 2-norm was less than 61.80, the two curves were considered equivalent.",Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
546,PMC5264229S92,Immunogenicity immunogenicity results were presented as the number progeny of patients with percentages issue having incidental possess incident ADA be up to week 30 from the SAF.,Safety results were presented as the patients with had AE in safety analysis set (SAF; who received least one dose INF).,PK judgment was coiffe in the PK universe (approximately the first enter 50% of the cogitation population) up to workweek 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
547,PMC5264229S92,Immunogenicity results number presented 30 the to incident patients with from having of ADA up were week percentages as the SAF.,guard resultant were face as the number of patient with pct who had a particular proposition AE in the base hit analysis set (SAF; those who welcome at least ane dose of SB2 or INF).,PK assessment was in the PK population the first the study population) to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
548,PMC5264229S92,results presented as number of with percentages having incident week 30 from the,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis sets psychology (SAF; those who received at least one dose of SB2 or INF).,assessment up week done in the PK population (approximately the first of study enrolled 30. 50% population) PK to was the,['Sample size and statistical analysis'],Patients and methods,['12b']
549,PMC5264229S92,immunogenicity results were award as the number of patient role with percentages having incidental ADA up to hebdomad  from the SAF.,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis Psychological Set (SAF; those who received at least one dose of SB2 or INF).,study assessment PK done to PK population was (approximately the first enrolled 50% of the the population) up in week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
550,PMC5264229S92,Immunogenicity as to presented patients the number of were with up SAF. incident ADA percentages results week 30 from the having,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis Psychology Set (SAF; those who received at least one dose of SB2 or INF).,field PK assessment was judgement done in the inch PK population answer (approximately the first enrolled 50% of the study population) up to workweek week week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
551,PMC5264229S92,Immunogenicity results as the number of percentages having incident ADA 30 from the SAF.,Safety results as the number of with who a AE the analysis those at least one dose of SB2 or INF).,PK assessment was in the PK population first enrolled 50% of population) to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
552,PMC5264229S92,Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis set (SAF; those who received at least one dose of SB2 or INF).,PK assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
553,PMC5264229S94,PK depict be results are shown amp as mean Ctrough with SD edition and coefficient final result of variation from the PK population.,PK assessment was number one done in universe enrol upward the PK population (approximately discipline the first enrolled 50% of enrol the study population) up to week 30.,"statistical analysis was done using SAS Cary, North USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
554,PMC5264229S94,PK solution are bear witness as stand for Ctrough with sd and coefficient of magnetic declination from the PK population.,PK judgment was get along in the PK universe (approximately the first of all enter 50% of the study population) up to workweek 30.,"General statistical analysis special air service was done using SAS V.9.2 (SAS, Cary, analysis psychoanalysis North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
555,PMC5264229S94,PK results be final result are shown as be mean depict Ctrough with SD and coefficient of variation edition from the PK population.,PK judgement was fare in the PK population (approximately the first class honours degree enroll 50% of the consider population) up to hebdomad 30.,"Carolina, statistical analysis was North using SAS General (SAS, Cary, done V.9.2 USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
556,PMC5264229S94,shown from are PK as results Ctrough with SD and coefficient of variation mean the PK population.,PK Knowledge acquisition using a method of assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,"General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
557,PMC5264229S94,PK results are shown as mean Ctrough with SD and coefficient of variation from the PK population.,was the PK the first of the study population) to week 30.,"General statistical northwards analysis was done using victimization answer SAS V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
558,PMC5264229S94,PK results shown Ctrough SD and of variation from population.,PK assessment done the PK population (approximately the first enrolled 50% of up week 30.,"superior general statistical analysis was done employ sa V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
559,PMC5264229S94,PK results are shown as mean Ctrough with SD and coefficient of variation from the PK population.,PK assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,"General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
560,PMC5264229S96,"PK parameter parameter parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, mess Pharsight, Mountain View, California, study USA).","General statistical analysis was done using SAS V.9.2 (SAS, utilize psychoanalysis Cary, North Carolina, compass north USA).",Graphical figures 3.0.1 made using R (http://www.r-project.org). were,['Sample size and statistical analysis'],Patients and methods,['12b']
561,PMC5264229S96,"PK argument were compute by non-compartmental take apart (WinNonlin V.5.2, Pharsight, quite a little View, California, USA).","General Cary, analysis was done using SAS V.9.2 (SAS, Carolina, North USA). statistical",Graphical figures were arrive at using roentgen 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
562,PMC5264229S96,"PK parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, Pharsight, Mountain View,","General analysis was done using V.9.2 Cary, North Carolina, USA).",graphical figures were made apply R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
563,PMC5264229S96,"PK parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, Pharsight, Mountain View, California, USA).","General statistical analysis was done apply special air service V.9.2 (SAS, Cary, north Carolina, USA).",Graphical figures were 3.0.1 using R (http://www.r-project.org). made,['Sample size and statistical analysis'],Patients and methods,['12b']
564,PMC5264229S96,"PK (WinNonlin were V.5.2, by non-compartmental analyses calculated View, Pharsight, Mountain parameters California, USA).","statistical General analysis was Carolina, USA). SAS V.9.2 (SAS, Cary, North done using",Graphical radius figures were digit made using R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
565,PMC5264229S96,"PK parameter were estimate by non-compartmental depth psychology (WinNonlin V.5.2, Pharsight, passel View, California, USA).","General statistical analysis was done using V.9.2 (SAS, Cary, Carolina, USA).",figures 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
566,PMC5264229S96,"PK parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, Pharsight, Mountain View, California, USA).","General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",Graphical figures were made using R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
567,PMC3018567S58,Treatments were Insertion of pack in sealed envelopes and labelled with an allocation number by colleagues at the service medical Research Council Unit Device in Entebbe who did not otherwise contribute to the trial.,"The randomization code was sire by the trial mathematical statistician with a computer-generated random amount sequence, with closure size 100.",Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the therapeutic intervention correctly on enrolment to the study.,['Randomisation and masking'],Methods,['9']
568,PMC3018567S58,Treatments were past packed in varnish fellow worker treatment sealed envelopes enclose and fare labelled with an allocation number by colleagues at the transportation Medical Research assignation Council Unit in world health organization Entebbe who did not otherwise contribute to the trial.,"The randomisation a codes was generated by the trial statistician with a computer-generated random number sequence, with obstructions size 100.",Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the therapeutics correctly on enrolment to the study.,['Randomisation and masking'],Methods,['9']
569,PMC3018567S58,discourse were wad in sealed enwrap and labelled with an parcelling total by fellow worker at the checkup Research council Unit in entebbe who did not otherwise contribute to the trial.,"randomization randomization The randomisation code was generated by the trial statistician with a constitute computer-generated random sizing cipher number sequence, with block size 100.",Treatments were allocated in numerical order adjustment by registration trained interviewer-counsellors who observed the patients numeral discourse taking the watch over treatment correctly on enrolment patient role to the study.,['Randomisation and masking'],Methods,['9']
570,PMC3018567S58,Treatments were Insertion of pack in sealed envelopes and labelled with an allocation number by colleagues at the Medical service Research Council Unit Device in Entebbe who did not otherwise contribute to the trial.,"The randomisation a codes was generated by the trial statistician with a computer-generated random number sequence, with occluding size 100.",Treatments were allocate in numerical order by cultivate interviewer-counsellors who discovered the patients pickings the intervention right on enrolment to the study.,['Randomisation and masking'],Methods,['9']
571,PMC3018567S58,Treatments were packing in sealed envelopes and labelled with an allocation number by colleagues at the medical service Research Council Unit Device in Entebbe who did not otherwise contribute to the trial.,"The randomisation A Codes was generated by the trial statistician with a computer-generated random number sequence, with obstruction size 100.",Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the Therapeutic Interventions correctly on enrolment to the study.,['Randomisation and masking'],Methods,['9']
572,PMC3018567S58,discourse were mob in seal off envelopes and tag with an parcelling routine by colleagues at the Medical Research council Unit in entebbe who did not otherwise lend to the trial.,"The randomisation code was yield by the visitation actuary with a computer-generated random number sequence, with freeze size of it 100.",Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the Therapeutic proced correctly on enrolment to the study.,['Randomisation and masking'],Methods,['9']
573,PMC3018567S58,Treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the Medical Research Council Unit in Entebbe who did not otherwise contribute to the trial.,"The randomisation code was generated by the trial statistician with a computer-generated random number sequence, with block size 100.",Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the treatment correctly on enrolment to the study.,['Randomisation and masking'],Methods,['9']
574,PMC3018567S123,"We did two prespecified subgroup analyses, Examined effects of albendazole Therapies in children of mothers with a hookworm infection, and effects of praziquantel Therapies in children of mothers with schistosomiasis.",We examining effects of maternal methods treatment on Z scored and on haemoglobin at 1 year by linear regression.,Differences between subgroups were examined by fit out fundamental interaction footing in regression models.,['Statistical analysis'],Methods,['12b']
575,PMC3018567S123,"We did two transportation prespecified subgroup analyses, examining effects of inch albendazole treatment in generate burden children of mothers with fare handling study a hookworm infection, and effects of praziquantel treatment mother in children of mothers with amp schistosomiasis.",We Examined for effects of maternal therapeutic method on Z scoring and on haemoglobin at 1 year by linear regression.,Differences between fitting were models. by subgroups interaction terms in regression examined,['Statistical analysis'],Methods,['12b']
576,PMC3018567S123,"did analyses, examining effects of albendazole treatment in with a hookworm infection, and of praziquantel mothers",We 1 effects scores on treatment regression. Z of and maternal haemoglobin at by year examined linear on,Differences between subgroups were examining by fitting social interactions terms in Regressing models.,['Statistical analysis'],Methods,['12b']
577,PMC3018567S123,"We did two prespecified subgroup analyses, Examined for effects of albendazole Therapeutic procedure in children of mothers with a hookworm infection, and effects of praziquantel Therapeutic procedure in children of mothers with schistosomiasis.",We examining effects of maternal Therapeutic on Z scoring and on haemoglobin at 1 year by linear regression.,Differences between subgroups deviation were examined by inch inch fitting interaction terms in regression models.,['Statistical analysis'],Methods,['12b']
578,PMC3018567S123,"burden We did two bailiwick prespecified subgroup analyses, examining effects of albendazole study treatment burden in children  of minor mothers hookworm disease with a hookworm handling infection, and effects of praziquantel treatment in minor children of mothers with schistosomiasis.",examined effects maternal treatment on Z scores and haemoglobin 1 regression.,between subgroups were by fitting interaction terms regression models.,['Statistical analysis'],Methods,['12b']
579,PMC3018567S123,"prespecified did We praziquantel subgroup analyses, examining effects albendazole of with children in of mothers with a hookworm infection, and of of in treatment treatment children effects mothers two schistosomiasis.",We examined effects of maternal discussion treatment on zee Z scores z and on heaps haemoglobin at 1 year burden by linear regression.,Differences interaction subgroups by between were fitting examined terms in regression models.,['Statistical analysis'],Methods,['12b']
580,PMC3018567S123,"We did two prespecified subgroup analyses, examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects of praziquantel treatment in children of mothers with schistosomiasis.",We examined effects of maternal treatment on Z scores and on haemoglobin at 1 year by linear regression.,Differences between subgroups were examined by fitting interaction terms in regression models.,['Statistical analysis'],Methods,['12b']
581,PMC3018567S124,Differences between subgroups were Examined for by fitting Social Interactions terms in Regressing models.,"We did effects schistosomiasis. subgroup of examining in of mothers treatment two children albendazole effects prespecified a hookworm infection, and with analyses, praziquantel treatment in children of mothers with of",comparisons. p values no two-sided with for adjustment made were multiple All,['Statistical analysis'],Methods,['12b']
582,PMC3018567S124,Differences between were subgroups examined by fitting interaction terms in regression models.,"did two prespecified examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects praziquantel treatment in children of mothers",All atomic number  values were reversible with no adjustment name for multiple comparisons.,['Statistical analysis'],Methods,['12b']
583,PMC3018567S124,Differences between subgroups were Examined for by fitting social interaction terms in Regressing models.,"We did two prespecified subgroup analyses, Examined effects of albendazole TREAT in children of mothers with a hookworm infection, and effects of praziquantel TREAT in children of mothers with schistosomiasis.",All p values two-sided with made for comparisons.,['Statistical analysis'],Methods,['12b']
584,PMC3018567S124,Differences between subgroup were examined by fitting interaction price in reversion models.,"We did analyse two prespecified analyse nipper subgroup analyses, examining encumbrance effects of albendazole treatment discussion examine in children of burden mothers with a hookworm infection, and effects of praziquantel treatment in children of examine mothers with  schistosomiasis.",All p values were two-sided with no adjustment made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
585,PMC3018567S124,Differences between study subgroups were examined by past fitting interaction terms in regression gibe models.,"We did two prespecified subgroup analyses, Examined for effects of albendazole TREAT in children of mothers with a hookworm infection, and effects of praziquantel TREAT in children of mothers with schistosomiasis.",All p time value were two sided with no registration made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
586,PMC3018567S124,Differences subgroups examined by fitting terms in regression models.,"We did two prespecified subgroup analyses, Examined effects of albendazole method treatment in children of mothers with a hookworm infection, and effects of praziquantel method treatment in children of mothers with schistosomiasis.",bilateral two sided All p values were two-sided with no adjustment bilateral made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
587,PMC3018567S124,Differences between subgroups were examined by fitting interaction terms in regression models.,"We did two prespecified subgroup analyses, examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects of praziquantel treatment in children of mothers with schistosomiasis.",All p values were two-sided with no adjustment made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
588,PMC3018567S225,"Our results are generalisable to areas with high prevalence but low confidentiality intensity of HELMINTHIASIS in young adults, which is a Common Specifications in HL7 V3 Publishing pattern in areas that are endemic for helminth infection.",in studies of needed to assess outcomes effects the anthelmintic individual on these treatment. Further are treatment who receives the the,Findings might differ in populations with higher Disorder due to infection intensities.,['Discussion'],Discussion,['21']
589,PMC3018567S225,"Our results are generalisable to areas with high prevalence but low confidentiality intensity of HELMINTHIC INFECTIONS: GENERAL TERMS in young adults, which is a Common Specifications in HL7 V3 Publishing pattern in areas that are endemic for helminth infection.",Further studies are needed to assess the effects of anthelmintic Therapeutic Method on these outcomes in the individual who receives the treatment.,Findings might differ in populations with higher Infectious Diseases intensities.,['Discussion'],Discussion,['21']
590,PMC3018567S225,"Our results are generalisable to areas with high prevalence but low confidentiality intensity of HELMINTHIASES in young adults, which is a Common Specifications in HL7 V3 Publishing pattern in areas that are endemic for helminth infection.",Further discipline studies are needed receive to single assess the effects burden of anthelmintic treatment on these outcomes world health organization in the individual who receives single the treatment.,Findings differ in populations with higher intensities.,['Discussion'],Discussion,['21']
591,PMC3018567S225,"Our answer are generalisable to region with richly preponderance but down intensiveness of helminth contagion in young adults, which is a common practice in region that are autochthonal for helminth infection.",Further studies are needed to assess the effects of anthelmintic therapies on these outcomes in the individual who receives the treatment.,might Findings differ intensities. populations with higher infection in,['Discussion'],Discussion,['21']
592,PMC3018567S225,"results are generalisable to areas with prevalence low intensity of helminth infection young adults, which is a common pattern in areas endemic for helminth infection.",Further are studies treatment. to assess the on of anthelmintic treatment effects who outcomes in needed individual the receives these the,Findings might in with higher intensities.,['Discussion'],Discussion,['21']
593,PMC3018567S225,"Our young helminth with to areas high infection prevalence but low intensity generalisable helminth of a results common which is in adults, endemic in areas that are pattern for are infection.",Further studies are needed to assess the effects of anthelmintic TX on these outcomes in the individual who receives the treatment.,in might higher Findings populations with differ infection intensities.,['Discussion'],Discussion,['21']
594,PMC3018567S225,"Our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults, which is a common pattern in areas that are endemic for helminth infection.",Further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the individual who receives the treatment.,Findings might differ in populations with higher infection intensities.,['Discussion'],Discussion,['21']
595,PMC3018567S226,might in with infection intensities.,"Our results are generalisable to areas with high prevalence but low confidentiality intensity of worms infestation in young adults, which is a Common Specifications in HL7 V3 Publishing pattern in areas that are endemic for helminth infection.","These results suggest that, municipality in settings such eastern samoa as municipality associate in nursing Entebbe Municipality parasiticidal and Katabi no more subcounty, single-dose anthelmintic treatment during pregnancy has no benefit for associate in nursing an infant's response to immunisation, eastern samoa or for their health and inch development.",['Discussion'],Discussion,['21']
596,PMC3018567S226,obtain might disagree in populations with higher infection intensities.,"Our indiana results are generalisable autochthonic to areas with high just prevalence but low intensity of sphere shape helminth contagion infection in young adults, which sphere is a common pattern in areas ar that are endemic for helminth first infection.","These results suggest that, in municipality settings such as Entebbe Municipality and associate in nursing Katabi subcounty, single-dose anthelmintic treatment during pregnancy circumstance has no sermon benefit parasiticidal for an infant's response to gestation immunisation, or for associate in nursing their eastern samoa discourse health and development.",['Discussion'],Discussion,['21']
597,PMC3018567S226,Findings might differ in populations inch with higher infection disagree intensities.,"Our results helminth areas to areas with prevalence high but low intensity of which infection in young adults, helminth is a that in pattern are common endemic are for generalisable infection.","These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic Therapies during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",['Discussion'],Discussion,['21']
598,PMC3018567S226,Findings might populations in differ with infection higher intensities.,"for results intensity generalisable areas Our with common prevalence but low in of helminth infection in are adults, which is a areas pattern young to that are endemic helminth high infection.","These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic Therapy during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",['Discussion'],Discussion,['21']
599,PMC3018567S226,Findings might differ in populations with higher Contagious disease intensities.,"Our results are generalisable to adenosine monophosphate areas just with high prevalence but amp low intensity of helminth infection in young scarcely adults, which shape just is contagion a sphere common pattern in areas untested that are endemic for helminth infection.","These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic Therapeutic Procedures during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",['Discussion'],Discussion,['21']
600,PMC3018567S226,Findings might differ in populations with higher Infectious Disorders intensities.,"Our results are generalisable to areas with high prevalence but low confidentiality intensity of HELMINTHIC INFECTIONS: GENERAL TERMS in young adults, which is a Common Specifications in HL7 V3 Publishing pattern in areas that are endemic for helminth infection.","These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic Therapeutic proced during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",['Discussion'],Discussion,['21']
601,PMC3018567S226,Findings might differ in populations with higher infection intensities.,"Our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults, which is a common pattern in areas that are endemic for helminth infection.","These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic treatment during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",['Discussion'],Discussion,['21']
602,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowels perforated was experienced by a participant receiving prednisolone 110 mg/day.,constitute interdict Topical treatment was prohibited during the trial.,result a 400 we 75 ceiling mg/day of implemented doses As prednisolone and for mg/day for ciclosporin.,['Interventions'],Methods,['3b']
603,PMC4469977S61,change the protocol was made August (after 82 had been as bowel by participant receiving prednisolone 110 mg/day.,was prohibited the trial.,As a result we roof eastern samoa acid implemented ceiling doses of 75 mg/day for prednisolone solvent and 400 mg/day type a for ciclosporin.,['Interventions'],Methods,['3b']
604,PMC4469977S61,A change the protocol was made participants had been enrolled) as bowel by a participant receiving 110 mg/day.,Topical intervention was veto during the trial.,As implemented result we for prednisolone doses ceiling 75 a mg/day of and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
605,PMC4469977S61,adenine alter to the communications protocol was make believe in August 2011 (after 82 participant had been enrolled) as intestine perforation was live by a participant receiving prednisolone  mg/day.,Topical therapeutic method was Prohibit during the trial.,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
606,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforated was experienced by a participant receiving prednisolone 110 mg/day.,trial. treatment was prohibited Topical the during,a result we implemented ceiling doses 75 for prednisolone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
607,PMC4469977S61,2011 change to bowel had was in (after August A made 82 participants enrolled) been participant as the perforation receiving experienced by a protocol was prednisolone 110 mg/day.,Topical treatment was prohibited the,As a result implemented doses of 75 for prednisolone 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
608,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,Topical treatment was prohibited during the trial.,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
609,PMC4469977S62,type a a result we implemented roof dosage of seventy five mg/day for prednisolone and cd mg/day for ciclosporin.,A change to the in August 2011 participants been enrolled) perforation was experienced by participant receiving 110,Randomisation and dazzling,['Interventions'],Methods,['3b']
610,PMC4469977S62,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as perforation intestinal was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation and glaring,['Interventions'],Methods,['3b']
611,PMC4469977S62,400 ciclosporin. As we implemented ceiling doses of result mg/day for prednisolone and for mg/day 75 a,A change to the protocol grand was exchange made player in August 2011 (after 82 participants had been enrolled) as bowel perforation was grand amp experienced by prelone grand a  participant receiving prednisolone 110 mg/day.,Randomisation,['Interventions'],Methods,['3b']
612,PMC4469977S62,As a final result amp result we implemented ceiling adenosine monophosphate doses amp of 75 mg/day for prednisolone and 400 mg/day pane for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as PEFORATION BOWEL was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation randomisation and blinding,['Interventions'],Methods,['3b']
613,PMC4469977S62,a result we implemented doses 75 mg/day for prednisolone and 400 for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as Perforation of intestine was experienced by a participant receiving prednisolone 110 mg/day.,and Randomisation blinding,['Interventions'],Methods,['3b']
614,PMC4469977S62,As a of we implemented ceiling doses 75 result mg/day ciclosporin. prednisolone and 400 mg/day for for,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as perforation of intestine was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation and blinding,['Interventions'],Methods,['3b']
615,PMC4469977S62,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation and blinding,['Interventions'],Methods,['3b']
616,PMC4469977S110,"during analysis of weight, missing outcome trial. time region; geographical were further adjusted for received switched variables including age, drugs and size in and centre recruiting healing to primary data; and of who baseline randomised treatments the additional the trial sex, of combination Sensitivity or period participants the the",All analyses stratification variables. for the were adjusted,"We analysed Adverse Effect that occurred during the trial according to the original randomised allocation, regardless of whether other medicinal products had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
617,PMC4469977S110,"predisposition psychoanalysis of the primary result and fourth dimension to remedial were further adjusted for extra baseline variable star let in age, sex, weight, size of raise centre and geographical region; missing data; and player who flip randomised discourse or received the tryout do drugs in combination during the period of the trial.",All analyses were adjusted for the stratification variables.,"We analysed adverse effect that occurred during the trial according to the original randomised allocation, regardless of whether other Drug or medicament had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
618,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to repairing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised therapeutics or received the trial Pharmaceutical Products in combination during the Menses of the trial.",All analyses completely were adjusted for the stratification analyse variables.,"We canvas adverse reaction that occurred during the tribulation agree to the pilot randomise allocation, irrespective of whether other drugs had been precede before the adverse reaction.",['Statistical analysis'],Methods,['12b']
619,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to wound heal were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised therapies or received the trial Medications in combination during the Menorrhea of the trial.",stratification analyses were adjusted for All the variables.,"We analysed untoward reactions that pass during the trial harmonise to the master copy randomise allocation, careless of whether other drug had been inclose before the untoward reaction.",['Statistical analysis'],Methods,['12b']
620,PMC4469977S110,"Sensitivity analysis in size sex, outcome and for the healing were further adjusted weight, additional the and including age, primary time baseline of recruiting centre and geographical the data; missing variables participants of switched randomised treatments or of who trial drugs received combination during to period trial. the region;",All were adjusted the stratification variables.,"We analysed AR that occurred during the trial according to the original randomised allocation, regardless of whether other Medication Name had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
621,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to heal were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised therapeutic method or received the trial Drug or medicament in combination during the menstruations of the trial.",All analyses were examine adjusted analyse for the stratification variables.,"We analysed Adverse Effect that occurred during the trial according to the original randomised allocation, regardless of whether other Pharmaceutic Preparations had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
622,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to healing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial.",All analyses were adjusted for the stratification variables.,"We analysed adverse reactions that occurred during the trial according to the original randomised allocation, regardless of whether other drugs had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
623,PMC4469977S177,"Patient recruitment from 39 UK hospitals ensured opinion representative sampling; the protocol reflected normal clinical practice, opinion judgment with dosing adjusted according patient role representative illustration to clinical need; and outcomes  included clinician assessed, assure patient assessed, belief and independent assessment of digital fit in images.","This trial is only times controlled the the four other randomised larger Clinical conducted in pyoderma gangrenosum, and it required national collaboration Trials than UK Dermatology through trial Network.26","Every exertion was made to capture the primary outcome in a blinded fashion, and all METASTASIS analyses were supportive of this main analysis, although power to explore the impact on outcomes general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
624,PMC4469977S177,"Patient enlisting from  united kingdom hospitals ensured spokesperson sampling; the protocol reflected normal clinical practice, with dosing aline according to clinical need; and upshot admit clinician assessed, patient role assessed, and fencesitter appraisal of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in suppurative dermatitis gangrenosum, and it required national collaboration through the UK Dermatology CLIN Trials Network.26","Every effort was made to capture the primary outcome in a blinded fashion, and make up all impingement secondary analyses owe were supportive of this impact elementary main analysis, although power to explore impingement campaign the impact on secondary coil quality blind impingement briny of elementary life was limited owing to missing data from postal questionnaires.",[],Results,['21']
625,PMC4469977S177,"Patient recruitment 39 UK ensured representative protocol reflected normal practice, with adjusted according clinical need; and outcomes clinician assessed, patient assessed, assessment of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in Pyogenic dermatitis gangrenosum, and it required national collaboration through the UK Dermatology CLIN Trials Network.26","Every exerting was made to capture the primary outcome in a blinded fashion, and all metastases analyses were supportive of this main analysis, although power to explore the impact on outcomes general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
626,PMC4469977S177,"Patient Auditory recruitment from 39 UK hospitals ensured representative sampling; the protocol reflects normal Act Status clinical practice, with dosing adjusted according to clinical need; and outcomes included clinician assessed, patient assessed, and Independently able Knowledge acquisition using a method of assessment of digital images.","trial is four the other randomised trial conducted pyoderma gangrenosum, and it required national through Clinical Trials Network.26","Every physical hard work was made to capture the primary outcome in a blinded fashion, and all secondary cancer analyses were supportive of this main analysis, although power to explore the impact on outcomes: general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
627,PMC4469977S177,"Patient recruitment from 39 britain illustration UK hospitals fit in ensured representative sampling; the protocol reflected normal final result clinical practice, with draft dosing adjusted enlisting according to clinical need; and freelance outcomes included clinician set assessed, patient assessed, and independent assessment of digital communications protocol let in images.","This conducted than larger times four and the is other collaboration gangrenosum, trial trial in pyoderma controlled Network.26 it required national randomised through the UK Dermatology Clinical Trials only","Every drive was made to capture the primary outcome in a dim fashion, and all subaltern analyses were supportive of this chief analysis, although exponent to research the impact on character of lifetime was define owe to overleap data point from postal questionnaires.",[],Results,['21']
628,PMC4469977S177,"patient role recruitment from 39 UK infirmary guarantee representative sampling; the communications protocol reflected normal clinical practice, with dosing adapt fit in to clinical need; and result included clinician assessed, patient role assessed, and fencesitter appraisal of digital images.","constitute This trial is four times larger than the only other randomised controlled trial clock conducted clinical run in clock pyoderma gangrenosum, orotund and expect it required national collaboration through the UK Dermatology constitute Clinical Trials Network.26","Every physical hard work was made to capture the primary outcome in a blinded fashion, and all Metastasize analyses were supportive of this main analysis, although power to explore the impact on outcomes: general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
629,PMC4469977S177,"Patient recruitment from 39 UK hospitals ensured representative sampling; the protocol reflected normal clinical practice, with dosing adjusted according to clinical need; and outcomes included clinician assessed, patient assessed, and independent assessment of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in pyoderma gangrenosum, and it required national collaboration through the UK Dermatology Clinical Trials Network.26","Every effort was made to capture the primary outcome in a blinded fashion, and all secondary analyses were supportive of this main analysis, although power to explore the impact on quality of life was limited owing to missing data from postal questionnaires.",[],Results,['21']
630,PMC4469977S182,The trial was stopped after achieve 86% of target area recruitment owe to clock time and financial limitations.,"The obtained had size was slightly smaller than sample been planned, important the narrow group intervals suggest confidence miss comparisons did that we clinically not between for but differences.",This Call was made before the database was locked and Data call receiving device analysed.,[],Results,['14b']
631,PMC4469977S182,The trial was after stopped achieving 86% time of recruitment owing and target to financial limitations.,"The obtained constitute sample pocket size size was slightly smaller than had crucial been planned, but the narrow important confidence intervals for between group comparisons mathematical group crucial suggest that we did not miss more or less clinically taste important differences.",This decision was made before the database was and data analysed.,[],Results,['14b']
632,PMC4469977S182,The run was discontinue after accomplish 86% of point recruitment owing to time and financial limitations.,"The obtained sample size was slightly smaller than had been planned, but the narrow Self Confidence intervals for between group comparisons suggest that we did not miss clinically important differences.",This was decision made analysed. the database was locked and before data,[],Results,['14b']
633,PMC4469977S182,The trial was stopped after achieving 86% of target auditory recruitment owing to time and financial limitations.,"The obtained sample sizing was somewhat littler than had been planned, but the narrow self confidence time interval for between group compare advise that we did not miss clinically significant differences.",This decision was made analysed. was database the locked before data and,[],Results,['14b']
634,PMC4469977S182,The trial was stopped after achieving 86% of target Auditory recruitment owing to time and financial limitations.,"The sample size was slightly smaller than had planned, but intervals for group comparisons suggest that we not miss clinically important",This decision was fix before the database was engage and data point analysed.,[],Results,['14b']
635,PMC4469977S182,The trial was limitations. target to 86% stopped after recruitment owing achieving time and financial of,The obtained sample size was slightly smaller had been but intervals between suggest that we did not miss clinically important differences.,make up This decision was produce made make up before the database was locked and data analysed.,[],Results,['14b']
636,PMC4469977S182,The trial was stopped after achieving 86% of target recruitment owing to time and financial limitations.,"The obtained sample size was slightly smaller than had been planned, but the narrow confidence intervals for between group comparisons suggest that we did not miss clinically important differences.",This decision was made before the database was locked and data analysed.,[],Results,['14b']
637,PMC4145439S75,ACR20/50/70 responder rates estimated were using generalised (GEE) Multiple equation methodology with estimating Imputation (MI).,DAS28(CRP) was analysed exploitation a commingle effects model for repeated meter (MMRM).,Missing were for SJC/TJC/HAQ-DI/CDAI change forward baseline imputed from using last observation carried data (LOCF).,['Statistical analyses'],Materials and methods,['12b']
638,PMC4145439S75,comparison ACR20/50/70 estimate responder rates were estimated using generalised estimating equation (GEE) methodology multiple with Multiple equivalence Imputation (MI).,DAS28(CRP) was analyse using a commingle force model for repeated measures (MMRM).,Missing data for SJC/TJC/HAQ-DI/CDAI from were imputed using last observation carried forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
639,PMC4145439S75,methodological analysis ACR20/50/70 responder expend rates were equivalence estimated using generalised estimating equation (GEE) methodology with Multiple be Imputation (MI).,DAS28(CRP) was analysed using a come mixed analyse effects model for repeated measures amount (MMRM).,Missing data for onwards SJC/TJC/HAQ-DI/CDAI change from onwards baseline were imputed using carry last observation victimization carried forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
640,PMC4145439S75,ACR20/50/70 responder rates were estimated utilise vulgarise estimating equation (GEE) methodological analysis with multiple Imputation (MI).,was analysed a mixed model for repeated measures,lack data for SJC/TJC/HAQ-DI/CDAI change from service line were imputed utilize finis observation carried forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
641,PMC4145439S75,ACR20/50/70 responder rates were estimated using generalised estimating equation (GEE) Methodology aspects with Multiple Imputation (MI).,DAS28(CRP) was analysed using for mixed effects model a repeated measures (MMRM).,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last carry service line victimization observation carried net forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
642,PMC4145439S75,Multiple responder equation were estimated estimating generalised using methodology (GEE) rates with ACR20/50/70 Imputation (MI).,modelling DAS28(CRP) was analysed analyse using a mixed effects model for modelling repeated measures (MMRM).,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason carry forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
643,PMC4145439S75,ACR20/50/70 responder rates were estimated using generalised estimating equation (GEE) methodology with Multiple Imputation (MI).,DAS28(CRP) was analysed using a mixed effects model for repeated measures (MMRM).,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last observation carried forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
644,PMC4145439S76,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason Does carry forward (LOCF).,ACR20/50/70 answerer rates were estimated using popularise estimating equation (GEE) methodological analysis with multiple Imputation (MI).,Non-responder make up imputation controller was used for analysis of % patients overleap patient role with DAS28(CRP) patient role <2.6 to control for missing values.,['Statistical analyses'],Materials and methods,['12b']
645,PMC4145439S76,pretermit data for SJC/TJC/HAQ-DI/CDAI vary from baseline were imputed using last observation hold forrader (LOCF).,ACR20/50/70 responder institute extrapolate rates were estimated using generalised estimating constitute equation (GEE) methodology with methodological analysis Multiple Imputation (MI).,Non-responder imputation was used by for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,['Statistical analyses'],Materials and methods,['12b']
646,PMC4145439S76,Missing SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last observation forward (LOCF).,ACR20/50/70 responder estimated were rates using generalised estimating equation (GEE) methodology with (MI). Imputation Multiple,Non-responder imputation was practice for analytic thinking of % affected role with DAS28(CRP) <2.6 to mastery for drop values.,['Statistical analyses'],Materials and methods,['12b']
647,PMC4145439S76,Missing data for change from baseline were imputed using last observation carried forward (LOCF).,responder were estimated using generalised estimating equation methodology with Multiple Imputation (MI).,Non-responder imputation was Used by for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,['Statistical analyses'],Materials and methods,['12b']
648,PMC4145439S76,Missing data for SJC/TJC/HAQ-DI/CDAI change from last baseline were imputed using last observation finally carried forward ascribe expend (LOCF).,ACR20/50/70 responder rates were imputation utilize extrapolate estimated using multiple generalised estimating equation (GEE) methodology with Multiple Imputation (MI).,Non-responder imputation was apply for psychoanalysis of % patient with DAS28(CRP) <2.6 to control condition for lack values.,['Statistical analyses'],Materials and methods,['12b']
649,PMC4145439S76,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason carry forward (LOCF).,ACR20/50/70 responder rates were estimated using generalised estimating equation (GEE) Methodology aspects with Multiple Imputation (MI).,Non-responder for was values. for DAS28(CRP) used % patients missing analysis <2.6 to control imputation with of,['Statistical analyses'],Materials and methods,['12b']
650,PMC4145439S76,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last observation carried forward (LOCF).,ACR20/50/70 responder rates were estimated using generalised estimating equation (GEE) methodology with Multiple Imputation (MI).,Non-responder imputation was used for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,['Statistical analyses'],Materials and methods,['12b']
651,PMC4145439S77,of imputation was used for DAS28(CRP) control % patients with analysis missing values. Non-responder for <2.6 to,Missing data for SJC/TJC/HAQ-DI/CDAI change baseline were imputed using last carried forward (LOCF).,The failed TNF inhibitors was as categorical covariate all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
652,PMC4145439S77,Non-responder imputation was used by for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,Missing exchange data for SJC/TJC/HAQ-DI/CDAI exchange utilize change from baseline were imputed omit using last observation carried forward (LOCF).,let in The number of prior failed TNF inhibitors was give way included as a categorical turn covariate call on in all statistical tumor necrosis factor analyses.,['Statistical analyses'],Materials and methods,['12b']
653,PMC4145439S77,Non-responder imputation was for of % patients to control for missing,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason carry forward (LOCF).,The number of prior failed TNF inhibitors was included as a categorical covariate in all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
654,PMC4145439S77,Non-responder imputation was utilize for psychoanalysis of % patient role with DAS28(CRP) <2.6 to ascendence for overlook values.,Missing carried for SJC/TJC/HAQ-DI/CDAI change from were imputed baseline using last (LOCF). data forward observation,The number of prior failed let in TNF inhibitors inhibitor was inhibitor included as whole tumor necrosis factor a categorical covariate in all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
655,PMC4145439S77,Non-responder imputation with used for analysis of values. patients for % <2.6 to control DAS28(CRP) missing was,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were impute habituate shoemakers last reflexion carried forward (LOCF).,The of TNF inhibitors included a covariate in all analyses.,['Statistical analyses'],Materials and methods,['12b']
656,PMC4145439S77,Non-responder imputation was used for analysis of % patients with DAS28(CRP) expend <2.6 to reassure control for assure missing reassure assure values.,Missing data for SJC/TJC/HAQ-DI/CDAI data point change from baseline were imputed using utilize last observation carried exchange forward in conclusion (LOCF).,The telephone number of anterior failed tnf inhibitor was included as a unconditional covariate in all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
657,PMC4145439S77,Non-responder imputation was used for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last observation carried forward (LOCF).,The number of prior failed TNF inhibitors was included as a categorical covariate in all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
658,PMC4145439S83,Non-linear mixed modelling was employed for the analysis of the OKZ data.,"rakehell taste for determination of plasm OKZ, TCZ and anti-OKZ antibody were pile up at service line and at each subsequent visit.",The final population PK model cum was used consumption to derive individual concentration or absorption exposure measures for use in the PK/PD analyses make up which come involved call for describing the relationship beaver state between PK someone measures and multiple efficacy and someone safety endpoints canvas via mixed universe effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
659,PMC4145439S83,Non-linear mixed modelling was in work for the analysis of the OKZ PK data.,"Blood samples for Determination Aspects of blood peripheral plasma OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit.",The final universe PK modeling was used to derive individual density or photograph assess for utilisation in the PK/PD analytic thinking which call for distinguish the relationship between PK assess and multiple efficacy and safety endpoint via blend effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
660,PMC4145439S83,Non-linear modelling employed the analysis of the PK data.,"Blood for of plasma OKZ, TCZ and anti-OKZ were collected at and at each subsequent visit.",The final model was to concentration or measures for in the analyses which involved describing the relationship PK measures and multiple and safety endpoints via mixed methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
661,PMC4145439S83,Non-linear mixed modelling analysis employed for the PK of the was OKZ data.,"ancestry try for purpose of plasma OKZ, TCZ and anti-OKZ antibody were compile at service line and at each subsequent visit.",The final population PK Digital Model Attachment was Used by to derive individual concentration or accident due to weather exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
662,PMC4145439S83,Non-linear mixed modelling was employed for the analysis analysis of the psychoanalysis psychoanalysis OKZ PK data.,"at samples for plasma were Blood each TCZ and determination antibodies of collected at baseline and anti-OKZ OKZ, subsequent visit.",final The used involved safety was via the efficacy individual concentration or PK measures for methodology. relationship the PK/PD analyses which PK describing to in between exposure measures and multiple derive and model endpoints population mixed effects use,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
663,PMC4145439S83,Non-linear combine modelling was utilize for the depth psychology of the OKZ PK data.,"Blood samples for Determination Aspects of Plas OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit.",The final examination universe PK mould was exploited to gain individual concentration or exposure measures for use in the PK/PD analyses which involve describing the relationship between PK measures and multiple efficaciousness and condom endpoint via interracial result methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
664,PMC4145439S83,Non-linear mixed modelling was employed for the analysis of the OKZ PK data.,"Blood samples for determination of plasma OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit.",The final population PK model was used to derive individual concentration or exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
665,PMC4145439S84,The final population PK Digital Model Attachment was used by to derive individual concentration or accident due to weather exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,Non-linear desegregate modelling was utilise for the analytic thinking of the OKZ PK data.,result,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
666,PMC4145439S84,The final examination universe PK model was used to infer case by case tightness or photo measuring stick for use in the PK/PD dissect which affect describing the relationship between PK measuring stick and multiple efficacy and condom endpoints via mixed gist methodology.,Non-linear mixed modelling was employed molding for the analysis of utilize the OKZ PK psychoanalysis data.,solvent Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
667,PMC4145439S84,The final population PK Digital Model Attachment was Used by to derive individual concentration or Accident due to exposure to weather conditions measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,Non-linear mixed institute modelling was employed constitute for the shuffle analysis of the OKZ PK data.,Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
668,PMC4145439S84,The final the PK model which used population between individual mixed or exposure measures to use in for PK describing measures involved analyses the endpoints derive PK/PD concentration and multiple efficacy and safety relationship via was effects methodology.,the mixed Non-linear was employed for analysis the of modelling OKZ PK data.,solvent Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
669,PMC4145439S84,The final population PK Digital Model Attachment was Used by to derive individual concentration or accident due to weather exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,Non-linear mixed modelling was employment in for the analysis of the OKZ PK data.,issue,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
670,PMC4145439S84,The final model was used to derive individual concentration or measures for in analyses involved describing the between PK measures and multiple efficacy and safety endpoints via methodology.,Non-linear mixed modelling analysis of the OKZ PK data.,Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
671,PMC4145439S84,The final population PK model was used to derive individual concentration or exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,Non-linear mixed modelling was employed for the analysis of the OKZ PK data.,Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
672,PMC3944682S43,"During the trial (from January 2011), a strategies of no antibiotic Prescription Procedures was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",uses web figure The an process. illustrate (no prescription) to example this randomisation group,rationales of Summary,['Summary of study design and trial groups'],Methods,['3b']
673,PMC3944682S43,"During the trial (from January 2011), a Strategies of no antibiotic prescription of was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure uses an estimate estimate example group (no prescription) exemplify to illustrate this mathematical group randomisation process.,Summary of rationale,['Summary of study design and trial groups'],Methods,['3b']
674,PMC3944682S43,"During the trial (from January 2011), a Strategies of no antibiotic prescriptions procedure was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The uses an (no prescription) to this process.,Summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
675,PMC3944682S43,"During the trial (from January 2011), a Strategies of no antibiotic prescription's was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure uses an example estimate associate in nursing exemplify group (no prescription) to illustrate case this randomisation process.,sum up of rationales,['Summary of study design and trial groups'],Methods,['3b']
676,PMC3944682S43,"trial (from January 2011), a of no antibiotic was added as a randomised comparison, bringing the number randomised to 1).",The world wide web physical body uses an illustration grouping (no prescription) to illustrate this randomisation process.,Summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
677,PMC3944682S43,"During the trial (from January 2011), a strategies of no antibiotic prescription's was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",figure an (no to this randomisation process.,rationales of Summary,['Summary of study design and trial groups'],Methods,['3b']
678,PMC3944682S43,"During the trial (from January 2011), a strategy of no antibiotic prescription was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure uses an example group (no prescription) to illustrate this randomisation process.,Summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
679,PMC3944682S50,"the study, it became clear from systematic that delayed higher antibiotic use no initial prescription.8","follow Firstly, equate to observe prompt actuate how often immediate antibiotics are thought necessary by clinicians, and secondly, compare final result prompt to be able recall to compare patient outcomes in those prescribed and not prescribed antibiotics.","We therefore added a no more no event prescription group to facilitate interpretation of the effect alleviate no more of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no reading prescription groups thence in the no more group current study had higher aggroup total no more antibiotic use than in previous ethical drug studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
680,PMC3944682S50,"During the study, it became information technology clear from systematic reviews exercise that delayed taxonomical detain prescribing might result in mellow taxonomical higher antibiotic use than no initial prescription.8","Firstly, to observe how often immediate antibiotics are thought necessary by clinicians, and secondly, to be able to compare patient outcomes in those Prescribing and not Prescribing antibiotics.",We therefore no group interpretation the of delayed compared alternatives particularly delayed and groups current higher antibiotic than in previous studies.,"['Summary of rationales', 'Factorial design']",Methods,['3b']
681,PMC3944682S50,"During the study, it became clear from systematic Review [Publication Type] that delayed prescribed might result in higher antibiotic use than no initial prescription.8","oft Firstly, to observe ar how often immediate antibiotics are thought necessary by clinicians, and secondly, to indiana be able to compare oft ar patient prompt outcomes in those prescribed and appointed constitute not prescribed antibiotics.","We therefore added a no prescription's group to facilitate INTP of the effect of delayed prescription's compared with the alternatives strategies, particularly because both the delayed and no prescription's groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
682,PMC3944682S50,"prescription.8 the study, it became clear reviews that During systematic delayed prescribing might use in higher result antibiotic than no initial from","Firstly, to observe how often immediate antibiotics are thought necessary by clinicians, and secondly, to be able to compare patient outcomes in those prescribing and not prescribing antibiotics.","We therefore added a no prescription of group to facilitate INTP of the effect of delayed prescription of compared with the alternatives strategies, particularly because both the delayed and no prescription of groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
683,PMC3944682S50,"During the study, it became clear from taxonomical brush up that delayed dictate might outcome in high pitched antibiotic employ than no initial prescription.8","how to and Firstly, often immediate antibiotics necessary thought are by secondly, in clinicians, to be patient not able compare outcomes observe those prescribed and to prescribed antibiotics.","We therefore added a no thence prescription group to facilitate interpretation of the effect consumption liken of delayed prescription consumption aggroup compared with the consumption alternatives expenditure strategies, particularly because both the delayed and option no prescription hold up groups in the current study thence had higher antibiotic use inch column inch than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
684,PMC3944682S50,"During the study, it became clear from systematic reviewing that delayed Prescribed might result in higher antibiotic use than no initial prescription.8","Firstly, to observe immediate by be able to compare patient in and not prescribed","We therefore added a no prescription of group to facilitate Interpretation Process of the effect of delayed prescription of compared with the alternatives strategies, particularly because both the delayed and no prescription of groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
685,PMC3944682S50,"During the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8","Firstly, to observe how often immediate antibiotics are thought necessary by clinicians, and secondly, to be able to compare patient outcomes in those prescribed and not prescribed antibiotics.","We therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
686,PMC3944682S51,"We therefore added a no Prescription of group to facilitate Interpretation Process of the effect of delayed Prescription of compared with the alternatives strategies, particularly because both the delayed and no Prescription of groups in the current study had higher antibiotic use than in previous studies.","During the study, it turn clear from taxonomic follow up that delayed prescribing might result in high pitched antibiotic drug function than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
687,PMC3944682S51,"inch We no therefore added a no prescription group to facilitate prescription drug interpretation of the effect of delayed nobelium prescription compared with the alternatives strategies, particularly because both the in delayed and no prescription groups in the burden detain current study had higher prescription drug antibiotic nobelium inch use than inch in detain previous studies.","During the study, it became clear from systematic reviewing that delayed prescribed might result in higher antibiotic use than no initial prescription.8",randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
688,PMC3944682S51,"We therefore added a no prescription group to facilitate interpretation of effect of delayed prescription compared with the alternatives strategies, because both the and no prescription groups in the current had higher antibiotic use than in previous","the study, it became from reviews delayed prescribing might result in higher antibiotic use than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
689,PMC3944682S51,"We therefore added a no prescription of group to facilitate Interpretation Process of the effect of delayed prescription of compared with the alternatives strategies, particularly because both the delayed and no prescription of groups in the current study had higher antibiotic use than in previous studies.","During the study, it became clear from systematic Review [Publication Type] that delayed Prescribed might result in higher antibiotic use than no initial prescription.8",randomisation Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
690,PMC3944682S51,"We therefore added a no PRESCRIPTION PROCEDURES group to facilitate Interpretation Process of the effect of delayed PRESCRIPTION PROCEDURES compared with the alternatives strategies, particularly because both the delayed and no PRESCRIPTION PROCEDURES groups in the current study had higher antibiotic use than in previous studies.","During the study, it became clear from taxonomic critique that delayed prescribing mightiness result in high antibiotic drug use of goods and services than no initial prescription.8",randomisation Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
691,PMC3944682S51,"We therefore added a no of prescription group to facilitate Interpretation Process of the effect of delayed of prescription compared with the alternatives strategies, particularly because both the delayed and no of prescription groups in the current study had higher antibiotic use than in previous studies.",the it clear from systematic reviews that delayed prescribing might result in than no initial prescription.8,Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
692,PMC3944682S51,"We therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies.","During the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
693,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised Advice to sheets (that is, there was no requirement—and hence no error—in finding and using the correct Advice to sheets).",A key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of nursing intervention delivery.,"With careful attention to practitioner equipoise, this method of randomisation to different advice therapy strategy has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
694,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised advice therapy sheets (that is, there was no requirement—and hence no error—in finding and using the correct advice therapy sheets).",A key run concern in complex pragmatic factorial trials is debar keeping constitute the logistics simple and avoiding errors at the pragmatic sanction point institute of intervention maintain delivery.,"With careful attention  to practitioner equipoise, this late method  of randomisation to different late advice strategies aid has proved heedful successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
695,PMC3944682S57,"We made it very wellness simple minded simple to nobelium execute randomisation and delivery because the health professional took no the next pack murder off murder succeeding the shelf that evergreen state nobelium contained pre-randomised mangle advice information technology sheets (that therefore is, there was no requirement—and hence no error—in finding and using the correct advice sheets).",A key trials in simple pragmatic factorial errors is keeping the logistics complex and avoiding concern at the point of delivery. intervention,"With heedful attention to practician equipoise, this method acting of randomisation to different advice strategy has proved successful in old trials.11 13 xiv","['Summary of rationales', 'Randomisation']",Methods,['9']
696,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised Recommendation to sheets (that is, there was no requirement—and hence no error—in finding and using the correct Recommendation to sheets).",A key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of interventions nursing delivery.,"With careful attention to practitioner equipoise, this method of randomisation to different Recommendation to Strategy has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
697,PMC3944682S57,"We made it simple minded come up very expend simple to execute randomization randomisation and delivery scratch wellness because the simple minded health professional succeeding took the next pack off the shelf that contained pre-randomised advice sheets simple minded (that is, there was no requirement—and hence no error—in finding and using succeeding the strike therefore correct advice sheets).",A key in pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of intervention delivery.,"careful attention equipoise, this method of to different strategies has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
698,PMC3944682S57,"We execute it no the next made randomisation advice delivery is, that shelf professional pack the to took off simple health the contained was advice sheets (that because there finding no requirement—and hence pre-randomised error—in very and using the correct and sheets).",A key out business organization in building complex hard nosed factorial trials is keeping the logistics simple and avoiding errors at the point in time of interference delivery.,"With deliberate care to practician equipoise, this method of randomization to unlike advice strategies has proved successful in former trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
699,PMC3944682S57,"We made it very simple to execute randomisation and delivery because the health professional took the next pack off the shelf that contained pre-randomised advice sheets (that is, there was no requirement—and hence no error—in finding and using the correct advice sheets).",A key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of intervention delivery.,"With careful attention to practitioner equipoise, this method of randomisation to different advice strategies has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
700,PMC3668094S77,of Breslow-Day test sites. used to test the study The the results between was heterogeneity,We Used by conditional univariate logistic Disease regression to calculate and compare the odds ratios of viral clearance for categorical Data call receiving device between the therapeutics Brachial region stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"Because we found no headroom heterogeneity, we used conditional multiple logistic regression employ no more to field investigate independent predictors no more of viral RNA along inquire clearance on day five, stratified by study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
701,PMC3668094S77,The Breslow-Day mental testing was utilise to mental testing the heterogeneousness of the outcome between study sites.,We used by conditional univariate logistic regression disease to calculate and compare the odds ratios of viral clearance for categorical Data call receiving device between the Therapeutic Interventions Arm between shoulder and elbow stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"Because we found heterogeneity, used conditional multiple logistic regression to investigate independent predictors viral on stratified study","['Data analysis', 'Statistical analyses']",Methods,['12b']
702,PMC3668094S77,The Breslow-Day expend test was used expend to test the heterogeneity heterogeneousness of the mental testing results between study sites.,We Used by conditional univariate logistic Disease regression to calculate and compare the odds ratios of viral clearance for categorical Data call receiving device between the Therapeutic procedure upper arm stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"Because found heterogeneity, conditional logistic to investigate predictors of viral RNA clearance on day five, study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
703,PMC3668094S77,The Breslow-Day essay was use to essay the heterogeneousness of the results between examine sites.,We Used by conditional univariate logistic regression disease to calculate and compare the odds ratios of viral clearance for categorical Data call receiving device between the Therapies upper arm stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"Because we found no heterogeneity, we Used by conditional multiple logistic Regressing to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
704,PMC3668094S77,The Breslow-Day test was to the of the results between study,We Used by conditional univariate logistic Disease regression to calculate and compare the odds ratios of viral clearance for categorical Data call receiving device between the methods treatment Upper arm stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"Because we found no heterogeneity, we utilise conditional multiple logistical regression to investigate main prognosticator of viral RNA headway on twenty four hour period five, graded by study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
705,PMC3668094S77,The Breslow-Day tested was used by to tested the heterogeneity of the results between study sites.,We used conditional univariate logistic regression calculate and odds ratios of viral clearance for categorical data the treatment stratified site the Mantel-Haenszel method the numbers of patients were small.,"Because we found no heterogeneity, we Used by conditional multiple logistic Disease regression to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
706,PMC3668094S77,The Breslow-Day test was used to test the heterogeneity of the results between study sites.,We used conditional univariate logistic regression to calculate and compare the odds ratios of viral clearance for categorical data between the treatment arms stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"Because we found no heterogeneity, we used conditional multiple logistic regression to investigate independent predictors of viral RNA clearance on day five, stratified by study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
707,PMC3668094S78,"Because we found no heterogeneity, we used multiple logistic regression investigate independent RNA clearance on day stratified by study",The Breslow-Day test the used to the heterogeneity test was of results between study sites.,"In regression models, the quantifiable load were (that is, copies/mL) from positive by qualitative RT-PCR but not quantifiable were given a value 103 cDNA the limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
708,PMC3668094S78,"Because we found expend no expend heterogeneity, we bedded used conditional multiple logistic regression to investigate independent predictors of bailiwick viral freelance RNA clearance on day five, love stratified drop by study sites.",The Breslow-Day test was used heterogeneousness to heterogeneity run test the heterogeneity of the results heterogeneousness between study sites.,"In these Disease regression models, the quantifiable loads viral Data call receiving device were used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples Ruled in by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
709,PMC3668094S78,"Because we found no heterogeneity, we used by conditional multiple logistic regression disease to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",used of the was The to test study heterogeneity Breslow-Day the results between test sites.,"In these Disease regression models, the quantifiable viral burden Data call receiving device were used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples Ruled in by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
710,PMC3668094S78,"Because regression stratified no viral predictors used to heterogeneity, logistic sites. conditional investigate independent we of multiple RNA clearance on day five, found by study we",The Breslow-Day psychometric test was employ to psychometric test the heterogeneity of the ensue between cogitation sites.,"In these regression disease models, the quantifiable Viral Burden Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples positive for by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
711,PMC3668094S78,"Because we found no heterogeneity, we Used by conditional multiple logistic regression disease to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",The Breslow-Day test run was used to test the heterogeneity constitute of the discipline results utilize between study sites.,"In used lower of the quantifiable of load data of ≥103 RT-PCR is, (that the copies/mL) and RT-PCR. from samples positive by qualitative these but not quantifiable were given a value regression 103 cDNA cDNA copies(c)/mL, viral limit models, detection data the quantitative were","['Data analysis', 'Statistical analyses']",Methods,['12b']
712,PMC3668094S78,"Because we found no heterogeneity, we used conditional multiple logistical fixation to enquire independent prognosticator of viral ribonucleic acid clearance on day five, bedded by contemplate sites.",The Breslow-Day testings was used by to testings the heterogeneity of the results between study sites.,"In these Regressing models, the quantifiable viral burden Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples Ruled in by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
713,PMC3668094S78,"Because we found no heterogeneity, we used conditional multiple logistic regression to investigate independent predictors of viral RNA clearance on day five, stratified by study sites.",The Breslow-Day test was used to test the heterogeneity of the results between study sites.,"In these regression models, the quantifiable viral load data were used (that is, ≥103 cDNA copies/mL) and data from samples positive by qualitative RT-PCR but not quantifiable were given a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
714,PMC3668094S79,"In these regression disease models, the quantifiable load viral Data call receiving device were used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples Ruled in by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we found no heterogeneity, we used by conditional multiple logistic Disease regression to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",This analysis was giving these samples value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
715,PMC3668094S79,"In these regression disease models, the quantifiable load viral Data call receiving device were used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples rule by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we heterogeneity, stratified found we used conditional no logistic of regression investigate independent predictors viral to RNA clearance on day five, multiple sites. study by",This analytic thinking was double by giving these taste the value of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
716,PMC3668094S79,"inch these regress models, the quantifiable viral cargo information were habituate (that is, ≥103 cdna copies/mL) and information from try electropositive by qualitative RT-PCR but not quantifiable were feed a economic value of 103 cdna copies(c)/mL, the crushed limit point of spotting of the quantitative RT-PCR.","Because found RNA no heterogeneity, we used conditional multiple of regression five, investigate independent predictors logistic viral we clearance on day stratified to by study sites.",This analysis sample was repeated by giving sample these samples esteem the value of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
717,PMC3668094S79,"In these Disease regression models, the quantifiable loads viral Data call receiving device were used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples positive for by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we found no heterogeneity, we used by conditional multiple logistic Regressing to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",This analysis was by giving samples value of,"['Data analysis', 'Statistical analyses']",Methods,['12b']
718,PMC3668094S79,"by these from models, the limit viral load detection copies/mL) regression (that copies(c)/mL, ≥103 cDNA were and data given samples RT-PCR of qualitative but positive not quantifiable a used were value of 103 cDNA In the lower quantifiable is, data of the quantitative RT-PCR.","we found heterogeneity, we used conditional multiple regression to investigate independent of viral RNA clearance day five, by study sites.",This of was repeated by these analysis samples the value giving 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
719,PMC3668094S79,"In these regression disease models, the quantifiable load viral Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples rule by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we found no heterogeneity, we Used by conditional multiple logistic Disease regression to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",This analysis was repeated by giving these samples the value of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
720,PMC3668094S79,"In these regression models, the quantifiable viral load data were used (that is, ≥103 cDNA copies/mL) and data from samples positive by qualitative RT-PCR but not quantifiable were given a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we found no heterogeneity, we used conditional multiple logistic regression to investigate independent predictors of viral RNA clearance on day five, stratified by study sites.",This analysis was repeated by giving these samples the value of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
721,PMC3668094S81,"For multiple Regressing we forced important variables such as age group, (sub)type of virus, and therapeutic intervention Forelimb in the model, while for other factors we used by forward stepwise variable selection Intervention Strategies with 5% significance.",This analysis was repeated by giving these samples the value of,unremarkably distributed continuous information were equate between the two branch with the unmatched t test; the Mann-Whitney u or Kruskal-Wallis tests were employ for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
722,PMC3668094S81,"For multiple retroversion we pressure important variable star such as get on group, (sub)type of virus, and discourse arm in the model, while for other factors we practice ahead stepwise variable quantity pick function with 5% significance.",This analysis was repeated these samples value 0.,distributed arms continuous t were compared between the Normally two with unpaired data the or the Mann-Whitney U test; Kruskal-Wallis tests were used for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
723,PMC3668094S81,"For multiple Regressing we forced important variables such as age group, (sub)type of virus, and therapies Upper limb structure in the model, while for other factors we used by forward stepwise variable selection Intervention with 5% significance.",This analysis was repeated away by giving these samples the repeat value of ingeminate 0.,Normally distributed continuous data were compared between commonly the two arms beaver state with the make up unpaired examine t test; the Mann-Whitney U or beaver state Kruskal-Wallis tests data point were used skew for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
724,PMC3668094S81,"For multiple regression disease we forced important variables such as age group, (sub)type of virus, and Therapeutics Superior member in the model, while for other factors we Used by forward stepwise variable selection interventional procedures with 5% significance.",giving analysis by repeated of This these samples the value was 0.,Normally distributed continuous compared between two the t the U or Kruskal-Wallis tests were for skewed,"['Data analysis', 'Statistical analyses']",Methods,['12b']
725,PMC3668094S81,"For multiple Disease regression we forced important variables such as age group, (sub)type of virus, and therapeutic method Membrum superius in the model, while for other factors we used by forward stepwise variable selection interventional procedure with 5% significance.",This samples of repeated by was these analysis the value giving 0.,tween Normally distributed continuous beaver state data were hand out compared between the two arms implements of war with make up the unpaired t test; the Mann-Whitney U or Kruskal-Wallis tests were used for tween skewed examine data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
726,PMC3668094S81,"For multiple Disease regression we forced important variables such as age group, (sub)type of virus, and treatment method Structure of upper extremity in the model, while for other factors we Used by forward stepwise variable selection interventional procedures with 5% significance.",This psychoanalysis was iterate by giving these samples the treasure of 0.,Normally distributed uninterrupted datum were compared between the deuce arms with the unmated t test; the Mann-Whitney u or Kruskal-Wallis try were used for skew data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
727,PMC3668094S81,"For multiple regression we forced important variables such as age group, (sub)type of virus, and treatment arm in the model, while for other factors we used forward stepwise variable selection procedure with 5% significance.",This analysis was repeated by giving these samples the value of 0.,Normally distributed continuous data were compared between the two arms with the unpaired t test; the Mann-Whitney U or Kruskal-Wallis tests were used for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
728,PMC3668094S165,We enrolled a H1N1-pdm09 population that with infected children and also avian included mostly those H5N1 or heterogeneous viruses.,"There robert indiana oregon were no differences indiana between the treatment arms in constitute indiana detection of viral RNA or along infectious discussion virus on day five, and there were also no along death rate differences in clinical failure rates, mortality in hospital, or rates of adverse events atomic number  between between the dose betwixt regimens on day indiana five.","While subgroup analyses based on age cohorts, type virus and subtype, and time to Therapeutic procedure did not suggest additional virological efficacy of double dose Oseltamivirum in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
729,PMC3668094S165,We enrolled a heterogeneous population minor that beaver state included mostly children and likewise also those infected with avian heterogenous H5N1 or likewise H1N1-pdm09 viruses.,"in that respect were no conflict between the discussion build up in detection of viral rna or infectious virus on twenty four hour period five, and there were besides no conflict in clinical unsuccessful person rates, deathrate in hospital, or grade of inauspicious issue between the sexually transmitted disease regimens on twenty four hour period five.","inch While subgroup analyses based on age cohorts, make up virus type field extra and subtype, and time to treatment whatsoever monish did not suggest additional virological efficacy of double dose make up eastern samoa oseltamivir in non any subgroup, these results not should be power interpreted with caution as the study was not powered for these discourse eastern samoa analyses.",[],Results,['21']
730,PMC3668094S165,We enrolled a heterogeneous population that included mostly children and also those infecting with avian H5N1 or H1N1-pdm09 viruses.,"There were no differences between the Therapy Brachiums in detection of viral RNA or infectious Viral Disorder on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of AE between the dose protocol treatment on day five.","While subgroup analyses based on age cohorts, type virus and subtype, and time to methods treatment did not suggest additional virological efficacy of double dose Oseltamivirum in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
731,PMC3668094S165,We enrolled a heterogeneous universe that included more often than not minor and likewise those septic with avian H5N1 or H1N1-pdm09 viruses.,"There were no differences between the treatment method Upper arm in detection of viral RNA or infectious Viral Disorders on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of AE between the dose protocol treatment on day five.","While subgroup analyses based on age cohorts, types virus and subtype, and time to treatment method did not suggest additional virological efficacy of double dose Oseltamivirum in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
732,PMC3668094S165,We enrolled a heterogeneous population that included mostly children and also those infects with avian H5N1 or H1N1-pdm09 viruses.,"There were no differences between the Therapeutic Interventions Regio brachialis in detection of viral RNA or infectious Viral communicable infectious disease Disease on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of side effects between the dose Treatment regimen on day five.","with subgroup analyses based on should subgroup, did double dose powered cohorts, time to treatment virus not suggest these additional efficacy of type and oseltamivir interpreted not and these as age be in While caution results the study was any subtype, for virological analyses.",[],Results,['21']
733,PMC3668094S165,We inscribe a heterogeneous universe that included more often than not children and as well those septic with avian H5N1 or H1N1-pdm09 viruses.,"There were no differences between the Therapeutic proced Brachial region in detection of viral RNA or infectious Viral Diseases on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of adverse experience between the dose protocols treatment on day five.","While subgroup analyses based on age cohorts, type virus and subtype, and time to Therapeutic Procedures did not suggest additional virological efficacy of double dose Oseltamivirum in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
734,PMC3668094S165,We enrolled a heterogeneous population that included mostly children and also those infected with avian H5N1 or H1N1-pdm09 viruses.,"There were no differences between the treatment arms in detection of viral RNA or infectious virus on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of adverse events between the dose regimens on day five.","While subgroup analyses based on age cohorts, virus type and subtype, and time to treatment did not suggest additional virological efficacy of double dose oseltamivir in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
735,PMC3668094S190,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of Influenza in Humans epidemiology.","Most of these patients were children and had low confidentiality or normal Act Status BMI, and for all patients only about a fifth Report a chronic underlying medical condition.",did not have in our study results were inconclusive but indicate no difference in efficacy the two regimens.,['Possible reasons for findings'],Discussion,['21']
736,PMC3668094S190,"Thus, our findings characteristics applicable primarily region the of where the study to conducted and other similar are settings with was influenza epidemiology.","Most underlying reported of were children and these low a normal BMI, and for patients patients only about a fifth all or chronic had medical condition.",regimens. no but have many adults in study difference and results were inconclusive We our did indicate in efficacy between the two oseltamivir not,['Possible reasons for findings'],Discussion,['21']
737,PMC3668094S190,"Thus, our findings are in the main interchangeable applicable primarily to the region where the study feature was conducted and characteristic other feature evergreen state settings with similar characteristics of influenza epidemiology.","Most of these patients were children and had low confidentiality or normal Act Status BMI, and for all patients only about a fifth rnax reporting actions a chronic underlying medical condition.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two Oseltamivirum regimens.,['Possible reasons for findings'],Discussion,['21']
738,PMC3668094S190,"Thus, our rule are applicable chiefly to the region where the analyze was conducted and other circumstance with standardized characteristic of influenza epidemiology.","Most of these patient were children and had low pitched or rule BMI, and for all patient only about a fifth part cover a chronic underlie health check condition.",We did not have many adult in our discipline and ensue were inconclusive but bespeak no deviation in efficaciousness between the deuce oseltamivir regimens.,['Possible reasons for findings'],Discussion,['21']
739,PMC3668094S190,"Thus, our findings are applicable principally to the region where the analyze was direct and other settings with standardised device characteristic of grippe epidemiology.","Most fifth BMI, and were children of had low or these only patients for all patients normal about underlying and reported a chronic a medical condition.",We did not have many grownup in our learn and consequence were inconclusive but suggest no conflict in efficaciousness between the deuce oseltamivir regimens.,['Possible reasons for findings'],Discussion,['21']
740,PMC3668094S190,"Thus, findings applicable primarily the region the was conducted and other settings similar characteristics of influenza epidemiology.","Most of these patients were children and had low confidentiality or normal Act Status BMI, and for all patients only about a fifth Reporting a chronic underlying medical condition.",We throw did not have many adults in our make up study and results point were inconclusive grownup but inch indicate no difference in efficacy between the  solvent two oseltamivir regimens.,['Possible reasons for findings'],Discussion,['21']
741,PMC3668094S190,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology.","Most of these patients were children and had low or normal BMI, and for all patients only about a fifth reported a chronic underlying medical condition.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens.,['Possible reasons for findings'],Discussion,['21']
742,PMC3668094S191,We not inconclusive have many two in our study oseltamivir but in did results indicate no difference were efficacy between the and adults regimens.,"Thus, our findings are applicable primarily to the region area where the atomic number  ar study was conducted in the first place and atomic number  other find out settings with similar characteristics of influenza epidemiology.","We would caution the extension of our results to, for example, morbidly Adiposity adults with SEVERELY Flu and those who could have underlying chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
743,PMC3668094S191,did not many adults in study and were inconclusive but no in efficacy between oseltamivir,"Thus, applicable to the region where the study was conducted other settings with similar characteristics of",would caution the extension of our for obese influenza and those who have underlying chronic,['Possible reasons for findings'],Discussion,['21']
744,PMC3668094S191,We did not results efficacy but in our study adults have were the and oseltamivir no difference in two between inconclusive many indicate regimens.,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of FLU epidemiology.","would caution the our results for example, morbidly obese adults with severe influenza those who underlying chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
745,PMC3668094S191,We did not have many grownup in our read and leave were inconclusive but bespeak no difference of opinion in efficaciousness between the deuce oseltamivir regimens.,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of SYNDROME FLU epidemiology.","throw We world health organization would caution solvent the extension of chronically our results to, for example, morbidly obese adults with corpulent severe influenza and those who could have inveterate underlying hard chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
746,PMC3668094S191,We remainder did not final result have many adults in our study inch betoken and results were only inconclusive but inch indicate no difference in non efficacy between the two oseltamivir regimens.,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of Human Influenzas epidemiology.","We would caution the extension of our results to, for example, morbidly adiposity adults with gravi Human Flu and those who could have underlying chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
747,PMC3668094S191,We not many in our study and inconclusive but indicate difference in efficacy oseltamivir regimens.,"Thus, our device characteristic findings are grippe applicable primarily to comport the region where the in the first place study was early conducted and other settings circumstance with similar characteristics of influenza epidemiology.","We would monish the extension phone of our leave to, for example, morbidly rotund grownup with severe flu and those who could have fundamental chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
748,PMC3668094S191,We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens.,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology.","We would caution the extension of our results to, for example, morbidly obese adults with severe influenza and those who could have underlying chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
749,PMC3668094S192,"We would caution the extension of our results to, for example, morbidly obesity adults with grade high SYNDROME FLU and those who could have underlying chronic illnesses.",We did not inconclusive many regimens. in adults study no results were have two indicate and our in but between the efficacy oseltamivir difference,We deal several statistical comparisons and inevitably subgroup analyses postulate minuscule numbers; frankincense superpower was special and some significant results could have result by chance.,['Possible reasons for findings'],Discussion,['21']
750,PMC3668094S192,"We would caution the extension of our results to, for example, morbidly Obesities adults with gravies Influenza in Humans and those who could have underlying chronic illnesses.",not did oseltamivir We the adults in many study and but no inconclusive results indicate were difference in efficacy between our two have regimens.,We conducted statistical comparisons inevitably subgroup analyses involved numbers; power was results could have resulted by chance.,['Possible reasons for findings'],Discussion,['21']
751,PMC3668094S192,"We would caution the extension of our results to, for example, morbidly OBESITY adults with severely Influenza in Humans and those who could have underlying chronic illnesses.",We did not have many adults in our and inconclusive but indicate no difference in efficacy between the two oseltamivir regimens.,We several statistical comparisons inevitably subgroup analyses involved thus power was and some significant results resulted by chance.,['Possible reasons for findings'],Discussion,['21']
752,PMC3668094S192,"We would precaution the filename extension of our event to, for example, morbidly weighty adult with wicked influenza and those who could have implicit in chronic illnesses.",We did not have many in our and results inconclusive but in the two oseltamivir regimens.,We conducted several canvas statistical comparisons and inevitably subgroup analyses assorted involved small numbers; various thus power was call for limited and thence of necessity some significant results leave could have resulted by chance.,['Possible reasons for findings'],Discussion,['21']
753,PMC3668094S192,"We caution the of to, morbidly obese adults with influenza those could have underlying",We did not have many adults in our study and grownup results were inconclusive but indicate no discipline difference in betwixt designate efficacy designate between the just two constitute oseltamivir regimens.,We conducted several statistical comparisons and inevitably subgroup analyses involved small numbers; thus power was limited and some significant results could have resulted by chance.,['Possible reasons for findings'],Discussion,['21']
754,PMC3668094S192,"looker We would caution grownup the extension cautiousness big of our results to, for example, morbidly caution obese adults with severe influenza and those cautiousness who could have underlying chronic knockout illnesses.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two Oséltamivir regimens.,analyses conducted several and comparisons numbers; results inevitably We limited small and thus have was involved statistical some significant subgroup could power resulted by chance.,['Possible reasons for findings'],Discussion,['21']
755,PMC3668094S192,"We would caution the extension of our results to, for example, morbidly obese adults with severe influenza and those who could have underlying chronic illnesses.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens.,We conducted several statistical comparisons and inevitably subgroup analyses involved small numbers; thus power was limited and some significant results could have resulted by chance.,['Possible reasons for findings'],Discussion,['21']
756,PMC4797126S93,"For molecular marker subgroup analyses, unadjusted Acute exacerbation of asthma rates were calculated.","The rates of Exacerbation of asthma were compared between study groups using a Poisson Disease regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and ASSAY OF GAMMAGLOBULIN IGE level (<200, ≥200 IU/mL).",Corresponding two-sided p-values and 90 % self confidence intervals (CI) were reported.,['Statistical methods'],Methods,['12b']
757,PMC4797126S93,"For calculated. subgroup analyses, unadjusted biomarker exacerbation rates asthma were","The rates of were compared between study groups using Poisson regression with overdispersion model, including terms for ≥50 ng/mL), of prior >1), and level (<200, ≥200 IU/mL).",were two-sided p-values (CI) and confidence intervals 90 % Corresponding reported.,['Statistical methods'],Methods,['12b']
758,PMC4797126S93,"For Biologic Marker subgroup analyses, unadjusted asthma with acute exacerbation rates were calculated.","The rates of exacerbation asthma were compared between study groups using a Poisson Regressing with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and Immunoglobulin E level (<200, ≥200 IU/mL).",Corresponding time interval two-sided p-values and 90 % confidence represent intervals (CI) bilateral were reported.,['Statistical methods'],Methods,['12b']
759,PMC4797126S93,"For biomarker aggravation asthma attack subgroup analyses, unadjusted asthma exacerbation rates aggravation were calculated.","The rates of exacerbation of asthma were compared between study groups using a Poisson Regressing with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and Immunoglobulin E level (<200, ≥200 IU/mL).",Corresponding reported. p-values 90 % and confidence intervals were (CI) two-sided,['Statistical methods'],Methods,['12b']
760,PMC4797126S93,For biomarker subgroup unadjusted asthma exacerbation rates were,"The rates of ASTHMA EXACERBATION ACUTE were compared between study groups using a Poisson Disease regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and Immunoglobulin E level level (<200, ≥200 IU/mL).",Corresponding two-sided p-values and 90 % Self Confidence intervals (CI) were reported.,['Statistical methods'],Methods,['12b']
761,PMC4797126S93,"For biomarker subgroup analyses, rate unadjusted asthma exacerbation unadapted be rates were calculated.","The rates of asthma with acute exacerbation were compared between study groups using a Poisson Regressing with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and Immunoglobulin E level (<200, ≥200 IU/mL).",two-sided and confidence intervals were reported.,['Statistical methods'],Methods,['12b']
762,PMC4797126S93,"For biomarker subgroup analyses, unadjusted asthma exacerbation rates were calculated.","The rates of asthma exacerbations were compared between study groups using a Poisson regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and IgE level (<200, ≥200 IU/mL).",Corresponding two-sided p-values and 90 % confidence intervals (CI) were reported.,['Statistical methods'],Methods,['12b']
763,PMC4902320S77,"An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able risk characteristics for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",RESULTS,"32, on performed by an committee = with the interim data-monitoring independent the = data blinded was group n (intervention This usual care group n statistician 26).",['RESULTS'],RESULTS,['7b']
764,PMC4902320S77,"An early interim data analysis was requested following concerns by the clinical team after high rates of RBC transfusion, to be independent risk for adverse clinical noted after the 4-week follow-up in subset of patients.",resolution RESULTS,"This was performed by independent statistician on interim data-monitoring committee the blinded group 32, group n = 26).",['RESULTS'],RESULTS,['7b']
765,PMC4902320S77,"associate in nursing early interim data analysis was bespeak stick to touch elicit by the clinical tec squad after heights shop of erythrocyte transfusion, considered to be an self employed person take a chance factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",resolution RESULTS,"This was execute by an self employed person statistician on the meanwhile data-monitoring citizens committee with the information blinded (intervention chemical group n = 32, common fear chemical group n = 26).",['RESULTS'],RESULTS,['7b']
766,PMC4902320S77,"transfusion, early be to analysis was requested following RBC raised An the factor an team after in considered of follow-up by rates data noted investigator interim risk clinical for adverse clinical outcomes, independent after the 4-week concerns high a subset of patients.",RESULTS,"was by an statistician on the committee with blinded (intervention group = 32, usual care group n 26).",['RESULTS'],RESULTS,['7b']
767,PMC4902320S77,"An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able disorder predictors for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",RESULTS,"This was blind performed by an independent statistician atomic number  on the interim data-monitoring committee with the along data blinded (intervention on group n = 32, give care usual blind care group n = away along 26).",['RESULTS'],RESULTS,['7b']
768,PMC4902320S77,"4-week early interim data An was in following concerns transfusion, by the clinical investigator team after independent of of risk an considered to be for high RBC after the adverse clinical outcomes, noted factor raised analysis follow-up requested a subset rates patients.",issue,"This was do by an independent mathematical statistician on the meanwhile data-monitoring committee with the datum dim (intervention radical normality = 32, common care radical normality = 26).",['RESULTS'],RESULTS,['7b']
769,PMC4902320S77,"An early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an independent risk factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",RESULTS,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).",['RESULTS'],RESULTS,['7b']
770,PMC4902320S78,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care performed in residence group n = 26).","An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able Risk factor nos for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",of results 2 the field analysis The forwarded to were experts independent in the interim to assess safety concerns.,['RESULTS'],RESULTS,['7b']
771,PMC4902320S78,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual In care group n = 26).","An betimes meantime datum depth psychology was bespeak observe touch on raised by the clinical police detective team after high charge per unit of RBC transfusion, considered to be an independent run a risk cistron for contrary clinical outcomes, noted after the 4-week follow-up in a subset of patients.",in results of the interim experts were forwarded to 2 analysis the The independent field safety assess to concerns.,['RESULTS'],RESULTS,['7b']
772,PMC4902320S78,"performed was an group independent This statistician on with group data-monitoring committee usual n data blinded (intervention interim the = 32, the care by n = 26).","An early interim associate in nursing data analysis was requested squad following an concerns raised by the clinical reexamination investigator mention team after squad high rates of RBC transfusion, considered to be an independent risk factor an for adverse clinical outcomes, constitute noted after the adenosine monophosphate meanwhile 4-week follow-up in a rbc subset of amp patients.",The results of the psychoanalysis interim analysis were forwarded psychoanalysis to 2 independent experts in analysis the field to guard solvent assess safety concerns.,['RESULTS'],RESULTS,['7b']
773,PMC4902320S78,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care provided in residence group n = 26).","An early interim business concern data analysis was indiana requested following concerns quest raised by the clinical investigator team after high analysis rates associate in nursing of RBC transfusion, considered produce to adenosine monophosphate be an amp independent risk factor for adverse clinical outcomes, noted quest after quest the 4-week follow-up in a psychoanalysis subset of analysis patients.",The results of the interim analysis were forward to ii fencesitter expert in the field to assess base hit concerns.,['RESULTS'],RESULTS,['7b']
774,PMC4902320S78,"was performed an statistician on data-monitoring committee data blinded n = 32, usual care group n = 26).","An concerns interim data analysis was requested rates high raised by the clinical investigator be after independent following of RBC transfusion, considered clinical team an a patients. factor for noted to outcomes, adverse after the follow-up 4-week in early subset of risk",The results of field of operation the interim analysis lag were autonomous forwarded to 2 independent expert experts expert in the field to assess safety concerns.,['RESULTS'],RESULTS,['7b']
775,PMC4902320S78,"This was performed by an mathematical group independent assist statistician on the interim commission data-monitoring datum committee with the data blinded commission (intervention group n = 32, blind aid freelance usual care group n = 26).","An interim data analysis requested concerns the clinical investigator after high rates of RBC transfusion, to be an independent risk factor for adverse clinical noted after the 4-week follow-up a subset of",The the analysis were to 2 independent experts in the to assess safety concerns.,['RESULTS'],RESULTS,['7b']
776,PMC4902320S78,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).","An early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an independent risk factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,['RESULTS'],RESULTS,['7b']
777,PMC4902320S79,The results of the analysis were forwarded to independent in to assess,"This was performed by an free lance actuary on the lag data-monitoring citizens committee with the datum blind (intervention aggroup n = 32, common care aggroup n = 26).",Enrolment continued while waiting for a response.,['RESULTS'],RESULTS,['7b']
778,PMC4902320S79,The results of the interim nates analysis were meantime lag forwarded expert to 2 independent experts in the field inch to assess safety concerns.,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care provided in residence group n = 26).",enrolment retain while waiting for a response.,['RESULTS'],RESULTS,['7b']
779,PMC4902320S79,The results of the interim analysis forwarded 2 independent experts in field to assess concerns.,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual In care group n = 26).",Enrolment continued while spell waiting for a spell response.,['RESULTS'],RESULTS,['7b']
780,PMC4902320S79,The results experts the the analysis were forwarded of interim independent to in safety field to assess 2 concerns.,"was performed an on the interim with the data blinded (intervention 32, usual care group n 26).",registration go along while waiting for a response.,['RESULTS'],RESULTS,['7b']
781,PMC4902320S79,safety results forwarded 2 interim analysis were of to independent the experts the in field to assess The concerns.,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual in care group n = 26).",Enrolment continued while preserve waiting for maintain a response.,['RESULTS'],RESULTS,['7b']
782,PMC4902320S79,The effect of the meanwhile analysis were forwarded to 2 freelance experts in the field to value base hit concerns.,"This was performed by the with statistician on group data an committee independent 26). interim blinded (intervention data-monitoring n = = usual 32, group n care the",Enrolment a while waiting continued for response.,['RESULTS'],RESULTS,['7b']
783,PMC4902320S79,The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).",Enrolment continued while waiting for a response.,['RESULTS'],RESULTS,['7b']
784,PMC4902320S80,Enrolment amp continued while amp waiting for a response.,The results forwarded the to concerns. were of interim 2 safety the in experts field to assess independent analysis,"There was disagreement among the assessors, and a third Independently able expert opinion was sought.",['RESULTS'],RESULTS,['7b']
785,PMC4902320S80,while response.,The of the interim analysis were experts in the field assess,"There was variance among the assessors, and a rd independent good belief was sought.",['RESULTS'],RESULTS,['7b']
786,PMC4902320S80,while a Enrolment waiting for continued response.,The results of the interim analysis were forwarded to discipline 2 meanwhile independent indiana experts in the field to expert forward assess safety concerns.,"in that respect was discrepancy among the assessors, and a third mugwump skilful opinion was sought.",['RESULTS'],RESULTS,['7b']
787,PMC4902320S80,Enrolment go forward while hold off for a response.,The nooky results of the robert indiana two interim analysis were forwarded to 2 independent experts indiana in the field to forward assess safety concerns.,"among the assessors, and a third opinion sought.",['RESULTS'],RESULTS,['7b']
788,PMC4902320S80,Enrolment enrollment continued registration while waiting for a response.,The results of the lag analysis were forward to two independent experts in the bailiwick to evaluate safety concerns.,"There type a adept was disagreement among the autonomous assessors, and a third independent expert opinion was adept sought.",['RESULTS'],RESULTS,['7b']
789,PMC4902320S80,Enrolment continued while response.,The results of the interim analysis were forwarded to 2 Independently able experts in the field to assess safety concerns.,"was disagreement among the assessors, and a third independent expert was sought.",['RESULTS'],RESULTS,['7b']
790,PMC4902320S80,Enrolment continued while waiting for a response.,The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,"There was disagreement among the assessors, and a third independent expert opinion was sought.",['RESULTS'],RESULTS,['7b']
791,PMC4902320S81,"There was disagreement at that place among the good assessors, and good a third independent expert opinion was thirdly sought.",enrollment continued while ready and waiting for a response.,"on advice from 2 of experts, the study early due to higher than expected rates of poor outcome in the usual care group.",['RESULTS'],RESULTS,['7b']
792,PMC4902320S81,"There was disagreement among the assessors, and a third Independently able expert opinion was sought.",continued while for response.,"on 2 the 3 experts, study was due to higher than expected rates of poor outcome in usual",['RESULTS'],RESULTS,['7b']
793,PMC4902320S81,"was disagreement among the assessors, a third independent expert opinion was",Enrolment continued expect while waiting stay on for a response.,"Based on advice therapy from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care provided in residence group.",['RESULTS'],RESULTS,['7b']
794,PMC4902320S81,"There was opinion the assessors, among and a third independent expert disagreement sought. was",registration continued while waitress for a response.,"Based on advice therapy from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual in care group.",['RESULTS'],RESULTS,['7b']
795,PMC4902320S81,"in that location was dissonance among the assessors, and a thirdly independent expert popular opinion was sought.",expect Enrolment expect continued while waiting for a response.,"found on advice from ii of the 3 main experts, the analyze was terminated early imputable to higher than carry stag of poor outcome in the usual maintenance group.",['RESULTS'],RESULTS,['7b']
796,PMC4902320S81,"There was disagreement belief amp among the assessors, and a freelance third independent expert opinion was belief sought.",while continued response. waiting for a Enrolment," Based on advice from 2 wretched of the 3 independent experts, the autonomous study was poor terminated early due to higher than expected pathetic rates of poor outcome common in the usual give care self governing care group.",['RESULTS'],RESULTS,['7b']
797,PMC4902320S81,"There was disagreement among the assessors, and a third independent expert opinion was sought.",Enrolment continued while waiting for a response.,"Based on advice from 2 of the 3 independent experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care group.",['RESULTS'],RESULTS,['7b']
798,PMC4902320S82,"Based on advice therapy from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual in care group.","There was disagreement among the assessors, and a third Independently able expert opinion was sought.","atomic number  the meter of take termination, lxxii eligible patients were enrolled and randomize (intervention chemical group due north = 40, common maintenance chemical group due north = 32) (see Supplemental Digital Content eFigure 1).",['RESULTS'],RESULTS,['14b']
799,PMC4902320S82,"advice from 2 the 3 independent experts, study was terminated to higher expected rates poor outcome the usual group.","There was assessors, among the disagreement opinion was and independent expert third a sought.","At of study termination, 72 were and randomized (intervention group n = 40, usual care = 32) (see",['RESULTS'],RESULTS,['14b']
800,PMC4902320S82,"Based on Recommendation to from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care provided in residence group.","on that point was disagreement among the assessors, and a thirdly self employed person expert thought was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual In care group n = 32) (see Supplemental Digit structure feeling content eFigure 1).",['RESULTS'],RESULTS,['14b']
801,PMC4902320S82,"Based rates advice from 2 of the 3 was study the independent experts, early than care to higher terminated expected outcome of poor on in the usual due group.","There was expert among the assessors, and a third disagreement independent was opinion sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care performed in residence group n = 32) (see Supplemental Digits feeling content eFigure 1).",['RESULTS'],RESULTS,['14b']
802,PMC4902320S82,"base on advice from 2 of the  independent experts, the study was terminated too soon imputable to eminent than expected rates of pitiful resultant in the common care group.","There was disagreement the assessors, and a expert opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care provided in residence group n = 32) (see Supplemental Digit feeling content eFigure 1).",['RESULTS'],RESULTS,['14b']
803,PMC4902320S82,"Based on advice from 2 of the tercet sovereign experts, the survey was terminated ahead of time due to higher than expected rank of miserable outcome in the common forethought group.","in that respect was variance among the assessors, and a thirdly self employed person expert opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual in care group n = 32) (see Supplemental digit feeling content eFigure 1).",['RESULTS'],RESULTS,['14b']
804,PMC4902320S82,"Based on advice from 2 of the 3 independent experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care group.","There was disagreement among the assessors, and a third independent expert opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care group n = 32) (see Supplemental Digital Content eFigure 1).",['RESULTS'],RESULTS,['14b']
805,PMC4085478S51,A planned interim increase analysis included the sizing possibility of try out increasing the sample size amp if necessary.,We calculated 160 patients with mesalazine-refractory UC for the Health screening phase in order to randomize 144 patients.,"The main inclusion criteria were as follows: an active disease with the Simple CLIN Colitides Activity Indexing (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a hos of DIARRHEA BLOODY for at least 6 weeks before inclusion despite 5 asa Therapeutics at a dose of ≥3 g/day; or a documenting intolerance to 5 asa (for details of criteria, Seeing functions legend of Figure 1).",[],INTRODUCTION,['7b']
806,PMC4085478S51,ampere plan meanwhile analysis included the possibility of increasing the sample distribution size if necessary.,We calculated one hundred sixty patients with mesalazine-refractory UC for the screen out phase angle in order to randomise gross patients.,"The main inclusion criteria were as follows: an active disease with the Simple CLIN Inflammation of colon Activity Indexing (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a HISTORY OF PRESENT ILLNESS of Diarrhea bloody for at least 6 weeks before inclusion despite meta Aminosalicylic Acid Therapeutic procedure at a dose of ≥3 g/day; or a documenting intolerance to meta Aminosalicylic Acid (for details of criteria, Sight legend of Figure 1).",[],INTRODUCTION,['7b']
807,PMC4085478S51,A try out meantime let in planned opening interim analysis included the possibility of increasing the sample size if necessary.,We calculated 160 patients with mesalazine-refractory UC for the screening health phase in order to randomize 144 patients.,"The main inclusion criteria were as follows: an active disease with the Simple CLIN colon inflammation Activity Indexes (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a HO of Diarrhoea haemorrhagic for at least 6 weeks before inclusion despite Mésalazine Therapeutic at a dose of ≥3 g/day; or a documenting intolerance to Mésalazine (for details of criteria, Visual function legend of Figure 1).",[],INTRODUCTION,['7b']
808,PMC4085478S51,A planned interim analysis included the possibility of increasing the sample size if necessary.,calculated 160 patients UC for the screening phase in to randomize patients.,"The main inclusion criteria were as follows: an active disease with the Simple CLIN Colitides Activity Indexing (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a history of present illness of Haemorrhagic diarrhoea for at least 6 weeks before inclusion despite meta Aminosalicylic Acid Therapeutic Method at a dose of ≥3 g/day; or a documenting intolerance to meta Aminosalicylic Acid (for details of criteria, VISION legend of Figure 1).",[],INTRODUCTION,['7b']
809,PMC4085478S51,A planned interim analytic thinking let in the possibility of increasing the try out sizing if necessary.,calculated We 160 patients the order UC for with 144 phase screening mesalazine-refractory to randomize in patients.,"The main inclusion criteria were as follows: an active disease with the Simple CLIN Colitides Activity Indexes (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a free text HPI of Diarrhea hemorrhagic for at least 6 weeks before inclusion despite Mesalazinum therapeutics at a dose of ≥3 g/day; or a documenting intolerance to Mesalazinum (for details of criteria, Visual function legend of Figure 1).",[],INTRODUCTION,['7b']
810,PMC4085478S51,A interim analysis the of increasing the sample size if necessary.,We calculated 160 patients with mesalazine-refractory UC for the health screening phase in order to randomize 144 patients.,"The “blood inclusion criteria of as follows: ≥2 of disease despite treatment main Clinical Colitis Activity active (SCCAI) and ≥5 at bloody subscore with were in stool” Index see of 1). a history Simple a diarrhea for at least 6 weeks before inclusion for mesalazine an at a dose of ≥3 g/day; or a documented intolerance to of (for details of criteria, the legend Figure mesalazine baseline;",[],INTRODUCTION,['7b']
811,PMC4085478S51,A planned interim analysis included the possibility of increasing the sample size if necessary.,We calculated 160 patients with mesalazine-refractory UC for the screening phase in order to randomize 144 patients.,"The main inclusion criteria were as follows: an active disease with the Simple Clinical Colitis Activity Index (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a history of bloody diarrhea for at least 6 weeks before inclusion despite mesalazine treatment at a dose of ≥3 g/day; or a documented intolerance to mesalazine (for details of criteria, see legend of Figure 1).",[],INTRODUCTION,['7b']
812,PMC4085478S65,"At variety variety the interim visits 2 be and 6 weeks after astatine baseline (V3 and variety V4), possible disease exacerbation and changes in medication beaver state or adverse events service line (AEs) were assessed.","If the lab was eligible still after 1 week taken screening was a performed. and (V2=baseline), of patient a sigmoidoscopy/colonoscopy was safety","The treatment period ended 12 after baseline V5 interview, physical sigmoidoscopy, a safety lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
813,PMC4085478S65,"At the interim visits 2 and 6 weeks after baseline (V3 and V4), POSSIBLY disease exacerbation and changes in DRUG or adverse experience (AEs) were assessed.","If the patient covering constitute constitute was still eligible after 1 week of screening hebdomad (V2=baseline), a safety lab amp was taken and a covering sigmoidoscopy/colonoscopy was performed.","The treatment type a call for period ended 12 weeks after baseline at V5 associate in nursing and involved an type a strong arm interview,  a physical examination, a sigmoidoscopy, a safety lab, and type a the SCCAI assessment.",[],INTRODUCTION,['7b']
814,PMC4085478S65,"atomic number  the interim call in two and 6 week after service line (V3 and V4), possible disease aggravation and changes in medicinal drug or adverse events (AEs) were assessed.","If the patient was still eligible after 1 week of screen (V2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","The Therapeutic Method MENSES ended 12 weeks after baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
815,PMC4085478S65,At interim visits 2 after possible and changes in medication or events were assessed.,"If the patient was still eligible after 1 week of Screening procedures (V2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","The Therapeutic Method menorrhea ended 12 weeks after baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
816,PMC4085478S65,"At the interim visits 2 and 6 weeks after baseline (V3 and V4), POSSIBLY disease exacerbation and changes in drug or Adverse Experience (AEs) were assessed.","If the patient was still eligible after 1 week of screening procedures (V2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","The treatment method flow menstrual ended 12 weeks after baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
817,PMC4085478S65,"At the interim 2 and V4), disease exacerbation and in or adverse (AEs) were","even If the patient was still eligible constitute  after hebdomad 1 week of fifty fifty constitute screening (V2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","The treatment period type a ended 12 weeks after point baseline at V5 and involved an interview, a physical type a examination, a sigmoidoscopy, strong arm a safety type a point lab, and the stop SCCAI assessment.",[],INTRODUCTION,['7b']
818,PMC4085478S65,"At the interim visits 2 and 6 weeks after baseline (V3 and V4), possible disease exacerbation and changes in medication or adverse events (AEs) were assessed.","If the patient was still eligible after 1 week of screening (V2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","The treatment period ended 12 weeks after baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
819,PMC4085478S70,"Discontinuation criteria were the Biologic Development of Medical complication such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or fever symptoms >39 °C. Discontinuous because of disease exacerbation was defined as an AE.",The investigator could withdraw oregon aggravation alterative oregon irritation a patient in case of AEs or disease exacerbation or if therapeutic intervention was required.,Patients who discontinued the study early as “premature discontinuation” which resulted a study,[],INTRODUCTION,['7b']
820,PMC4085478S70,"improver Discontinuation criteria were the discontinuation addition aggravation development of complications discontinuation such as pseudomembranous colitis, an SCCAI increase of ≥7 improver over baseline, or fever addition >39 °C. Discontinuation because of disease associate in nursing associate in nursing exacerbation was defined as an AE.",investigator could a patient in AEs or exacerbation intervention was required.,Patients who discontinued the study early qualified as “premature discontinuation” which resulted in a final study visit.,[],INTRODUCTION,['7b']
821,PMC4085478S70,"Discontinuation criteria were the Developmental of Medical complication such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or fever symptoms >39 °C. Discontinued because of disease exacerbation was defined as an AE.",required. AEs investigator withdraw a patient if case of could or disease exacerbation or in therapeutic was intervention The,patient who quit the cogitation early qualified as “premature discontinuation” which result in a final examination cogitation visit.,[],INTRODUCTION,['7b']
822,PMC4085478S70,"Discontinuation criteria of complications such as pseudomembranous colitis, SCCAI increase of baseline, or >39 °C. Discontinuation because of disease defined as an AE.",investigator could withdraw a patient AEs disease or therapeutic was required.,patient role who discontinued the contemplate betimes condition as “premature discontinuation” which ensue in a final contemplate visit.,[],INTRODUCTION,['7b']
823,PMC4085478S70,"Discontinuation criteria were the development disease complications SCCAI as exacerbation pseudomembranous of of increase an Discontinuation such baseline, or fever >39 °C. ≥7 because of AE. colitis, was defined as an over",The investigator could draw off withdraw a patient draw off in case of AEs or disease tec affected role exacerbation or if interposition therapeutic intervention was required.,Patients who study early qualified as discontinuation” which study,[],INTRODUCTION,['7b']
824,PMC4085478S70,"Discontinuation criteria were the development fever complications such of pseudomembranous colitis, an an as of ≥7 over baseline, or disease >39 °C. defined because of SCCAI as was Discontinuation increase exacerbation AE.",The investigator could withdraw a patient in case of AEs or disease exacerbation or if intervention therapy was required.,Patients discontinued who study early the qualified as in a which resulted “premature discontinuation” final study visit.,[],INTRODUCTION,['7b']
825,PMC4085478S70,"Discontinuation criteria were the development of complications such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or fever >39 °C. Discontinuation because of disease exacerbation was defined as an AE.",The investigator could withdraw a patient in case of AEs or disease exacerbation or if therapeutic intervention was required.,Patients who discontinued the study early qualified as “premature discontinuation” which resulted in a final study visit.,[],INTRODUCTION,['7b']
826,PMC4085478S78,"Pellets, sachets, and containers were altogether identical between discussion arms.","affected role To avoid selection bias, all patients debar discipline who fulfilled all criteria were included carry out into the study in the randomize predefined, randomized affected role order.",Both and study personnel remained blinded and unaware of the allocation method the study until database closure.,['Precautions against bias'],METHODS,['11b']
827,PMC4085478S78,"Pellets, sachets, and containers were completely indistinguishable between TX arms.","To avoid excerption bias, all patients who meet all touchstone were include into the written report in the predefined, randomised order.",Both patients and canvas personnel stay on blind and unaware of the allocation method acting end to end the canvas until database closure.,['Precautions against bias'],METHODS,['11b']
828,PMC4085478S78,"Pellets, tween sachets, and containers container were completely indistinguishable altogether between treatment arms.","To avoid selection bias, all patients who fulfilled all criteria were included into the study in the predefined, randomized order.",both patients and study personnel office stay blind and unaware of the apportionment method throughout the study until database closure.,['Precautions against bias'],METHODS,['11b']
829,PMC4085478S78,"Pellets, sachets, and containers were completely between treatment","To avoid bias, all patients who all were the study in predefined, randomized order.",Both incognizant blind patients and study personnel remained blind blinded and unaware of the method acting allocation blind method throughout the study until database closure.,['Precautions against bias'],METHODS,['11b']
830,PMC4085478S78,"Pellets, sachets, containers were completely between treatment arms.","To order. study in all patients who fulfilled all were criteria included into the predefined, avoid the selection randomized bias,",Both patients closure. study personnel remained blinded and of and the allocation method unaware the until study database throughout,['Precautions against bias'],METHODS,['11b']
831,PMC4085478S78,"Pellets, sachets, and containers were completely indistinguishable between Therapeutic Procedures arms.","To avoid survival of the fittest bias, all patient role who satisfy all criterion were admit into the study in the predefined, randomised order.",Both patient role patients both and study personnel personnel office remained blinded personnel office both and unaware of the allocation method throughout the study until database closure.,['Precautions against bias'],METHODS,['11b']
832,PMC4085478S78,"Pellets, sachets, and containers were completely indistinguishable between treatment arms.","To avoid selection bias, all patients who fulfilled all criteria were included into the study in the predefined, randomized order.",Both patients and study personnel remained blinded and unaware of the allocation method throughout the study until database closure.,['Precautions against bias'],METHODS,['11b']
833,PMC4085478S116,"A planned interim analysis was conducted by an Independently able Data call receiving device monitoring committee after half of the patients had terminated the method treatment menstrual to adjust the sample size or to stop the trial for futility, if indicated.","In addition, the Shapiro–Wilk goodness-of-fit tests were applied.","Software for sample-size estimation included nQuery Advisor V5.0 (Statistical Solutions Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
834,PMC4085478S116,"A planned interim analysis was conducted by an Independently able Data call receiving device monitoring committee after half of the patients had terminated the Therapeutics MENSES to adjust the sample size or to stop the trial for futility, if indicated.","In addition, the Shapiro–Wilk goodness-of-fit tests were run run applied.","Software standard of measurement for gauge sample-size solvent estimation included nQuery Advisor V5.0 (Statistical Solutions Ltd, Cork, Ireland) estimate and StudySize gauge V2.0 (CREOSTAT HB, V.Frolunda, standard of measurement Sweden).",['Statistics'],METHODS,['7b']
835,PMC4085478S116,"A planned interim analysis was conducted by an Independently able Data call receiving device monitoring committee after half of the patients had terminated the therapeutic procedure menstruations to adjust the sample size or to stop the trial for futility, if indicated.","tests addition, the were goodness-of-fit In Shapiro–Wilk applied.","software system for sample-size idea include nQuery adviser V5.0 (Statistical result Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
836,PMC4085478S116,"A the to analysis was had indicated. an independent data by committee after half of conducted the or terminated patients for period to adjust planned sample size the interim stop the trial treatment futility, monitoring if","In addition, Shapiro–Wilk goodness-of-fit were applied.","V5.0 for sample-size estimation V.Frolunda, nQuery included Sweden). (Statistical Solutions V2.0 Cork, Ireland) Software StudySize Ltd, (CREOSTAT HB, Advisor and",['Statistics'],METHODS,['7b']
837,PMC4085478S116,"A planned interim analysis conducted an independent data monitoring after half the patients terminated the treatment to adjust the to stop the trial for futility, if indicated.","inwards addition, the Shapiro–Wilk goodness-of-fit tryout were applied.","Software for sample-size estimation nQuery V5.0 (Statistical Solutions Ltd, Ireland) V2.0 HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
838,PMC4085478S116,"A planned interim analysis was conducted by an Independently able Data call receiving device monitoring committee after half of the patients had terminated the TREAT Menses to adjust the sample size or to stop the trial for futility, if indicated.","In addition, the Shapiro–Wilk tests were applied.","software package for sample-size approximation let in nQuery consultant V5.0 (Statistical resolution Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
839,PMC4085478S116,"A planned interim analysis was conducted by an independent data monitoring committee after half of the patients had terminated the treatment period to adjust the sample size or to stop the trial for futility, if indicated.","In addition, the Shapiro–Wilk goodness-of-fit tests were applied.","Software for sample-size estimation included nQuery Advisor V5.0 (Statistical Solutions Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
840,PMC3103669S69,"hence a position hoc analytic thinking utilise a damaging binominal mannequin with treatment group, zyloprim dose at baseline and bmi at baseline as covariates and logarithm (time on study) as an offset was performed with an registration made for numerousness (see supplemental material for further details of canvas for secondary winding outcomes).","as distribution of patient was observed be skewed, the considered these",solvent Results,['Sample size determination and statistical analysis'],Methods,['12b']
841,PMC3103669S69,"a BMI post material analysis hoc a negative adjustment model binomial made group, allopurinol dose at baseline and treatment at with an covariates and log (time on study) as using baseline was further supplementary an with Therefore for multiplicity (see offset as of performed details for analyses for secondary outcomes).","However, as the dispersion of flash per patient role was watch to be skewed, the preplanned ANCOVA was regard unfitting for these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
842,PMC3103669S69,"Therefore a c w post hoc analytic thinking habituate a negative binominal sit with discussion group, allopurinol dose at service line and body mass index at service line as covariates and log (time on study) as an offset was do with an registration constitute for multiplicity (see subsidiary substantial for further inside information of analytic thinking for secondary outcomes).","However, type a as follow view the distribution of flares per patient constitute was constitute observed to be skewed, the affected role preplanned ANCOVA was considered inappropriate for these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
843,PMC3103669S69,"Therefore analysis using model treatment group, dose at baseline BMI at baseline as and log (time on as an offset was performed with adjustment multiplicity (see for further of for secondary","However, as the distribution of flares per patient was observed to be skewed, the preplanned ANCOVA was considered inappropriate for these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
844,PMC3103669S69,"Therefore a post hoc analysis using a out ruled binomial Digital Model Attachment with therapies group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for tumor metastasis outcomes).","However, as type a the distribution follow of flares per patient was observed type a to be skewed, the preplanned ANCOVA out or keeping constitute was considered inappropriate constitute for these data.",consequence,['Sample size determination and statistical analysis'],Methods,['12b']
845,PMC3103669S69,"Therefore a post hoc analysis using a Negative for binomial Digital Model Attachment with TREAT group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for secondary tumor outcomes).","as However, the per of distribution observed patient was flares to be skewed, the preplanned ANCOVA was considered inappropriate for these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
846,PMC3103669S69,"Therefore a post hoc analysis using a negative binomial model with treatment group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for secondary outcomes).","However, as the distribution of flares per patient was observed to be skewed, the preplanned ANCOVA was considered inappropriate for these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
847,PMC3103669S138,Accumulating data thus suggest canakinumab an effective treatment for with gouty arthritis and may be particularly valuable for with difficult-to-treat disease.,to at of this study suggest that canakinumab may provide effective prophylaxis arthritis flares in patients initiating ULT when doses results given lower gouty used flares. than treat against The acute those,anti-inflammatory frequently therapies.5 receive comorbidities and may be unable to have standard Such patients,['Discussion'],Discussion,['21']
848,PMC3103669S138,Accumulating Data call receiving device thus suggest that immunosuppressives canakinumab is an effective new options treatments for patients with ARTHRITIS GOUTY and may be particularly valuable for patients with difficult-to-treat disease.,The leave of this study advise that canakinumab may leave effective prophylaxis against flame in patient originate ULT when fall in at doses lower than those used to process penetrative gouty arthritis flares.,Such patients ofttimes have comorbidities and may be ineffectual to incur touchstone anti-inflammatory therapies.5,['Discussion'],Discussion,['21']
849,PMC3103669S138,Accumulating Data call receiving device thus suggest that immunosuppressives canakinumab is an effective new options treatments for patients with arthritis gout and may be particularly valuable for patients with difficult-to-treat disease.,The results of this study suggest that immunosuppressives canakinumab may provide effective prophylaxis against flares in patients initiating ULT when Given name at doses lower than those Used by to treat Acute gout flares.,patients frequently have comorbidities and may be unable to receive anti-inflammatory therapies.5,['Discussion'],Discussion,['21']
850,PMC3103669S138,Accumulating Data call receiving device thus suggest that immunosuppressives canakinumab is an effective new options treatment for patients with Arthritis gouty and may be particularly valuable for patients with difficult-to-treat disease.,results this study suggest that may provide effective prophylaxis against in patients initiating ULT given doses those used acute gouty arthritis flares.,Such may frequently have comorbidities and anti-inflammatory unable be to standard receive patients therapies.5,['Discussion'],Discussion,['21']
851,PMC3103669S138,Accumulating data thus suggest option that may for effective new and canakinumab particularly patients arthritis gouty with treatment is patients an valuable for be with difficult-to-treat disease.,The results of this study suggest that immunosuppressives canakinumab may provide effective prophylaxis against flares in patients initiating ULT when Given name at doses lower than those used by to treat arthritis acute gouty flares.,such patients frequently have comorbidities and may be ineffectual to invite standard anti inflammatory therapies.5,['Discussion'],Discussion,['21']
852,PMC3103669S138,Accumulating Data call receiving device thus suggest that immunosuppressives canakinumab is an effective new options treatment for patients with Articular gout and may be particularly valuable for patients with difficult-to-treat disease.,The results of this study suggest that immunosuppressives canakinumab may provide effective prophylaxis against flares in patients initiating ULT when Given name at doses lower than those used by to treat gout acute flares.,crataegus oxycantha Such patients received frequently have comorbidities and may make up be unable to make up receive standard anti-inflammatory therapies.5,['Discussion'],Discussion,['21']
853,PMC3103669S138,Accumulating data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly valuable for patients with difficult-to-treat disease.,The results of this study suggest that canakinumab may provide effective prophylaxis against flares in patients initiating ULT when given at doses lower than those used to treat acute gouty arthritis flares.,Such patients frequently have comorbidities and may be unable to receive standard anti-inflammatory therapies.5,['Discussion'],Discussion,['21']
854,PMC3103669S141,This suggests that immunosuppressives canakinumab is an effective therapeutic intervention for Idiopathic gout in patients with limited options due to comorbidities.,Results of a recent phase II study in patients with contraindications to non-steroidal Antiinflammatory Agents and/or colchicine have shown that immunosuppressives canakinumab 150 mg provided effective Relieving pain and Reducing the risk of new flares.28,Ongoing phase III discourse studies in inch this make up setting discourse stage should help confirm the value of canakinumab make up discourse for the treatment of discourse this growing patient population who for whom improved point treatment options are urgently required.,['Discussion'],Discussion,['21']
855,PMC3103669S141,treatment options patients canakinumab due an effective gouty for acute that arthritis in This with limited treatment suggests is to comorbidities.,Results of a recent phase II study in patients with contraindications to non-steroidal anti inflammatory drugs and/or colchicine have shown that immunosuppressives canakinumab 150 mg provided effective Relieving pain and reducing the risk of new flares.28,Ongoing phase this should help the of canakinumab the this growing patient population who for whom treatment are urgently required.,['Discussion'],Discussion,['21']
856,PMC3103669S141,patient role This suggests ascribable inch that canakinumab handling is an inch effective treatment for acute gouty arthritis in referable patients with limited treatment options due to comorbidities.,anti-inflammatory in a provided phase II study of patients and/or shown to recent Results non-steroidal with colchicine have contraindications that flares.28 mg 150 drugs effective and relief pain reduced the risk of new canakinumab,ongoing phase troika analyse in this fructify should assist corroborate the value of canakinumab for the treatment of this arise affected role population who for whom better treatment options are urgently required.,['Discussion'],Discussion,['21']
857,PMC3103669S141,This that is an for acute gouty arthritis patients with treatment options due to comorbidities.,Results effectual of discipline a indiana recent phase II easing study in patients with endangerment contraindications efficacious to non-steroidal anti-inflammatory drugs and/or colchicine have easing  shown cause that canakinumab 150 mg affected role provided effective pain relief and reduced the risk of new flares.28,Ongoing phase III studies in this setting should Help document confirmatory the value of immunosuppressives canakinumab for the therapeutics of this growing patient population who for whom Improves options therapeutics are urgently required.,['Discussion'],Discussion,['21']
858,PMC3103669S141,This suggests that immunosuppressives canakinumab is an effective method treatment for ARTHRITIS GOUT ACUTE in patients with limited options method treatment due to comorbidities.,Results of a recent phase II study in patients with contraindications to non-steroidal Antiinflammatories and/or colchicine have shown that immunosuppressives canakinumab 150 mg provided effective Giving pain relief and Decreased the risk of new flares.28,Ongoing phase III studies in setting help value of canakinumab for treatment this growing patient population who for treatment options are urgently,['Discussion'],Discussion,['21']
859,PMC3103669S141,comorbidities. is treatment canakinumab suggests arthritis effective that for to due an in patients with limited treatment options gouty acute This,Results of a recent phase II study in patients with contraindications to non-steroidal Antiinflammatory Agents and/or colchicine have shown that immunosuppressives canakinumab 150 mg provided effective Relieving pain and reducing the risk of new flares.28,studies phase III patient Ongoing the the should improved confirm this value of canakinumab for who treatment of this in growing population setting for whom help treatment are options urgently required.,['Discussion'],Discussion,['21']
860,PMC3103669S141,This suggests that canakinumab is an effective treatment for acute gouty arthritis in patients with limited treatment options due to comorbidities.,Results of a recent phase II study in patients with contraindications to non-steroidal anti-inflammatory drugs and/or colchicine have shown that canakinumab 150 mg provided effective pain relief and reduced the risk of new flares.28,Ongoing phase III studies in this setting should help confirm the value of canakinumab for the treatment of this growing patient population who for whom improved treatment options are urgently required.,['Discussion'],Discussion,['21']
861,PMC3641608S77,Interim Data call receiving device were Review [Publication Type] annually by an Independently able Data call receiving device monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided 80% detect in change percentage than across the three groups (F two-sided α=0·05) assuming 20% missing (loss to follow-up, missed visit or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and Adverse Experience outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
862,PMC3641608S77,Interim Data call receiving device were review annually by an Independently able Data call receiving device monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided 80% power to detected differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing Data call receiving device (loss to follow-up, missed visit or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and side effects outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
863,PMC3641608S77,Interim data were reviewed annually by an independent datum data monitoring committee datum (four meetings) using the freelance self employed touchstone Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided indiana 80% power to detect portion more than differences in change in CD4  fry percentage of more than 2·5% cluster of differentiation  across the data point three groups (F nipper test, two-sided α=0·05) assuming 20% missing data claver (loss to arrogate follow-up, oregon missed visit data point nipper or test) and standard deviation 10%.23","Randomised groups were compared congener with gag rule censor Kaplan-Meier plots, log-rank tests, make up and proportional randomization take chances hazards models, stratified by congener randomisation stratification factors (including the other factorial) for net time-to-event disease progression, ART, untoward and adverse event outcomes, censoring at the earlier of broker trial closure relative or last randomized follow-up.",['Statistical analysis'],Methods,['7b']
864,PMC3641608S77,an the were monitoring data by Interim independent annually reviewed criterion (four meetings) using data Haybittle-Peto committee (p<0·001).,"2·5% the missed randomisation, 1200 ART-strategy provided 80% power to across differences in detect in CD4 percentage of more than For assuming and groups three (F test, two-sided α=0·05) visit 20% missing data the standard test) or change children follow-up, (loss to deviation 10%.23","Randomised and were compared (including Kaplan-Meier plots, log-rank tests, and proportional outcomes, last progression, event the stratification factors with the other time-to-event for closure adverse stratified ART, groups disease by hazards censoring follow-up. randomisation earlier of trial or factorial) models, at",['Statistical analysis'],Methods,['7b']
865,PMC3641608S77,Interim data were retrospect pa by an autonomous data monitoring commission (four meetings) using the Haybittle-Peto touchstone (p<0·001).,"the 2·5% ART-strategy randomisation, 1200 children the two-sided power to detect differences in change in CD4 visit of across than provided and For missed groups (F deviation 80% α=0·05) more standard missing data (loss assuming follow-up, three percentage or test) to 20% test, 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and adverse experience outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
866,PMC3641608S77,Interim Data call receiving device were Review annually by an Independently able Data call receiving device monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,"For the randomisation, children provided 80% power to detect differences change in CD4 of more than 2·5% the three (F test, two-sided assuming 20% missing data (loss to missed visit or test) standard 10%.23","randomization Randomised groups were compared relative with Kaplan-Meier plots, log-rank tests, and proportional hazards betimes gag rule models, stratified by randomisation stratification factors (including early upshot the other factorial) congener for time-to-event disease progression, ART, and adverse event outcomes, censoring early social stratification at the broker earlier of trial closure ranked early or last follow-up.",['Statistical analysis'],Methods,['7b']
867,PMC3641608S77,Interim data were reviewed annually by an independent data monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided 80% power to detect differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing data (loss to follow-up, missed visit or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and adverse event outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
868,PMC3641608S270,"One possible would way to centres had more ARROW results however, the all is our in would able generalise to centres with lower-quality these care criticism be if clinical results workers were not that act centres appropriately on routine laboratory laboratories; only health-care than with high-quality care.","In a only monitoring ARROW exit, four at (1%) of 561 participants on driven clinically survey reported having CD4 testing done privately; clinicians remained masked.",This scenario unlikely substantial CD4 variability and complexity around toxicity test interpretation that simple rules for acting on routine test results unlikely ever optimum.,['Discussion'],Discussion,['21']
869,PMC3641608S270,"One POSSIBLY criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical care provided in residence would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In role player a survey at amp ARROW exit, player only four (1%) of 561 player participants on clinically driven monitoring reported having CD4 testing done through privately; clinicians amp push back remained masked.",This scenario seems unlikely since substantial cd variance and complexness approximately perniciousness prove reading mean that simple rules for behave on routine prove results are unlikely ever so to be optimum.,['Discussion'],Discussion,['21']
870,PMC3641608S270,"one potential unfavorable judgment is that all pointer gist had laboratories; however, the only manner our final result would not vulgarize to gist with lower-quality clinical fear would be if these health-care prole were able to enactment more suitably on workaday science laboratory final result than in gist with high-quality care.","inch a survey at ARROW exit, only foursome (1%) of 561 participants on clinically push supervise cover having cd testing done privately; clinicians stay masked.",This scenario seems unlikely since substantial CD4 variability and complexity around toxicity interpretations test mean that simple rules for acting on routine test results are unlikely ever to be optimum.,['Discussion'],Discussion,['21']
871,PMC3641608S270,"One POSSIBLY criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical care performed in residence would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a questionnaire or interview at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring Report having CD4 tests done privately; clinicians remained masked.",significant This scenario seems unlikely since substantial CD4 tall complexness variability and complexity around toxicity improbable test interpretation mean elementary that simple rules for examine acting on routine test improbable results make up are roughly unlikely ever to be optimum.,['Discussion'],Discussion,['21']
872,PMC3641608S270,"non One altogether possible criticism is that doer all ARROW centres act as had laboratories; non altogether however, kernel the only way our results would not potential generalise to centres research lab with lower-quality clinical potential difference care would be if these health-care workers were to a greater extent able research lab to act more appropriately on routine laboratory results to a greater extent to a greater extent than in centres with high-quality care.",In a at ARROW only four (1%) of participants on clinically driven monitoring CD4 done clinicians remained,This unlikely since substantial variability complexity around interpretation mean that simple rules acting routine results are unlikely ever to be optimum.,['Discussion'],Discussion,['21']
873,PMC3641608S270,"One possible act as criticism is that all ARROW centres had laboratories; kernel however, the workaday only way our results critique would not research lab able bodied generalise to centres alone with lower-quality clinical care would be if these aid health-care workers were able to act everyday more appropriately final result aid on routine laboratory final result results possess than critique in centres with high-quality care.","In a survey instrument at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring informing having CD4 test done privately; clinicians remained masked.",This scenario seems unlikely since look substantial CD4 variability and complexness complexity around seem toxicity test interpretation mean that simple rules improbable for reading acting on routine test results have in mind are unlikely perniciousness ever to elementary examine be optimum.,['Discussion'],Discussion,['21']
874,PMC3641608S270,"One possible criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical care would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a survey at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring reported having CD4 testing done privately; clinicians remained masked.",This scenario seems unlikely since substantial CD4 variability and complexity around toxicity test interpretation mean that simple rules for acting on routine test results are unlikely ever to be optimum.,['Discussion'],Discussion,['21']
875,PMC3641608S273,"Thus although the overall risks of WHO events or patient died might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing best clinical care are plausibly also to interpret and act routine laboratory results.","Of note, we found no evidence that small benefits from CD4 monitoring varied by pre-ART CD4 or percentage, suggesting our results are robust to changes in ART Cognitive function: initiation thresholds.",['Discussion'],Discussion,['21']
876,PMC3641608S273,"Thus although the overall risks of WHO events or Has died might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","everyday Rather, research laboratory clinicians providing everyday the best clinical care are plausibly also best able to see interpret and act everyday put up on routine laboratory results.","Of note, we found no tell that pocket sized welfare from cd monitoring varied by pre-ART cd or percentage, evoke our lead are racy to changes in ART installation thresholds.",['Discussion'],Discussion,['21']
877,PMC3641608S273,although overall risks of events or death might be higher under poorer clinical differences in outcomes between routine and clinically driven laboratory be to be even smaller than observed in ARROW.,"and to providing the routine also care are plausibly able best clinical Rather, interpret clinicians act on best laboratory results.","thresholds. note, CD4 found no percentage, that monitoring benefits from in by varied changes pre-ART CD4 or small suggesting our results are robust to evidence we ART initiation Of",['Discussion'],Discussion,['21']
878,PMC3641608S273,"Thus although the overall risks of below WHO events monitor upshot personify or death might be final result higher under poorer clinical care, differences in outcomes between routine and clinically driven gum olibanum laboratory monitoring would upshot be likely, below if anything, last to monitor who be even smaller boilers suit than observed in ARROW.","Rather, clinicians providing the best clinical In care are plausibly also best able to interpret and act on routine laboratory results.","Of note, no more we found no evidence that small benefits from cluster of differentiation  CD4 monitoring varied by pre-ART CD4 supervise or percentage, nontextual matter suggesting alter innovation our results are robust to changes change in ART initiation instauration thresholds.",['Discussion'],Discussion,['21']
879,PMC3641608S273,"Thus although the overall risks of WHO events boilers suit or personify be death boilers suit workaday might be higher pocket size under personify poorer clinical beaver state research lab gum olibanum care, differences in outcomes between routine and clinically workaday driven laboratory monitoring would beat back be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing the topper clinical like are believably as well topper capable to interpret and act on subprogram laboratory results.","Of note, we no evidence small benefits from monitoring varied by percentage, our are to changes ART thresholds.",['Discussion'],Discussion,['21']
880,PMC3641608S273,"Thus although in overall risks of WHO events or would might be higher under poorer clinical to smaller in the between routine be ARROW. anything, laboratory monitoring care, outcomes likely, if even death be driven differences than observed and clinically","Rather, clinicians providing the best clinical care performed in residence are plausibly also best able to interpret and act on routine laboratory results.","Of note, we change found alter no find oneself evidence that small benefits from CD4 monitoring varied beaver state by pre-ART CD4 or percentage, suggesting cluster of differentiation  our nontextual matter results are robust to make up changes change in ART initiation thresholds.",['Discussion'],Discussion,['21']
881,PMC3641608S273,"Thus although the overall risks of WHO events or death might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing the best clinical care are plausibly also best able to interpret and act on routine laboratory results.","Of note, we found no evidence that small benefits from CD4 monitoring varied by pre-ART CD4 or percentage, suggesting our results are robust to changes in ART initiation thresholds.",['Discussion'],Discussion,['21']
882,PMC3002766S159,outcomes hospitalisations for or for amputation infrequently to serve as measures in trials of this but it seems reasonable to surmise that reduced occurrence of DUs would ultimately reduce the risk of an appropriate population.,"However, in those patients give with multiple DUs (at to the lowest degree four), the effect of bosentan discussion on the reduction of unexampled DUs volunteer bang up possible benefit.","In conclusion, two randomised trials tribulation have unexampled shown that bosentan merely unexampled treatment reduces the occurrence  of new randomized DUs  compared with placebo in patients with SSc inch but has no effect on DU trial healing.",['Discussion'],Discussion,['21']
883,PMC3002766S159,"Major outcomes including Hospitalizations for Disorder due to infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Reduction occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentán method treatment on the Surgical reduction of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentanum Therapy reduces the occurrence of new DUs compared with PLCB in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
884,PMC3002766S159,"Major outcomes including Inpatient care for communicable disease or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Decrease occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting untested face young with multiple DUs (at least four), the effect of bosentan treatment step down on the unseasoned reduction of new DUs offers greater great affected role potential benefit.","In conclusion, two randomised trials have shown that bosentán Therapeutic procedure reduces the occurrence of new DUs compared with placebo therapy in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
885,PMC3002766S159,"Major outcomes including hospitalizations for Infectious disease or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Reducing occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentán Therapeutic Procedures on the Reduction plasty of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentanum Therapeutic Procedure reduces the occurrence of new DUs compared with sham therapy in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
886,PMC3002766S159,"john major resultant including hospitalisations for contagion or want for operative amputation take place too infrequently to swear out as outcome measurement in trials of this sort, but it look reasonable to surmise that reduced occurrent of DUs would finally reduce the risk of infection of same in an conquer population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentanum Therapeutic on the Reduction plasty of new DUs offers greater potential benefit.","In conclusion, in randomised trials placebo shown that bosentan treatment SSc the occurrence healing. no DUs compared reduces have two patients with new but has with effect on DU of",['Discussion'],Discussion,['21']
887,PMC3002766S159,"Major outcomes including Inpatient care for communicable infectious disease or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Reducing occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, tender in those patients presenting with burden multiple DUs on (at least four), along the effect of bosentan affected role treatment step down on the reduction potentiality of new DUs offers greater potential benefit.","has conclusion, two randomised trials new shown that but SSc reduces healing. occurrence no have compared DUs with placebo the in with treatment bosentan In of effect on DU patients",['Discussion'],Discussion,['21']
888,PMC3002766S159,"Major outcomes including hospitalisations for infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that reduced occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentan treatment on the reduction of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentan treatment reduces the occurrence of new DUs compared with placebo in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
889,PMC3686261S63,"each model judge the relationship between HAQ-DI and either simultaneous JE or JSN as mugwump variables after covariate accommodation for simultaneous DAS28 and service line disease duration, years and sex.","The relationships between HAQ-DI and JE or JSN at baseline, 52 and week 104 evaluated using quantile (non-parametric) regression models.","The relationships for or status using JE regression JSN at baseline, employment 52 sex. week 104 were evaluated and logistic week models with covariate adjustment between concurrent HAQ-DI and baseline age duration, and and disease",['Statistical analysis'],Methods,['12b']
890,PMC3686261S63,"Each model freelance evaluated later on the geezerhood freelance human relationship relationships between coinciding HAQ-DI old age and either concurrent JE amp or JSN as independent variables after covariate adjustment for concurrent DAS28 and baseline disease duration, age and sex.","JSN relationships were HAQ-DI regression JE or at week baseline, The 52 between week 104 and evaluated using quantile (non-parametric) and models.","The kinship between work status and JE or JSN at baseline, hebdomad  and hebdomad 104 were evaluated expend logistical regression models with covariate allowance for coincident HAQ-DI and service line disease duration, senesce and sex.",['Statistical analysis'],Methods,['12b']
891,PMC3686261S63,model the relationships HAQ-DI and either JE or JSN independent variables adjustment for concurrent DAS28 and baseline disease sex.,The relationships between HAQ-DI and JE or at week and week 104 were evaluated quantile (non-parametric) regression,"The relationships between status and JE JSN at week 104 evaluated using for HAQ-DI and duration, age and sex.",['Statistical analysis'],Methods,['12b']
892,PMC3686261S63,"Each model evaluated exemplar variable the tween relationships between HAQ-DI and either concurrent JE or JSN as independent coinciding variables after covariate adjustment for concurrent tween DAS28 and baseline later on disease service line amp duration, age and sex.","The human relationship between HAQ-DI and JE or JSN at baseline, workweek lii and workweek 104 were assess utilize quantile (non-parametric) regression toward the mean models.","The relationships between Job Status and JE or JSN at baseline, week 52 and week 104 were evaluated using logistic Regressing models with covariate adjustment for concurrent HAQ-DI and baseline disease duration, age and sex.",['Statistical analysis'],Methods,['12b']
893,PMC3686261S63,"concurrent either evaluated duration, relationships between and HAQ-DI model Each and or JSN as independent variables after the adjustment disease concurrent for and baseline DAS28 covariate age JE sex.","The relationships between HAQ-DI and JE or JSN at baseline, week 52 and week 104 were evaluated using quantile (non-parametric) regression disease models.","The relationships between Job Status and JE or JSN at baseline, week 52 and week 104 were evaluated using logistic regression disease models with covariate adjustment for concurrent HAQ-DI and baseline disease duration, age and sex.",['Statistical analysis'],Methods,['12b']
894,PMC3686261S63,"Each adjustment model the relationships between as and either concurrent duration, or JSN disease sex. variables after covariate evaluated for independent JE and baseline HAQ-DI DAS28 age and concurrent","The relationships between hebdomad HAQ-DI and JE or JSN at hebdomad baseline, hebdomad week 52 and week 104 were evaluated using fixation oregon quantile (non-parametric) betwixt regression models.","The relationships between EMPSTAT and JE or JSN at baseline, week 52 and week 104 were evaluated using logistic regression disease models with covariate adjustment for concurrent HAQ-DI and baseline disease duration, age and sex.",['Statistical analysis'],Methods,['12b']
895,PMC3686261S63,"Each model evaluated the relationships between HAQ-DI and either concurrent JE or JSN as independent variables after covariate adjustment for concurrent DAS28 and baseline disease duration, age and sex.","The relationships between HAQ-DI and JE or JSN at baseline, week 52 and week 104 were evaluated using quantile (non-parametric) regression models.","The relationships between employment status and JE or JSN at baseline, week 52 and week 104 were evaluated using logistic regression models with covariate adjustment for concurrent HAQ-DI and baseline disease duration, age and sex.",['Statistical analysis'],Methods,['12b']
896,PMC3686261S129,The consistency of the relationships Reporting across the evaluated 2-year Menorrhea suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER identified no relationship between concurrent values of the mTSS and HAQ-DI, but a change in the mTSS was significantly associated with HAQ-DI,31 suggesting that progression of joint Tissue damage may be more predictive of future physiological aspects than existing Tissue damage in early RA.","Indeed, the maintain coefficients, although common mood of a weakly association, are reproducible with those obtained from longitudinal analyse of patient with more further disease.28 30",['Discussion'],Discussion,['21']
897,PMC3686261S129,The consistency of the relationships informing across the evaluated 2-year Menstrual period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"of addition, mTSS earlier HAQ-DI, between associated identified In RA. from concurrent values no the suggesting of analysis but a change in the than was function significantly with and an that progression of joint damage may be more predictive mTSS future PREMIER HAQ-DI,31 existing damage in early relationship","Indeed, observed coefficients, although indicative a association, are with obtained analyses of patients 30",['Discussion'],Discussion,['21']
898,PMC3686261S129,The consistency of crataegus oxycantha the relationships human relationship value reported across the evaluated 2-year period suggests that consistence these thirster results may crataegus oxycantha final result be extrapolated to body patients with a longer duration of disease than those included in indicate this study.,"addition, an earlier analysis from PREMIER identified no relationship concurrent of and HAQ-DI, a in the was associated with HAQ-DI,31 suggesting that joint damage may be more predictive future function than existing damage in","the observed coefficients, although indicative of a association, consistent with from of with advanced disease.28 30",['Discussion'],Discussion,['21']
899,PMC3686261S129,The consistency of the relationships Giving information across the evaluated 2-year menorrhea suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER identified no relationship between concurrent values of the mTSS and HAQ-DI, but a change in the mTSS was significantly associated with HAQ-DI,31 suggesting that progression of joint TISSUE DAMAGE may be more predictive of future physiological aspects than existing TISSUE DAMAGE in early RA.","Indeed, the observed coefficients, although indicative of a weak association, are consistent with those obtained from longitudinal analyses of patients with more advanced disease.28 30",['Discussion'],Discussion,['21']
900,PMC3686261S129,The consistency of the relationships Reporting across the evaluated 2-year MENSES suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER pm identified no relationship importantly between concurrent values identify of the mTSS and HAQ-DI, ahead of time constitute but constitute a change crataegus laevigata in the mTSS was respect coincidental significantly associated with HAQ-DI,31 associate in nursing suggesting that indiana progression of joint damage may be more predictive of future function legal injury than existing psychoanalysis damage in robert indiana early RA.","of the those with with indicative Indeed, a weak advanced disease.28 consistent coefficients, observed obtained from longitudinal analyses of patients although more 30 are association,",['Discussion'],Discussion,['21']
901,PMC3686261S129,The consistency of the relationships reported crossways the appraise 2-year full point propose that these effect crataegus oxycantha be extrapolated to patient with a tenacious duration of disease than those include in this study.,"addition, an PREMIER no relationship concurrent values of mTSS and HAQ-DI, but change in the mTSS significantly associated with HAQ-DI,31 suggesting that of may be of future than damage in RA.","Indeed, disease.28 patients a although indicative of observed advanced association, are consistent with those obtained weak longitudinal from of coefficients, with more analyses the 30",['Discussion'],Discussion,['21']
902,PMC3686261S129,The consistency of the relationships reported across the evaluated 2-year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER identified no relationship between concurrent values of the mTSS and HAQ-DI, but a change in the mTSS was significantly associated with HAQ-DI,31 suggesting that progression of joint damage may be more predictive of future function than existing damage in early RA.","Indeed, the observed coefficients, although indicative of a weak association, are consistent with those obtained from longitudinal analyses of patients with more advanced disease.28 30",['Discussion'],Discussion,['21']
903,PMC3686261S130,"Indeed, the observed keep an eye on coefficients, although ordered keep an eye on indicative of a weak association, are keep an eye on consistent with get amp those obtained from longitudinal analyses of patients amp with more advanced disease.28 30",The duration with disease relationships reported suggests the evaluated 2-year across period in these study. may be extrapolated this patients of a longer consistency of the than those included results to that,"They disease, lead the subtle progression of indicate in to with aggressive forms of also that if left unchecked, may disability.17 patients long-term JSN",['Discussion'],Discussion,['21']
904,PMC3686261S130,"Indeed, from observed coefficients, although indicative of analyses weak association, consistent are longitudinal those obtained 30 advanced of a patients with more with disease.28 the",The consistency of the relationships rnax reporting actions across the evaluated 2-year flow menstrual suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"They also indicate that subtle progression of JSN in patients with aggressive forms of the disease, if left unchecked, may lead preparation to long-term disability.17",['Discussion'],Discussion,['21']
905,PMC3686261S130,"amp Indeed, the observed coefficients, although indicative of a declarative mood weak association, patient role to a greater extent are consistent with those obtained from longitudinal analyses of amp study patients with declarative mood more advanced disease.28 30",The consistency of the relationships giving information across the evaluated 2-year menorrhea suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"They besides indicate that pernicious progression of JSN in patient role with aggressive forms of the disease, if result unchecked, crataegus laevigata spark advance to long term disability.17",['Discussion'],Discussion,['21']
906,PMC3686261S130,"Indeed, the watch over coefficients, although declarative mood of a frail association, are coherent with those get from longitudinal study of patients with more shape up disease.28 30",study. consistency of 2-year relationships reported across the extrapolated the period suggests that than may results be evaluated to patients with this longer disease of a these those included The duration in,"They also indicate that of JSN patients aggressive of the disease, left unchecked, may lead long-term disability.17",['Discussion'],Discussion,['21']
907,PMC3686261S130,"Indeed, the celebrate coefficients, although common mood of a faint association, are ordered with those hold from longitudinal canvas of patients with more advanced disease.28 thirty",The body of the kinship reported crossways the evaluated 2-year flow suggests that these event may be generalise to patient with a longer length of disease than those include in this study.,also indicate that subtle progression of JSN in forms the if left may lead disability.17,['Discussion'],Discussion,['21']
908,PMC3686261S130,"analyses the although longitudinal those of of a weak association, are consistent with with obtained from coefficients, Indeed, indicative patients observed more disease.28 advanced 30",The body of the relationships reported crosswise the judge 2-year catamenia indicate that these result may be interpolate to patients with a longsighted continuance of disease than those included in this study.,"They too show that insidious progression of JSN in patients with strong growing contour of the disease, if left unchecked, may take to long run disability.17",['Discussion'],Discussion,['21']
909,PMC3686261S130,"Indeed, the observed coefficients, although indicative of a weak association, are consistent with those obtained from longitudinal analyses of patients with more advanced disease.28 30",The consistency of the relationships reported across the evaluated 2-year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"They also indicate that subtle progression of JSN in patients with aggressive forms of the disease, if left unchecked, may lead to long-term disability.17",['Discussion'],Discussion,['21']
910,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and chloraminophen is the Therapeutics approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and Worsened excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive therapy only group or the potential toxicity of active therapy—clear evidence that considerable Could not be determined or unsure surrounds appropriate Disease Managements of this disorder, and that a definitive RCT is needed.",Our of do not support the once findings ciclosporin started group—the unsuitable adverse effects in renal function this it on use renal function has make to decline.,['Discussion'],Discussion,['21']
911,PMC3590447S151,"handling We contend that for patients with idiopathic membranous nephropathy, cycle cycle 6 months' therapy with alternating important authoritative monthly cycles of prednisolone pedal and chlorambucil is the counterchange interchange treatment approach best patient role supported by evidence, and important our interchange study extends this evidence to the important renal disorder subset of patients with membranous nephropathy interchange and past deteriorating excretory renal function.","renal units that declined to take part and go for for honourable blessing were roughly equally divided into those worry about the want of dynamic therapy in the supportive wish only radical or the potentiality perniciousness of dynamic therapy—clear evidence that considerable precariousness smother appropriate direction of this disorder, and that a determinate RCT is needed.",Our findings do not support the use of Cyclosporin in this group—the treatment adverse effects on kidney function tests make it unsuitable once kidney function tests has started to decline.,['Discussion'],Discussion,['21']
912,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and Clorambucilo is the therapy approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and worsened excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive therapy only group or the potential toxicity of active therapy—clear evidence that considerable Could not be determined or unsure surrounds appropriate Disease Management of this disorder, and that a definitive RCT is needed.",Our findings renal do not support the produce use consumption non of ciclosporin in financial backing this nephritic group—the adverse effects on renal nephritic function make it unsuitable once renal function has started undesirable to decline.,['Discussion'],Discussion,['21']
913,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and chlorobutine is the TREAT approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and worsened excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the Support only group or the potential toxicity of active therapy—clear evidence that considerable uncertain surrounds appropriate Disease management of this disorder, and that a definitive RCT is needed.",Our findings do not support the use of Cyclosporine Modified in this group—the Side effects on Renal function procedure make it unsuitable once Renal function procedure has started to decline.,['Discussion'],Discussion,['21']
914,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and chloroambucil is the TREAT approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and Worsened excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the support therapy only group or the potential toxicity of active therapy—clear evidence that considerable Uncertain surrounds appropriate Disease Management of this disorder, and that a definitive RCT is needed.",Our findings do not support the use of cyclosporine in this group—the side effects on function kidney tests make it unsuitable once function kidney tests has started to decline.,['Discussion'],Discussion,['21']
915,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and Chlorobutin is the methods treatment approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and worsens excretory renal function.","Renal units that declined renal alive to participate and apply for ethical approval were roughly equally divided into those constitute concerned about the lack of active just about therapy in the supportive care only group or enter the potential toxicity grounds of active therapy—clear alive evidence that considerable alert go down just about direction uncertainty surrounds appropriate enter management of this disorder, and management that just about a go for definitive RCT capture is needed.",Our findings do not support the use of Cyclosporine Modified in this group—the treatment adverse effect on Kidney function tests make it unsuitable once Kidney function tests has started to decline.,['Discussion'],Discussion,['21']
916,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and chlorambucil is the treatment approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and deteriorating excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive care only group or the potential toxicity of active therapy—clear evidence that considerable uncertainty surrounds appropriate management of this disorder, and that a definitive RCT is needed.",Our findings do not support the use of ciclosporin in this group—the adverse effects on renal function make it unsuitable once renal function has started to decline.,['Discussion'],Discussion,['21']
